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 As the threat of microbial resistance to antibiotics grows, we must turn in 
new directions to find new drugs effective against resistant infections. 
Antimicrobial peptides (AMPs) and host-defense peptides (HDPs) are a class of 
natural products that have been well-studied towards this goal, though very few 
have found success clinically. However, as there is much known about the 
behavior of these peptides, work has been done to manipulate their sequences 
and structures in the search for more drug-like properties. Additionally, novel 
sequences and structures mimicking those seen in nature have been discovered 
and characterized. 
 Herein, we demonstrate our ability to finely tune the antimicrobial activity 
of various peptides, such that they can be provided with more clinically desirable 
characteristics. Our results show that gramicidin A (gA) can be made to be less 
toxic via incorporation of unnatural cationic amino acids. This is achieved by 
synthesizing lysine analogues with diverse hydrophobic groups alkylated to the 
side-chain amine. Through exploring different groups, we achieved peptide 
structures with improved selectivity for bacterial over mammalian membranes. 
Additionally, we were able to achieve novel broad-spectrum gram-negative 
 ii 
activity for gA peptides. 
 In efforts to combat bacterial resistance to cationic antimicrobial peptides 
(CAMPs), we have directed our reported amine-targeting iminoboronate 
chemistry towards neutralizing Lys-PG in bacterial membranes. Originally 
incorporating 2-APBA into gA, we found this to hinder the peptide’s activity. 
However, we were successful in increasing the potency of gA3R, a cationic 
mutant of gA, towards S. aureus by using a co-treatment of this peptide with a 
Lys-PG binding structure. Currently, we are exploring this strategy further. 
 Finally, we describe our work towards establishing a novel cyclic peptide 
library incorporating a 2-APBA warhead for iminoboronate formation with a 
given target. In this, we have achieved intermolecular reduction of 
iminoboronates, strengthening the stringency of library screening. Although we 
were unsuccessful in finding a potent hit for binding of the lipid II stem peptide, 
screening against human transferrin yielded selective hits. Currently we are 
investigating these hits to understand their activity and therapeutic potential. 
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Introduction 
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1.1 Antibiotic Resistance 
 Before the discovery of penicillin by Alexander Fleming1, infectious 
diseases were a life-threatening condition. But as this and other antibiotics began 
to see civilian use nearly 80 years ago, health care was revolutionized. Mortality 
rates from infections have steadily decreased in this time compared to unrelated 
causes of death (Figure 1-1).2 Additionally, it opened the door for other lifesaving 
practices, such as surgery for repair to internal organs or organ transplants, by 
making them less risky post-op. However, these amazing benefits have not come 
without their troubles. Perhaps due to the rapid increase in their use, the misuse 
or the over prescribing of different antibiotics, we are currently facing a refreshed 
epidemic caused by bacterial resistance to antibiotics. 
 
 The increased use of antibiotics put pressure on the bacteria to come up 
with designed mechanisms against them for their own survival, and this is a 
challenge they met at full force. On average, antibiotics survive on the market for 
Figure 1-1: Curves showing the crude mortality rate for all causes (black), non-
infectious diseases (blue) and infectious diseases (pink). A clear decrease in the blue 
line compared to the pink line can be observed in the late 1930’s, around the time of 
deployment of penicillin and other early antibiotics. Taken from ref. 2. 
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about a decade before resistance can be observed (Figure 1-2).3,4  As the golden era 
of antibiotics came to an end in the 1960s, it became clear that the practice of 
mining soil for natural products with antibiotic properties was no longer going to 
be sufficient to keep up with the new demand.5 The lag that followed in novel 
antibiotic discovery gave bacteria ample time to develop greater resistances, and 
this was notably observed in the clinic. Taking penicillin as an example, practically 
all clinical gram-positive infections were susceptible to this treatment in the late 
1940’s but by the late 1990’s, a high majority of these were now resistant to not 
only penicillin but also other important drugs from the same class.6 With the 
number of available drugs to treat such infections dwindling, there has been a near 
desperate initiative towards the discovery of novel antibiotics. 
 
 Antibiotic resistance has grown to such a dangerous level for several 
reasons. First of all, several antibiotics use the same mechanism of action to target 
bacteria. This creates strains resistant to one or more classes of antibiotics instead 
Figure 1-2: Timeline demonstrating the year of antibiotic deployment (top) and when 
the first resistance was observed in the clinic (bottom). Taken from ref. 4. 
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of just a single drug.5 Also, there are several non-specific resistance mechanisms 
that can be effective towards multiple classes of antibiotics; this includes decreased 
cell penetration and the expression of transmembrane proteins that act as efflux 
pumps for varied hydrophobic molecules.7,8 Resistance mechanism of these types 
require especially creative strategies to circumvent them. Finally, there is the risk 
of horizontal gene transfer across species. Commonly, several different species of 
bacteria can be found in close proximity. With this probability of contact, 
resistance genes are being found in some species with no prior deliberate exposure 
to a specific antibiotic. It is also not unlikely that this occurred before commercial 
use of these drugs, as they are natural products and many come from different 
bacterial species. This exchange of genes should be considered more threatening, 
as it can lead to “superbugs” with resistance to several different antibiotics.9 
 In the late 1950’s, scientists began to seek a way to fight against resistant 
infections in the clinic. An early example of this was the development of β-
lactamase inhibitors. Responsible for resistance to penicillin and other β-lactam-
containing antibiotics (Figure 1-3A), the first β-lactamase was discovered in E. coli 
in 1940, before penicillin was even on the market as an antibiotic.10 β-lactamases 
are enzymes which catalyze the opening up of the β-lactam ring in these 
antibiotics, rendering them inactive. Early β-lactamase inhibitors, such as 
clavulanic acid (Figure 1-3B), behaved as “suicide inhibitors;”11 designed to favor 
binding to enzyme with a structure mimicking the drug, they formed covalent 
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adducts with the enzyme, inactivating it. When the two molecules are co-
administered, this allows the β-lactam antibiotic to survive and act as was 
intended. The first example of a drug combination like this on the market was 
amoxicillin-clavulanate, approved in the United States in 1984.12 Unfortunately, 
within several years of clinical use, species were isolated with resistance to these 
types of combinations. 
 
 
 Perhaps the greatest lesson that has been learned from this history of 
antibiotic resistance is that new discovery methods are necessary to combat it. 
Additionally, the focus should be put on novel mechanisms of action, such that 
new drugs can have a chance for a longer lifetime on the market before resistance 
is overwhelming. 
1.2 From the End of the Golden Era to Now: The State of Antibiotic Discovery 
 The approach popularized by Selman Waksman and Fleming of mining soil 
for novel antibiotics was quickly adopted by many pharmaceutical companies 
after seeing the success of penicillin.13 This strategy was initially extremely 
successful; nearly two-thirds of all known antibiotic drugs were discovered from 
Figure 1-3: Chemical structures of (A) antibiotic penicillin with the common β-lactam 
structure in red and (B) β-lactamase inhibitor, clavulanic acid. The β-lactamase 
inhibitors form a more stable covalent intermediate with the enzymes responsible for 
β-lactam resistance, preventing them from deactivating the more potent drug. 
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species of Streptomyces using this method. However, primarily due to the 
rediscovery of known compounds,5,14 this type of discovery venture has seen little 
success in producing anything novel since the mid-1980s. With the rate of bacterial 
resistance quickly catching up to that of drug discovery, it was clear that an 
alternative was vehemently needed. 
 Near the end of the golden era of antibiotic discovery, two different classes 
of synthetic antibiotics were developed: fluoroquinolones and oxazolidinones 
(Figure 1-4). Fluoroquinolones were a crucial discovery, as they were observed to 
have broad-spectrum activity; at the time, ciprofloxacin was reported as effective 
in 98.2% of more than 20,000 tested bacterial strains.15 Fluoroquinolones were 
especially important because they acted through a novel mechanism and therefore 
were not susceptible to the resistances mechanisms known at the time. 
Additionally, they were relatively slower to develop resistance than earlier 
antibiotics, as they target two separate proteins.16 To date, more than 10,000 
quinolones have been synthesized. 
 
Figure 1-4: Structures of example A) fluoroquinolone (ciprofloxacin) and B) 
oxazolidinone (linezolid) synthetic antibiotics. The core structures for each family of 
antibiotics is shown in blue. 
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 When first discovered, oxazolidinones were considered relatively less 
ground breaking. Although the first patent for this class of antibiotics was 
obtained by Dupont in 1978, it took nine years before any derivative was tested 
clinically in humans and another 13 years before the first drug (linezolid) was put 
on the market.17 Currently considered a “reserve antibiotic,” linezolid is active 
against all gram-positive species, importantly including MRSA and vancomycin 
resistant Enterococci (VRE). So far, only few cases of resistance have been 
reported.18 
 The success of fluoroquinolones and oxazolidinones, partnered with the 
decline in natural product discovery, led to a drive towards synthetic antibiotic 
discovery in the late 1980’s to early 1990’s. These efforts were notably increased in 
the mid-90’s as a result of the determination of a complete bacterial genome.19 With 
this on hand, the discovery and validation of new possible targets for antibiotics 
grew. Furthermore, by studying the similarities across species, the focus was put 
on targets with the best chance at broad-spectrum applicability.20 
At this time, many pharmaceutical companies began to invest in high-
throughput screening (HTS) programs. In 2007, GlaxoSmithKline published a 
review of their findings over the seven years of HTS campaigns.21 Although they 
were successful in identifying several potential targets for antibiotic treatments, 
through 70 campaigns they were only able to obtain five leads; none of these 
progressed to clinical trials. The efforts of GSK are mirrored in many of its 
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competitors that took similar approaches to antibiotic discovery.19 There are many 
reasons why so many failed. Unfortunately, what appeared to be emphasized by 
these efforts is that the previous natural products appeared to have privileged 
structures to allow them to penetrate bacterial cells, and designing novel 
structures towards this goal appeared to be more nontrivial than anticipated. This 
observation and the minimal return on expensive investments led many 
pharmaceutical companies to back out of antibiotic discovery all together.  
Due to the mass abandonment of this direction of research, there have been 
few new clinically useful classes of antibiotics discovered since daptomycin in 
1985.5 Currently, many discovery efforts have shifted back to natural product 
mining, looking at previously untapped sources in the hope of avoiding 
rediscovery of known compounds.22,23 
1.3 Host-Defense Peptides (HDPs) 
 Host-defense peptides (HDPs), as part of nature’s front line of defense 
against infection,24,25 have been a severely neglected class of antibiotics. Being 
found in nearly every life form, HDPs are vastly abundant. Most commonly, these 
peptides are short, cationic and amphiphilic in structure.26 These features allow 
many of them to fold well into and disrupt cellular membranes of bacteria, a non-
specific target that gives them broad-spectrum activity.27–29 Initially given the 
name of antimicrobial peptides (AMPs), it was later observed that peptides in this 
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class can also behave as innate immunity modulators, changing their moniker to 
HDPs to demonstrate this broader role.30 
As mentioned above, many HDPs have been observed to have membrane-
targeting antimicrobial activity. They are believed to be effective by folding into 
the membrane and disrupting its integrity, typically creating pores or causing full 
lysis of the cell. Several general models have been proposed for how the peptides 
are able to do this,27 but usually this is best described in a case-by-case basis. With 
further studies of their behavior, several more specific mechanisms for how HDPs 
kill bacteria have been discovered.24,31 For example, nisin, produced by Lactococci 
and commonly used as a food preservative, was found to act by binding lipid II 
with high affinity to disrupt the cell wall.32 
1.4 Commercial Use of Peptides as Antibiotics  
Over the years, some HDPs have found commercial approval and success, 
such as nisin,33 polymyxin B,34 and daptomycin,35 but most have not. Hurdles met 
with the development of HDPs include those met by peptide drugs in general, 
such as expensive costs of large scale synthesis and short serum half-lives due to 
proteolytic degradation. Additionally, many have been limited in clinical use due 
to toxicity caused by a lack of membrane selectivity.26 Nonetheless, as solutions to 
many of these issues are being investigated, HDPs still remain a promising 
prospect in antibiotic research. 
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1.4.1 Nisin 
 Lantibiotics have been a prominent class of HDPs studied for their 
antimicrobial properties.36 They contain multicyclic structures, characterized by 
their thioether linkages. Along with their observed activities towards gram-
positive bacteria, they are also attractive due to their low cytotoxicity and low 
tendency to produce antimicrobial resistance. A prominent example from this 
class is nisin.33 
Figure 1-5: Notable examples of HDPs and their sources. Highlighted in yellow are 
nisin, which is currently used as a food preservative, and Polymixin B, which is 
approved for use with drug-resistant gram-negative infections. Modified from ref. 26. 
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 Nisin has been used since the mid-1980s in the United States as a broad-
range food preservative, preventing spoiling caused by bacteria growth. 
Considering its usage, nisin’s mechanism of action has been well studied.32,37,38 By 
binding to lipid II, it can both inhibit peptidoglycan synthesis and use lipid II as 
an anchor for membrane pore formation. This type of dual functionality is 
typically suggested to be partially responsible for the lower occurrence of 
antimicrobial resistance. However, nisin and other lantibiotics involve a more 
complicated synthetic route; this may be one of the primary reasons they have not 
been utilized clinically as of yet. 
1.4.2 Polymyxins 
 Polymyxin B is a mixture of lipopeptides with a bactericidal mechanism via 
permeabilization of the outer-membrane of gram-negative species.39 This 
detergent-like mechanism allows for polymyxins to behave as a broad-spectrum 
drug. Produced by Bacillus polymyxa and related species, the peptide mixture is 
collected and purified after the fermentation of the bacteria in an optimized 
growth media.40 Although five different polymyxin mixtures have been reported, 
only two have been used clinically: polymyxin B and E (colistin). 
When they were first introduced in the 1950s, polymyxins were not studied 
well enough to reveal their nephrotoxic side effects.41 As these became more 
apparent, the use of polymyxin B and colistin became much less frequent and now 
both are reserved for use in gram-negative infections with resistance to other 
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antibiotics.42 With interest in these drugs revived, further studies into their 
pharmacokinetics and pharmacodynamics have allowed for optimized dosing 
protocols, reducing this side effect. 
1.4.3 Daptomycin 
 The most recent novel class of antibiotic to be approved, daptomycin, is also 
a lipopeptide, with a similar structure to polymyxins. However, it is specific 
towards gram-positive bacteria, with a mechanism of action involving pore 
formation mediated by the binding of the phosphatidylglycerol head group.43 
Originally discovered in the late 1980s by researchers at Eli Lilly,44 daptomycin 
originally failed in phase I/II clinical trials due to side effects towards skeletal 
muscle.45 Only after its rights were acquired by Cubist Pharmaceuticals in 1997 
was daptomycin successful in FDA-approval for gram-positive infections. In a dog 
study performed by Cubist, it was found that the negative side effects towards the 
skeletal muscle could be abated through a careful dosing regimen.46 
 Originally expected to be resistant to resistance, daptomycin resistance was 
reported in the United States.47 Most frequently, resistance is reported in vivo 
during patient treatment, making mechanisms difficult to reproduce in vitro. 
Although the antimicrobial mechanism of resistance has not yet been confirmed, 
it is speculated to be caused by target modification. Specifically, resistance is 
believed to result from the acylation of the PG head group, preventing the binding 
of daptomycin.48 
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1.5 Conclusion 
 The need for new and novel antibiotics is becoming overwhelming. It has 
become apparent that the traditional discovery platform of panning for small 
molecule natural products will not be sustainable, as the occurrences of infections 
resistant to these classes of drugs is growing. A somewhat neglected class of 
natural product antibiotics is host defense peptides (HDPs). 
Recently, with the approval of lipopeptide daptomycin and advances in the 
synthesis and formulation of these peptides, HDPs have a revived potential for the 
goals against antibiotic resistance. Herein, we describe the work that we have been 
doing towards discovering a novel peptide antibiotic. Specifically, we have 
addressed this goal through three different avenues: 
1) The use of unnatural cationic amino acids to gain selectivity for natural 
antimicrobial peptide, gramicidin A (Chapter 2) 
2) Overcoming resistance towards cationic antimicrobial peptides 
(CAMPs) through the use of amine-specific 2-acetylphenyl boronic acid 
(2-APBA) warheads (Chapter 3) 
3) Library discovery of novel peptide structures containing 2-APBA 
warheads by screening against a validated bacterial target (Chapter 4). 
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Chapter 2 
Creating Selectivity with Cationic Mutants of Gramicidin A 
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2.1 Introduction 
2.1.1 Gramicidin A 
 Gramicidin A (gA) is a HDP produced by Bacillus brevis first discovered in 
the 1930s.1 As part of the bacteria’s external self-defense mechanism, gA is released 
from the cells with a mixture of related peptides into their surroundings. With a 
unique structure of alternating L- and D-amino acids, the active form of gA folds 
into lipid bilayers as a β-helix.2,3 This secondary structure displays all of the side 
chains on the outside of the helix, where they can interact with the tails of 
membrane phospholipids. With 6.3 residues per turn, the folded helix has an inner 
diameter of about 4 Å. A monomer of the peptide, being about 10 Å long, spans 
half of the typical membrane lipid bilayer. Peptides in opposite faces of the 
membrane can dimerize in a head-to-head fashion via six hydrogen bonds.4,5 
When this occurs, a channel is produced that is large enough to accommodate 
monovalent cations and water molecules.6,7 
 
Figure 2-1: Primary sequence and secondary structure of gramicidin A. Its β-helical 
structure, showing all of the side chains being projected on the outside, produces a 4Å 
wide pore. Also shown is the folding of gA in a lipid bilayer, with gating of the channel 
occurring due to the formation and dissociation of the dimer. PBD file 1JNO, solved by 
solution phase NMR in micelles. 
20 
 
 The antimicrobial activity of gA lies in its channel forming ability. As it 
allows for the passive movement of small cations across the membrane, the critical 
ion gradient between the cytoplasm and the extracellular environment is 
disrupted upon treatment with the peptide, leading to cell death. As part of the 
mixture tyrothricin, gA and its related structures gB and gC were one of the first 
commercially available antibiotics.8,9 However, the high hydrophobic content of 
gA makes it non-selective, with potent activity towards eukaryotic cells also 
observed. As such, gramicidin A’s clinical use has since been limited to part of a 
topical mixture of antibiotics, called Polysporin, in Canada.10 
 Gramicidin A has many attractive features for development as a systemic 
antibiotic.10,11 This includes its alternating sequence of natural and unnatural 
amino acids as well as its modified N- and C-termini. Both of these features are 
beneficial for stability from proteolytic degradation. The lack of the difficult 
linkages prevalent in other HDPs, such as the thioether bonds found in lantibiotics, 
makes it relatively more simple to scale up its chemical synthesis. Finally, its broad 
spectrum activity towards gram-positive bacteria and general mechanism of 
action increases its possibilities for clinical use. The greatest drawbacks preventing 
gA from widespread use is its aforementioned high toxicity towards human cells 
along with its miniscule water solubility. 
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 The common cationic charge of HDPs is believed to contribute to their 
selectivity for microbial membranes.12 An inherent difference between microbial 
and eukaryotic membranes is their lipid composition, especially on the outer 
leaflet. Microbial membranes are predominantly made up of negatively charged 
phospholipids, such as phosphatidylglycerol and cardiolipin. In contrast, 
mammalian cell membranes are composed of higher amounts of zwitterionic 
lipids, including phosphatidylcholine and sphingomyelin. HDPs including 
cationic residues gain selectivity by taking advantage of favorable electrostatic 
interactions for membrane association. 
 Previously, our group had worked on mimicking this characteristic for 
selectivity by mutating different residues on gA to cationic lysines or arginines.10,11 
Briefly, peptides with specific combinations of cationic residues in place of D-
leucines at positions 10, 12 and 14 were synthesized and studied for their ability 
to tune the activities from those of wild type gA. These positions were chosen as 
they lie near the membrane-water interface and thus would best tolerate mutations 
that result in a decrease in hydrophobicity.13,14 From this, we learned that 
increasing cationic charge leads to decreased toxicity to human red blood cells, as 
measured by the leakage of hemoglobin. The red blood cells showed the greatest 
resistance to hemolysis with gA-5, which is the triple lysine mutant of gA. 
However, a trend in decreasing potency towards the gram-positive bacteria 
Staphylococcus aureus was also observed for the peptides with multiple cationic 
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charges. This was most likely a result of the difference in hydrophobicity between 
leucine and lysine, decreasing the general ability of the peptide to favorably 
interact with lipid tails.10  Attempts to tune this potency back with di- and 
trimethylated versions of lysine were not as successful as hoped for; it would 
appear that the hydrogen bonding capability of the lysine plays an important role 
in the peptide’s interactions with the lipid’s phosphate group.11 These results do 
suggest, however, that attempts to tune the net hydrophobicity of the peptide via 
monoalkylation of the lysine side chain may be more fruitful. 
 
We hypothesized that a systematic tuning of the hydrophobicity, and 
therefore the membrane association, could be achieved by incorporating 
Figure 2-2: Hypothesis of cationic gA mutants for selectivity. The incorporation of 
monoalkylated lysines should maintain cationic charge for selectivity towards 
bacterial membranes over red blood cells. By tuning the alkyl group on lysine, we 
expect to be able to tune the antimicrobial potency. 
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monoalkylated D-lysine analogues into the gA sequence at positions 10, 12 and 14 
(Figure 2-2). By synthesizing D-lysine with various substitutions, we sought to 
determine a structure activity relationship between the different analogues. 
Various potencies of these cationic gA mutants were observed towards gram-
positive bacteria, including a strain of methicillin-resistant S. aureus (MRSA). 
Additionally, two of the mutants, the benzyl-lysine (Figure 2-3D, gA3K(Bn)) and 
4-(aminomethyl)benzyl-lysine (Figure 2-3H, gA3K(4AMBn)) peptides, showed 
potent activity against important gram-negative bacteria, which is an 
unprecedented observation for gA peptides. Furthermore, gA3K(4AMBn) showed 
little hemolytic activity at its minimum inhibitory concentration (MIC) for the 
tested bacteria, indicating a high degree of selectivity was maintained. Overall, the 
presented results suggest monoalkylation and subsequent incorporation of lysine 
analogues into gramicidin A is a viable strategy to achieve both high potency and 
selectivity. 
2.2 Synthesis of gA Mutants Containing Alkylated Lysines 
2.2.1 Synthesis of Alkylated Lysines 
 In our initial work with di- and trimethylated lysine, Fmoc-D-Lys(Me)2-OH 
was synthesized via reductive amination with formaldehyde as the alkylating 
agent and sodium cyanoborohydride as the hydride donor; to ensure full 
conversion to the dimethyl species, the reaction was performed using 5 eq of 
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formaldehyde.11 We envisioned that monoalkylated analogues of lysine could be 
obtained by carefully controlling the stoichiometry of lysine to alkylating agent 
and the time of the reaction. 
 
In reductive amination, the alkylating agent used is the aldehyde or ketone 
derivative of the group you wish to install on the amine (see Scheme 2-1), making 
this strategy very attractive for us, as it would allow for very broad substrate 
options that were relatively inexpensive. Initially, we set out with the goal of 
synthesizing Fmoc-D-Lys(Me)-OH, such that we could use it for comparison to the 
di- and trimethylated versions of gA-5. Unfortunately, this product was not easily 
obtained from our proposed route. We turned instead to a protocol which first 
added a benzyl protecting group to the amine before methylation; the desired 
product could be obtained by removing the benzyl group with palladium on 
carbon under a H2 atmosphere.15 Although the desired intermediate of Fmoc-D-
Lys(Bn,Me)-OH was obtained as the major product after subsequent reductive 
amination steps, debenzylation was never achieved. 
Scheme 2-1: The General Synthetic Route for Monoalkylated Lysine Derivatives in 
Preparation for Solid-Phase Peptide Synthesis 
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In these initial attempts, we learned several things about the nature of this 
reaction. First of all, we observed a high percentage of Fmoc-deprotection during 
work-up of the reaction. It was found that, upon concentration of the product by 
rotorary evaporation, the remaining sodium cyanoborohydride was cleaving the 
Fmoc group. This was easily remedied by first quenching the borohydride with 
0.5 N HCl before extraction.  
As was used for the synthesis of Fmoc-D-Lys(Me)2-OH, the initial starting 
material used was the formate salt of Fmoc-D-Lys-OH. However, this resulted in 
only about 50% conversion of the initial starting material during benzylation with 
a 1.3:1 ratio of Fmoc-D-Lys(Bn)-OH to Fmoc-D-Lys(Bn)2-OH. Upon switching to 
the HCl salt as a starting material, we were able to obtain up to 85% conversion of 
staring material with the product mixture being a 7:1 ratio of Fmoc-D-Lys(Bn)-OH 
to Fmoc-D-Lys(Bn)2-OH. This drastic difference led us to investigate the role of 
acid in the conversion of the free amine and the ratio of alkylated products. In 
order to do this, we used the free base Fmoc-Lysine-OH with varying amounts of 
trifluoroacetic acid (TFA) and monitored the reaction by analytical HPLC. Results 
can be seen in Table 2-1. After considering these results, we chose to use the 
conditions in the final entry of Table 2-1; this was due to HCl salt being three times 
less expensive than the free base. This general protocol was followed for all other 
lysine derivatives. 
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Table 2-1: Optimization of Acidic Conditions for Benzylation of Lysine 
Starting Material Equivalents TFA Conversion Ratio Mono:Di 
Fmoc-Lysine-OH 0.3 57% 1.7:1 
Fmoc-Lysine-OH 0.75 80.5% 4:1 
Fmoc-Lysine-OH 1.0 82.5% 14:1 
Fmoc-Lysine-OH 1.1 89% 10:1 
Fmoc-Lysine-OH 1.5 42% No dialkyl 
Fmoc-Lysine-OH HCOOH Salt 0 52.5% 1.3:1 
Fmoc-Lysine-OH HCl Salt 0 85% 7:1 
 The other condition optimized for this series of substrates was the reaction 
time for each aldehyde before the addition of sodium cyanoborohydride. Best 
displayed with the 2-pyridine carboxaldehyde substrate (Table 2-2), conversion of 
the starting material was dependent on allowing the association of the aldehyde 
and lysine to reach equilibrium before reduction. Without this step, we observed 
a quicker conversion of the monoalkylated product to the dialkylated, decreasing 
the overall conversion of the starting material as the aldehyde is consumed. As 
such, sodium cyanoborohydride was added to the reaction after one hour, 
balancing optimal conversion with reaction time efficiency. The two exceptions to 
this were the Fmoc-D-Lys(iPr)-OH and Fmoc-D-Lys(Cy)-OH. For both of these 
derivatives, ketones served as alkylating agents and no dialkylated product was 
observed. This is most likely due to steric hindrance of a second attack by the 
amine. Therefore, much higher concentrations of the ketone could be used and no 
pre-equilibration time was necessary. For the iPr substrate, the reaction was 
performed with its alkylating agent (acetone) as the solvent and still no 
dialkylation was observed. 
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Table 2-2: Dependence of Equilibration Time on Alkylation with 2-Pyridine Carboxaldehyde 
 Time Before Addition of NaCNBH
3
 Conversion of Lysine  
 0 min 24%  
 30 min 63%  
 1 hour 74%  
 12-14 hours 73%  
 
 
 
After alkylation, the crude material was taken forward for Boc-protection 
of the side chain to prepare the amino acids for Fmoc-based solid-phase peptide 
synthesis (SPPS). Final products were purified using silica gel column 
chromatography. In total, eight derivatives were synthesized in sufficient yields 
Figure 2-3: Structures of synthesized lysine derivatives. Under each structure is the 
overall yield of the two steps. A) Fmoc-D-Lys(iPr)(Boc)-OH; B) Fmoc-D-Lys(Cy)(Boc)-
OH; C) Fmoc-D-Lys(CyMe)(Boc)-OH; D) Fmoc-D-Lys(Bn)(Boc)-OH; E) Fmoc-D-Lys(2-
pyr)(Boc)-OH; F) Fmoc-D-Lys(3-pyr)(Boc)-OH; G) Fmoc-D-Lys(4-pyr)(Boc)-OH; H) 
Fmoc-D-Lys(4AMBn)(Boc)-OH. 
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for peptide synthesis (Figure 2-3). The naming scheme for amino acids and their 
corresponding peptides are included in Table 2-3. 
 
2.2.2 Synthesis and Structural Characterization of Cationic gA Peptides 
All peptides were synthesized using Fmoc/HBTU based SPPS, as 
previously reported by our group.10 Briefly, the peptide is elongated on a Fmoc-
Trp(Boc) functionalized Wang resin. The Formyl-Val-OH was installed as a 
peptide building block, instead of Fmoc-Val-OH, to incorporate the N-terminal 
modification. After this, the peptides were cleaved from resin using 40% 
ethanolamine in DMF then precipitated with water. TFA treatment afforded the 
crude side-chain deprotected peptide after ether precipitation. Finally, peptides 
were purified using preparative scale RP-HPLC and the pure products were 
characterized for purity (>95%) by LC/MS. 
Table 2-3: List of Aklylated Lysines and their Corresponding Peptides 
Amino Acid Alkylating Substrate Peptide Name 
Fmoc-D-Lys(iPr)(Boc)-OH Acetone gA3K(iPr) 
Fmoc-D-Lys(Cy)(Boc)-OH Cyclohexanone gA3K(Cy) 
Fmoc-D-Lys(CyMe)(Boc)-OH Cyclohexane carboxaldehyde gA3K(CyMe) 
Fmoc-D-Lys(Bn)(Boc)-OH Benzaldehyde gA3K(Bn) 
Fmoc-D-Lys(2-pyr)(Boc)-OH 2-pyridine carboxaldehyde gA3K(2pyr) 
Fmoc-D-Lys(3-pyr)(Boc)-OH 3-pyridine carboxaldehyde gA3K(3pyr) 
Fmoc-D-Lys(4-pyr)(Boc)-OH 4-pyridine carboxaldehyde gA3K(4pyr) 
Fmoc-D-Lys(4AMBn)(Boc)-OH Tert-butyl-4-formyl benzyl carbamate gA3K(4AMBn) 
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 The mechanism of action of gA and related mutants are dependent on their 
ability to fold into a β-helix. As such, we sought to confirm that the mutations we 
had made to the peptide’s sequence did not negatively affect its secondary 
structure. To do this, we analyzed the circular dichroism (CD) signature of each 
peptide in model membrane systems (Figure 2-4). The channel-forming 
conformation of gA is characterized by positive maxima at wavelengths of 218 and 
235 nm.16,17 Of these two points, the maxima at 218 nm corresponds to the 
backbone amides, being slightly red-shifted from a typical CD signature for α-
helices, distinguishing the two. The other maximum at 235 nm falls in the 
wavelength region where UV absorbent side chains tryptophan, tyrosine and 
phenylalanine are observed. This region is known to be altered based on the local 
environment of these side chains.  
Figure 2-4: Circular dichroism signatures of gA mutants. Samples are prepared in A) 
SDS and B) DPC micelles. The designed negative control, gA3K(L,D,D), is unable to 
fold into a β-helix due to its clashing stereochemistry at residue 10. Both gA3K(Cy) and 
gA3K(CyMe) suffered from low solubility in the SDS micelle solution, which led to 
their poorly defined signature. Since both peptides had better solubility and a better 
signature in DPC, their structure was believed to be intact. 
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Given this information, we confirmed from studying our peptides in both 
SDS and DPC micelles that the β-helical backbone structure was intact. 
Unsurprisingly, the second maxima of the peptides did not overlap well with that 
of the wild type structure, as the mutations occurring at the residues surrounding 
the tryptophans are expected to have an effect on their local environment. 
Included as a negative control is peptide gA3K(L,D,D), in which the 
stereochemistry of residue 10 is reversed. As can be observed from its flat CD 
signature in SDS micelles, this peptide is unable to fold into a β-helix due to this 
side chain mismatch. 
Two peptides, namely gA3K(Cy) and gA3K(CyMe), suffered from poor 
solubility with SDS micelle solutions, leading to a dampened signal. However, 
their improved signatures with DPC micelles allowed us to conclude that this was 
indeed due to lower solubility compared to the other peptides and not a loss of 
structure. 
2.3 Studies of gA3K Peptides’ Activities in Cell-Based Assays 
2.3.1 Antimicrobial Activity Towards Gram-Positive Bacteria 
 Gramicidin A in its wild-type form, similar to many membrane-targeting 
peptides, only has antimicrobial activity towards gram-positive species of 
bacteria. Especially relevant is its activity against S. aureus, whose methicillin 
resistant strains are one of the most prevalent threats to public health.18,19 All 
peptides were initially tested against Bacillus subtilis and S. aureus using a standard 
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microdilution assay.20 The most potent peptides were then studied with a strain of 
MRSA to evaluate if they could maintain activity against resistant bacteria. The 
concentration of a stock solution of each peptide in DMSO was determined by UV-
vis spectroscopy, measuring the absorbance of the tryptophan residues at 280 nm. 
An aliquot from this stock was then diluted to a final concentration of 1.0 mM, 
serving as the highest concentration used for each minimum inhibition 
concentration (MIC) assay. Under the assay conditions, this yielded a final 
concentration of 10 µM. The remaining peptide solutions were obtained through a 
two-fold serial dilution starting at 1.0 mM. The MIC is determined to be the lowest 
concentration that prevents growth of the bacteria cultures. The results for each 
peptide are listed in Table 2-4. 
Several of the peptides in this series achieved wild type-like activity against 
B. subtilis, including gA3K(Bn), gA3K(Cy), gA3K(CyMe) and gA3K(4AMBn). 
Peptides which were observed to be more potent to B. subtilis in comparison to 
gA3K were also observed to have relatively improved activity toward S. aureus. 
Those peptides with the most potent activity towards S. aureus were observed to 
maintain similar activities with MRSA. Unsurprisingly, gA3K(L,D,D), which was 
shown to be unable to form channel-active β-helical conformation, was not active 
towards any of the tested species. For this reason, we retained this peptide as a 
negative control for further studies. 
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Table 2-4: Measured MIC (μM) of gA Mutants Against Various Gram-
Positive Bacteria 
 B. subtilis S. aureus MRSA 
gA-WT 2.5 2.5 2.5 
gA3K[a] 5 >10 (80%) Not tested 
gA3K(iPr) >10[b] (40%) >10 (0%)[c] Not tested 
gA3K(Cy) 1.2 5 5 
gA3K(CyMe) 1.2 2.5 1.2 
gA3K(Bn) 1.2 5 2.5 
gA3K(2pyr) 10 >10 (45 ± 1%) Not tested 
gA3K(3pyr) >10 (33 ± 16%) >10 (19 ± 7%) Not tested 
gA3K(4pyr) >10 (37 ± 26%) >10 (0%)[c] Not tested 
gA3K(4AMBn) 1.2 >10 (93 ± 1%) Not tested 
gA3K(L,D,D) >10 (0%)[c] >10 (0%)[c] Not tested 
MIC values are determined as the lowest concentration where no bacteria 
growth is observed when bacteria have grown past logarithmic phase. 
Peptides which had potent activity (MIC <10 μM) were run twice with 
triplicate samples in each to confirm activity. [a] Data for gA3K previously 
reported. [b] For those peptides which did not achieve full killing at the 
maximum concentration, percent inhibition is given in parentheses with 
error given as the standard deviation between triplicate samples. [c] No error 
given because all samples observed to have no inhibition or slightly 
improved growth compared to the untreated samples. 
 At this point, we were interested in determining a rational structure activity 
relationship for these peptides. However, based on the MIC data with S. aureus, 
several of the peptides were indistinguishable and only broad correlations could 
be drawn. We began to consider an alternative way to compare the antimicrobial 
activity of these peptide to one another. As their mechanism is bactericidal, we 
chose to study each peptide’s ability to kill S. aureus in a minimal growth 
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environment. This cell killing assay was first optimized using one of the most 
potent peptides, gA3K(CyMe). 
 
 We chose two relevant buffers, a standard 1xPBS buffer (pH 7.4) and a 10 
mM tris acetate buffer (pH 7.4) that was used in mechanistic studies (see Section 
2.4). S. aureus cell cultures were grown to an OD600 = 0.6, then exchanged to the 
respective buffer before dilution to 5 x 105 cfu/mL in the same way as the MIC 
assay. gA3K(CyMe) was added to a final concentration of its MIC (2.5 µM) and its 
activity was monitored at several time intervals (Figure 2-5). At each time point, 
an aliquot was removed from the sample and diluted 100 times before being 
spread on a LB agar plate. The plates were then incubated at 37℃ overnight and 
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Figure 2-5: Bactericidal activity of gA3K(CyMe) with S. aureus. Time dependent 
activity was measured at 2.5 µM with S. aureus in two different buffer conditions, 
1xPBS (blue) and 10 mM tris acetate (red). Both buffers show nearly complete killing 
of S. aureus after one hour. 
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the colonies on each plate were counted. The percent cell reduction was 
determined by comparing each point with a corresponding sample with no 
peptide treatment. 
 These results show that gA3K(CyMe) displayed rapid killing kinetics in 
minimal media. We chose to study the remaining peptides in the tris acetate buffer 
with a 10-minute incubation time, in order to make results as closely comparable 
to the mechanistic studies presented in the next section of this chapter. Each 
peptide was studied at a final concentration of 1.25 µM in an attempt to distinguish 
the most potent mutants from each other (Figure 2-6). As none of the pyridinyl 
series behaved well in the MIC assay, they were not included in this study. Instead, 
gA3K(iPr) was used as a representative inactive compound. 
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 From this cell killing assay, we observed an unexpected result with regards 
to gA3K(4AMBn). Although this peptide did not perform well in the MIC assay, 
it was one of the best peptides in this assay. Most likely, there is something in the 
LB media used in the MIC assay trapping this peptide due to its higher cationic 
charge. We also used this assay to evaluate whether these peptides can overcome 
serum inhibition, which is much more representative of the in vivo environment, 
compared to gA WT. To do this, we repeated the assay with the most potent 
peptides using buffer that contained 10% v/v human serum in 10 mM tris acetate 
buffer (Figure 2-7). With the exception of gA3K(4AMBn), the activities of these 
peptides were severely inhibited by the presence of human serum. This is, again, 
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Figure 2-6: Cell killing activity of select peptides towards S. aureus. Peptides were 
added at a final concentration of 1.25 µM to S. aureus cells in 10 mM tris acetate buffer 
(pH 7.4) at a density of 5 x 105 cfu/mL. Triplicate samples were incubated for 10 
minutes then diluted 100 times before spreading on a LB agar plate. After overnight 
incubation, the number of colonies formed on each plate were counted and compared 
to that of an untreated sample to determine percent killing. 
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most likely due to the higher cationic charge of this peptide, resulting in fewer 
non-specific hydrophobic interactions between the peptides and serum proteins. 
 
2.3.2 Antimicrobial Activity Towards Gram-Negative Bacteria 
 It is generally known that gA and closely related peptides will not be active 
towards gram-negative species of bacteria. This is thought to be because of the 
additional challenge presented by the outer membrane. However, after observing 
the interesting activity of gA3K(4AMBn), we hypothesized that this type of 
structure might allow for gram-negative activity. As such, we chose to study the 
activity of this peptide towards gram-negative relevant species. In order to directly 
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Figure 2-7: Cell killing activity of select peptides towards S. aureus in the presence of 
human serum. Peptides were added at a final concentration of 1.25 µM to S. aureus cells 
in 10 mM tris acetate buffer (pH 7.4) with 10% v/v human serum at a density of 5 x 105 
cfu/mL. Triplicate samples were incubated for 10 minutes then diluted 100 times 
before spreading on a LB agar plate. After overnight incubation, the number of colonies 
formed on each plate were counted and compared to that of an untreated sample to 
determine percent killing. 
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analyze the role of the extra charge, we also studied the activity of gA3K(Bn) (Table 
2-5). 
Table 2-5:  Measured MICs (μM) gA Mutants towards Various Gram-negative Bacteria 
  E. coli K. pneumoniae P. aeruginosa  
 gA3K(Bn) 10 >25[a] (72 ± 11%) >12.5 (28 ± 15%)  
 gA3K(4AMBn) 10 10 12.5  
 MIC values are determined as the lowest concentration where no 
bacteria growth is observed.  Peptides which had potent activity 
(MIC <10 μM) were run twice with triplicate samples in each to 
confirm activity. [a] For those peptides which did not achieve full 
killing at the maximum concentration, percent inhibition is given in 
parentheses with error given as the standard deviation between 
triplicate samples. 
 
 We first tested the peptides’ activities towards Escherichia coli, as it was 
readily available in the lab and traditionally serves as a good model system. We 
found that both peptides had relatively potent activity with MICs of 10 µM. With 
these preliminary results, we chose to examine other gram-negative species and 
purchased strains of Klebsiella pneumoniae and Pseudomonas aeruginosa. These two 
species were selected as both of them are part of the ESKAPE pathogens, which 
are the bacteria with resistant strains considered to be the most threatening by 
WHO. We were happy to see that gA3K(4AMBn) was able to maintain similar 
potency with both of these important pathogens, even though gA3K(Bn) did not. 
Similar to the work done with S. aureus, we wanted to establish a way to 
differentiate the activities of similar peptides towards E. coli. Considering our 
hypothesized mechanism of action, we expected that the peptides would require 
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a longer incubation time in the cell killing assay. Consequently, we chose to switch 
to using a M9 minimal media supplemented with 0.20% sodium succinate as the 
carbon source, which has been reported to maintain cell viability with limited 
growth for as long as 24 hours.21 We monitored the cell killing ability of 
gA3K(4AMBn) at 10 µM for E. coli in this M9 media (Figure 2-8). We observed 
nearly complete killing after 2 hours with the cell density of the untreated sample 
maintaining good viability up to 3 hours. As such, we chose to use an incubation 
of 2 hours for further studies. 
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Figure 2-8: Bactericidal activity of gA3K(4AMBn) with E. coli. Time dependent activity 
with gA3K(4AMBn) at 10 µM towards E. coli in M9 minimal media with 0.20% sodium 
succinate. The untreated sample (blue) maintains similar cell counts after two hours 
while the gA3K(4AMBn) treated sample (red) shows nearly complete killing after 2 
hours. 
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 Using these conditions, we studied other peptides from this gA series 
(Figure 2-9). In this assay, both gA3K(Cy) and gA3K(CyMe) performed with 
potency close to that of gA3K(Bn). Interestingly, even though they had the same 
MIC for E. coli, gA3K(4AMBn) was much more potent than gA3K(Bn) in this 
experiment. The results of this assay suggest that the alkylated lysines are crucial 
for this observed activity towards gram-negative bacteria, as gA3K performed 
near the same potency as our negative control. 
 
2.3.3 Toxicity of gA Mutants Towards Human Red Blood Cells 
 Keeping in mind that our goal in designing this series of peptides was to 
enhance potency while maintaining selectivity, we needed to evaluate any change 
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Figure 2-9: Cell killing of select gA mutants towards E. coli. Peptides were added at a 
final concentration of 10 µM to E. coli cells in M9 minimal media with 0.20% sodium 
succinate (pH 7.4) at a density of 5 x 105 cfu/mL. Triplicate samples were incubated for 
2 hours then diluted 100 times before spreading on a LB agar plate. After overnight 
incubation, the number of colonies formed on each plate were counted and compared 
to that of an untreated sample to determine percent killing. 
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in toxicity that we had caused with these mutations. One of the quickest and most 
straightforward ways to do this is by measuring a peptide’s activity with human 
red blood cells (hRBCs). Not having a nucleus or other organelles, hRBCs can be 
thought of as a complex model membrane system that has an accurate composition 
for mammalian plasma membranes. Additionally, being rich in UV-active 
hemoglobin, hRBCs have an inherent reporter for membrane permeabilization. 
 To measure the hemolytic activity of the peptides,22 hRBCs are suspended 
in PBS buffer (pH 7.4) and treated with the same final concentration of peptides as 
in the bacterial MIC assay. After one hour of incubation at 37°C, the samples are 
centrifuged and an aliquot of the supernatant is added to a 96-well plate; final 
samples are diluted two-fold with DI water to prevent signal saturation. To 
determine the percent hemolysis that has occurred, a separate sample is prepared 
with the addition of 1% Triton-X100 to fully lyse the cells. This sample is then set 
as 100% hemolysis and the peptide treated samples are scaled accordingly (Figure 
2-10). HC50s are reported as the concentration of peptide that results in the leakage 
of 50% of the total hemoglobin. 
This data shows that some of the more potent peptides, namely gA3K(Bn) 
and gA3K(CyMe), displayed similar toxicity profiles to gA WT (HC50 = 2.5 µM). 
However, gA3K(Cy) was found to be about five-fold less toxic than gA WT; having 
similar bacterial potencies, this would allow gA3K(Cy) to be a more selective 
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peptide compared to gA WT. Additionally, gA3K(4AMBn) showed improved 
toxicity compared to gA3K. These two examples demonstrate our ability to tune 
potency of gA3K mutants without significantly increasing human toxicity. 
 
 
2.4 Mechanistic Studies of gA3K Mutants 
Interested in gaining some insight into how and why these peptides possess 
the activities discussed above, we began to perform studies to gain a structure 
activity relationship. With the mechanism of action for gA WT having been well 
studied and widely accepted to be a result of its membrane pore formation, we 
focused on studies that would examine different aspects of this. A cartoon 
demonstrating the critical steps in this mechanism is provided in Figure 2-11. 
Peptide HC50 (µM) 
gA WT 2.5 
gA3K >100 
gA3K(iPr) >10 
gA3K(Cy) 20 
gA3K(CyMe) 3 
gA3K(Bn) 3 
gA3K(2pyr) >10 
gA3K(3pyr) >10 
gA3K(4pyr) >10 
gA3K(4AMBn) >100 
Figure 2-10: Hemolytic activity of gA mutants. Percent hemolysis is calculated 
compared to a fully lysed sample treated with 1% Triton-X100. Error bars represent the 
standard deviation of triplicate samples. HC50 values are provided in the given table. 
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2.4.1 Membrane Binding vs. Cell Killing 
With the first step of the gA mechanism being association with the 
membrane, we sought to design an assay that would allow for the measurement 
of binding to live bacteria cells. A common way of doing this is simply attaching 
a fluorophore to the peptide of interest and measure cell labeling using flow 
cytometry or fluorescence. In our case, there were a few different characteristics 
that kept us from using this strategy. Specifically, there was a lack in 
understanding of the consequences to the peptide’s structure that could come from 
attaching a bulky, hydrophobic structure in the sequence. Overall, this would 
likely lead to inaccurate data on how the peptide is able to insert into the 
membrane. 
Instead, we turned to the intrinsic absorbance and fluorescence of the four 
tryptophans within the gA sequence. With measuring absorbance, we predicted 
Figure 2-11: Depiction of the mechanism of action of gA. 1) Membrane association; 2) 
Membrane insertion as the channel-forming β-helix; 3) Translocation within the 
membrane to form dimer; 4) Disruption of cation gradient across the membrane. 
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to see an increase in tryptophan absorbance with increasing concentrations of 
peptide, as more of it binds to the cell. In the case of fluorescence, the properties 
of tryptophan are known to change based on its local environment, such that the 
fluorescence should increase upon insertion into a hydrophobic membrane. 
Considering these two characteristics, we first attempted to determine the degree 
of binding by measuring the change in either absorbance or fluorescence with the 
addition of peptides to bacteria cultures. Unfortunately, both techniques gave us 
several problems with sensitivity and reproducibility. The cause of most of these 
issues was suspected to come from the presence of other sources of tryptophan 
along with other structures that absorb at 280 nm in our samples. For these 
reasons, we chose to develop a HPLC-based method, such that we could be 
confident the absorbance we focused on was from the gA peptide alone. 
In order to measure the initial binding of each peptide, cells were grown to 
an OD600=0.6, then pelleted and exchanged into a tris-buffered saline solution (10 
mM tris acetate, 150 nM sodium chloride, pH 7.4). This buffer was chosen as it 
contained fewer components than either LB media or other common buffers, 
which would decrease the complication of the sample components when 
analyzing by LC/MS. After diluting to a final density of 5x105 cfu/mL, triplicate 
samples were treated with each peptide at a final concentration of 1.25 µM and 
incubated for 10 minutes. We chose to use this concentration as it was below the 
MIC for all studied peptides and therefore cell death was expected to cause little 
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interference. After this incubation period, cells were spun down at max speed and 
an aliquot of the supernatant was removed to be run on LC/MS. As a standard, 
samples were prepared under the same conditions without any cells. 
Initial optimization of conditions showed that gA WT was too hydrophobic 
to be analyzed in this way; it was thus eliminated from this study. Optimization 
also showed that the LC/MS system was not sensitive enough to distinguish the 
small changes in concentration we were expecting. To solve this problem, we 
chose to lyophilize the supernatant samples, allowing us to concentrate them by 
10-fold before analysis. As we were increasing the final concentration of the 
peptide, we redissolved each sample in a 1:1 ratio of water to acetonitrile, to ensure 
differences in solubility would not skew our analysis. Finally, in order to get full 
recovery of the peptides from the lyophilized sample, we eliminated the sodium 
chloride from our assay buffer. This was due to the observation that peptides from 
standard samples were not being fully recovered after lyophilization due to poor 
solubility of sodium chloride. 
Having observed a linear relationship between peak area and peptide 
concentration with our standards, we compared the peak area of each sample to 
that of the standard for a given peptide. As this would give us the concentration 
of the peptide that had been in the supernatant, the concentration of peptide 
bound to the cells was then considered to be the difference between the total 
concentration of peptide and the concentration found in the supernatant. By 
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comparing this to the total amount of peptide, a percent binding can be reported 
(Table 2-6). 
Table 2-6: Measured of Binding for gA Mutants 
Peptide % Bound – S. aureus % Bound – E. coli 
gA3K 49 ± 4.2 88 ± 7.7 
gA3K(iPr) 41 ± 0.63 N/A 
gA3K(Cy) 44 ± 3.3 58 ± 5.1 
gA3K(CyMe) 54 ± 5.1 49 ± 0.8 
gA3K(Bn) 65 ± 3.6 61 ± 9.2 
gA3K(2pyr) 43 ± 2.9 N/A 
gA3K(3pyr) 50 ± 1.3 N/A 
gA3K(4pyr) 52 ± 3.4 N/A 
gA3K(4AMBn) 61 ± 8.7 68 ± 6.7 
gA3K(L,D,D) 17 ± 30. None* 
* Negative value obtained for this peptide 
 This data shows that all of the peptides have relatively similar binding for 
both species tested, such that no trend can be observed between the MIC and 
binding. This is demonstrated further when comparing the degree of cell killing to 
that of binding (Figure 2-12). Without being able to confirm any correlation 
between cell binding and antimicrobial activity, we moved on to consider what 
occurs after membrane association that could be leading to this differentiation in 
activity. 
2.4.2 Measuring Membrane Permeability 
 Considering the steps following binding in the mechanism of action of gA 
(Figure 2-11), we imagined that membrane permeability (step 4) would be the most 
straightforward to measure directly in live cells. Additionally, given that the 
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membrane association of the peptides are relatively the same, measuring the 
degree of permeabilization can provide information on the net difference of the 
later steps. As of now, techniques have been developed that can look at the gA 
conformations and dimerization in model systems; in fact, a few of the mutants 
described here were studied using such a technique in collaboration with Prof. 
Figure 2-12: Comparing cell binding with cell killing activities of select gA mutants. 
Cell binding (red) and cell killing (blue) activities of gA mutants against A) S. aureus 
and B) E. coli. * Some negative values were found for this peptide and were considered 
to represent no binding. 
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David Russell’s lab at Texas A&M University.23  However, these have yet to be 
applied to in vitro systems. 
 Several options were considered and studied, including monitoring the β-
galactosidase activity on cell impermeable galactosides, but in the end, we found 
flow cytometry to provide the most reliable data. For this, we examined cell 
staining with propidium iodide (PI). PI is a fluorescent dye which intercalates with 
nucleic acids. As it is not membrane permeable, it is only able to stain cells which 
have compromised membranes. By treating our samples with PI followed by flow 
cytometry analysis, we were able to distinguish cells with and without membrane 
permeability. Comparing the number of cells in both of these populations, we 
were able to determine the degree to which treatment with different peptides 
created membrane disruption. 
 Samples of S. aureus and E. coli were prepared using the same conditions as 
their respective cell killing assays. After incubation was complete, PI was added 
to a final concentration of 0.2 µg/mL. The samples were then analyzed by flow 
cytometry, gating for forward and side scattering based on an untreated cell 
sample. Fluorescence was recorded for the cells within this gate and plotted as 
histograms (Figure 2-13). A clear division into two populations was observed, 
defined by the negative and positive controls. Those cells within the non-
fluorescent population were considered to have maintained membrane integrity 
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while those observed to be fluorescent were considered to have compromised 
membranes. 
 
 The flow cytometry data for S. aureus demonstrates that all peptide treated 
samples have nearly identical degrees of membrane permeabilization. This would 
suggest that membrane integrity cannot be used as a measure for a defined 
structure activity relationship. On the other hand, a clear trend can be seen for the 
E. coli samples that agrees with that which was observed from the cell killing assay. 
This agrees with the suggestion that peptides must reach the inner membrane of 
the gram-negative bacteria to achieve cell killing, as the samples with the highest 
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Figure 2-13: Flow cytometry analysis of cell permeability of select gA mutants. 
Histogram of PI fluorescence for A) S. aureus and B) E. coli cells treated with various 
peptides. Cells suspended in 70% isopropanol (IPA) in water were used as a positive 
control. The two populations are shown with double-headed arrows with the 
percentage of cells listed above. Histograms display averages of three samples for each 
peptide. 
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cell staining also have the best cell killing activity. It can then be suggested from 
this data that peptides with better membrane permeabilization in gram-negative 
cells will be more potent against these bacteria. 
2.5 Conclusions 
 In summary, we have demonstrated that the use of alkylated lysines in the 
gramicidin A structure is an effective strategy to improve upon potency and 
selectivity of this family of peptides. This work led to the first observation of a gA 
peptide, namely gA3K(4AMBn), with potent activities against several important 
gram-positive and gram-negative bacteria. Our efforts towards a mechanistic 
understanding of these peptides demonstrated that potency cannot be estimated 
by membrane association, but rather there is a clear correlation between peptide-
induced membrane permeability and cell killing in E. coli. Considering both of 
these observations, it would appear that less potent peptides most likely fail to 
either fold into the proper structure after membrane association or cannot 
efficiently travel through the lipid bilayer for dimerization. 
 Taking into consideration all of the results presented above, several 
peptides have displayed appealing characteristics for their development as 
antibiotics. Specifically, gA3K(Cy) and gA3K(4AMBn) both exhibit preferred 
selectivity for bacteria with much less toxicity towards hRBCs. Finally, while still 
more toxic than desired, gA3K(Bn) has an attractive broad-spectrum activity, 
which may allow it to be a more effective topical agent. 
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2.6 Experimental Procedures 
2.6.1 General Methods 
Fmoc-Trp-Wang resin and all Fmoc-protected amino acids were purchased from 
either Advanced Chemtech (Louisville, KY) or Chem Impex Int. Inc. (Wood Dale, 
IL). Unprotected valine and other chemicals were obtained from Sigma-Aldrich or 
Fisher unless otherwise indicated. Tert-butyl 4-formylbenzyl carbamate was 
purchased from Astatech Inc. (Bristol, PA). Peptide synthesis was carried out on a 
Tribute peptide synthesizer (Protein Technologies, Tucson, AZ). 1HNMR data 
were collected on a VNMRS 500 MHz or 600MHz NMR spectrometer, as indicated. 
Mass spectrometry data were generated by using an Agilent 6230 LC TOF mass 
spectrometer or obtained from the Boston College Mass-Spectrometry facility. The 
peptide concentration of all samples used in this study was determined by 
measuring their absorbance at 280 nm (ε = 22760 M-1cm-1 total of four tryptophan 
residues) on a Nanodrop 2000c UV/Vis spectrometer by cuvette. Gram-positive 
Bacillus subtilis (ATCC 663) and Staphylococcus aureus (ATCC 6538) were purchased 
as lyophilized cell pellets from Microbiologics (Cloud, MN). Gram-positive 
methicillin-resistant S. aureus (MRSA, ATCC 43300), Klebsiella pneumoniae (ATCC 
4352) and Pseudomonas aeruginosa (ATCC 27853) were purchased from ATCC 
(Manassas, VA). Gram-negative E. coli (BL21) was a gift from the lab of Prof. Mary 
F. Roberts at Boston College.  
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2.6.2 Synthesis of Unnatural Amino Acids 
Fmoc-D-Lysine(Bn)(Boc)-OH: Fmoc-D-lysine hydrochloride (1 eq, 4.94 mmol, 
2.0g) was dissolved in 200 proof ethanol (40 mL) and stirred with 
3Å molecular sieves. To this, freshly distilled benzaldehyde (1.2 
eq, 5.93 mmol, 0.629 g) was added. This mixture was allowed to 
stir for 1 hour before sodium cyanoborohydride (1.2 eq, 5.93 
mmol, 0.3725 g) was added. This was allowed to stir overnight. The mixture was 
acidified by adding 0.5 N aqueous hydrochloric acid dropwise to reduce any 
excess sodium cyanoborohydride. The mixture was decanted from the molecular 
sieves and the solvent was removed by rotary evaporation. The dried mixture was 
resuspended in acetone and centrifuged to remove borohydride salts. The 
supernatant was decanted from the pellet and the acetone was removed by rotary 
evaporation to give a white solid. The solid was dissolved in a 1:1 v/v 
water/tetrahydrofuran solution (30 mL) and put in an ice bath. This was allowed 
to stir as enough sodium bicarbonate was added to bring the pH of the solution to 
~8-9 (3.0 eq, 15 mmol, 1.26 g). To this mixture, di-tert-butyl dicarbonate (1.2 eq, 
6.00 mmol, 1.31 g) was added. The reaction was stirred in the ice bath for 30 min 
then allowed to stir overnight at room temperature. After 20 hours, the reaction 
showed to be incomplete, at which point an additional equivalent of di-tert-butyl 
dicarbonate (1.0 eq, 4.94 mmol, 1.078 g) and additional sodium bicarbonate to 
return the pH to ~8-9 (2.5 eq, 12.35 mmol, 1.04 g) were added with 20 mL of the 
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reaction solvent. This was stirred for an additional 15 hours. When the reaction 
was done, the mixture was first extracted with diethyl ether (2 x 75 mL). After the 
extraction, the aqueous layer was acidified with 2N hydrochloric acid to a pH of 
~6. This was then extracted with dichloromethane (3 x 75 mL). All organic layers 
were collected and washed with brine (1 x 350 mL) and dried over sodium sulfate. 
The product was purified by silica gel chromatography (1:1 ethyl acetate/hexanes 
with 1% by volume acetic acid) and the desired product was obtained as a white 
solid. Yield: 1.1827 g (42.9% yield). NMR: δ H (500 MHz, Methanol-d4) 7.77 (2 H, 
d, J 7.6), 7.66 (2 H, dd, J 10.3, 7.5), 7.36 (2 H, td, J 7.5, 2.8), 7.32 – 7.26 (4 H, m), 7.25 
– 7.17 (3 H, m), 4.41 (2 H, s), 4.34 (2 H, dd, J 7.1, 2.6), 4.20 (1 H, t, J 7.0), 4.12 (1 H, 
dd, J 9.4, 4.7), 3.27 – 3.10 (2 H, m), 1.88 – 1.75 (1 H, broad m), 1.72 – 1.59 (1 H, broad 
m), 1.57 – 1.29 (13 H, m); δ C (126 MHz, cd3od) 174.45, 157.23, 143.92, 141.16, 
128.13, 127.35, 126.74, 126.72, 124.82, 119.49, 79.83, 66.51, 53.72, 46.14, 30.94, 27.31, 
22.78. Calculated Mass: 558.27; ESI+ Mass Found: 559.28 [M+H]+. 
Fmoc-D-Lysine(iPr)(Boc)-OH: Fmoc-D-lysine hydrochloride (1 eq, 4.94 mmol, 
2.0g) was suspended in acetone (250 mL), which had been dried 
over sodium sulfate for 90 min, and stirred with 3Å molecular 
sieves for one hour. To this, sodium cyanoborohydride (1.1 eq, 
5.48 mmol, 0.3443 g) was added. This was allowed to stir for another hour. 
Methanol was added to dissolve any product that had crashed out of solution 
before the mixture was filtered to remove the molecular sieves. The solvent was 
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removed by rotary evaporation to produce a cream-colored solid. The solid was 
dissolved in a 1:1 mixture by volume water/tetrahydrofuran (50 mL) and stirred 
in an ice bath. To this, sodium bicarbonate was added to bring the pH to ~8-9 (3.0 
eq, 14.82 mmol, 1.24 g) followed by the di-tert-butyl dicarbonate (1.2 eq, 5.93 mmol, 
1.29 g). This was allowed to stir in the ice bath for 30 min then stirred at room 
temperature for two days. This was first concentrated by rotary evaporation to 
remove the THF. To the aqueous mixture, DCM (50 mL) was added. While stirring, 
2N HCl was added dropwise until the pH was ~3. The mixture was extracted once, 
then again with DCM (50 mL) and the organic layers were combined. The organic 
layer was washed with brine (1x100 mL) and dried over sodium sulfate. The final 
mixture was dried by rotary evaporation. The final product was obtained as a 
white solid after silica gel column purification (5% methanol, 1% acetic acid in 
DCM). Yield: 1.7629 g (69.8%). NMR: δ H (500 MHz, Methanol-d4) 7.79 (2 H, d, J 
7.5), 7.72 – 7.64 (2 H, m), 7.38 (2 H, t, J 7.5), 7.30 (2 H, td, J 7.5, 1.1), 4.34 (2 H, qd, J 
10.6, 7.1), 4.22 (1 H, t, J 7.1), 4.14 (1 H, dd, J 9.3, 4.7), 4.06 – 3.92 (1 H, broad m), 3.16 
– 3.01 (2 H, broad m), 1.94 – 1.80 (1 H, broad m), 1.76 – 1.65 (1 H, broad m), 1.64 – 
1.49 (2 H, broad m), 1.44 (9 H, s), 1.41 – 1.33 (2 H, m, broad), 1.13 (6 H, d, J 6.8); δ 
C (126 MHz, cd3od) 174.59, 157.27, 155.76, 143.74, 141.17, 127.63, 127.07, 126.43, 
124.40, 119.47, 79.35, 66.54, 53.92, 46.88, 31.02, 27.50, 27.14, 23.07, 19.49. Calculated 
Mass: 510.27 ESI+ Mass Found: 511.28 [M+H]+. 
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Synthesis of Fmoc-D-Lysine(2-pyr)(Boc)-OH: Fmoc-D-lysine hydrochloride (1 eq, 
4.94 mmol, 2.0g) was dissolved in 200 proof ethanol (15 mL) and 
stirred with 3Å molecular sieves. To this, 2-pyridine 
carboxaldehyde (1.5 eq, 7.41 mmol, 0.794 g) was added. This 
mixture was allowed to stir for 1 hour before sodium 
cyanoborohydride (1.5 eq, 7.41 mmol, 0.466 g) was added. This was allowed to stir 
overnight. The solution was acidified to pH ~3-4 using 2N HCl and decanted from 
the molecular sieves. The solvent was removed by rotary evaporation and a solid 
was obtained. The crude solid was dissolved in 30% THF in saturated sodium 
bicarbonate (150 mL) and stirred as di-tert-butyl dicarbonate (dissolved in 1 mL of 
THF) was added. This was allowed to stir for two hours and confirmed to be 
complete by TLC. The THF was removed by rotary evaporation. To the aqueous 
mixture, ethyl acetate (100 mL) was added. This was stirred as the mixture was 
acidified to pH ~3-4 using 2N HCl. The organic layer was removed and the 
aqueous layer was extracted with ethyl acetate (100 mL). The organic layers were 
combined and washed with brine (100 mL) then dried over sodium sulfate. The 
white solid obtained was purified by silica gel column purification (4:3:1 
hexanes/ethyl acetate/ethanol with 1% by volume acetic acid). Yield: 0.3317 g 
(12% yield). NMR: δ H (500 MHz, Acetone-d6) 8.50 (1 H, d, J 4.9), 7.85 (2 H, d, J 
7.5), 7.80 – 7.65 (3 H, m), 7.40 (2 H, t, J 7.5), 7.36 – 7.19 (4 H, m), 4.52 (2 H, s), 4.33 (2 
H, d, J 7.2), 4.24 (2 H, t, J 7.1), 3.33 (2 H, d, J 29.2), 1.91 (1 H, d, J 12.8), 1.84 – 1.71 (1 
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H, m), 1.67 – 1.54 (2 H, m), 1.52 – 1.26 (11 H, m); δ C (126 MHz, cd3od) 174.46, 
157.23, 148.26, 143.93, 143.75, 141.16, 137.43, 127.34, 126.74, 126.72, 126.30, 124.86, 
124.82, 119.48, 66.51, 53.81, 52.06, 51.99, 51.26, 48.09, 47.00, 30.97, 27.47, 27.39, 27.26, 
27.24, 27.15, 22.80. Calculated Mass: 559.27; ESI+ Mass Found – 560.28 [M+H]+. 
Fmoc-D-Lysine(3-pyr)(Boc)-OH: Fmoc-D-lysine hydrochloride (1 eq, 4.94 mmol, 
2.0g) was dissolved in 200 proof ethanol (15 mL) and stirred with 
3Å molecular sieves. To this, 3-pyridine carboxaldehyde (1.2 eq, 
5.93 mmol, 0.6349 g) was added. This mixture was allowed to stir 
for 1 hour before sodium cyanoborohydride (1.2 eq, 5.93 mmol, 
0.3725 g) was added. This was allowed to stir overnight. The solution was acidified 
to pH ~3-4 using 5% aqueous HCl and decanted from the molecular sieves. The 
solvent was removed by rotary evaporation and a solid was obtained. The mixture 
was dissolved in saturated sodium bicarbonate (100 mL). While stirring, di-tert-
butyl dicarbonate was added (1.1 eq, 5.36 mmol, 1.171 g, dissolved in 2 mL THF). 
This was allowed to stir for six hours. The mixture was then acidified using 1N 
HCl to a pH of ~2. This was then extracted with DCM (3x150 mL). The organic 
layers were combined and washed with brine (1x300 mL) and dried over sodium 
sulfate. The solvent was removed by rotary evaporation to provide a white solid. 
The final product was obtained as a white solid after silica gel column purification 
(5% methanol and 1% acetic acid by volume in DCM). Yield: 0.5687 g (20.6% yield). 
NMRs: δ H (600 MHz, Acetone-d6) 8.51 (2 H, d, J 34.6), 7.92 – 7.61 (5 H, m), 7.46 – 
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7.21 (5 H, m), 4.48 (2 H, s), 4.38 – 4.28 (m, 1H), 4.27 – 4.19 (2 H, m), 3.27 (2 H, d, J 
40.8), 1.95 – 1.84 (1 H, m), 1.81 – 1.69 (1 H, m), 1.63 – 1.26 (13 H, m); δ C (126 MHz, 
cd3od) 174.49, 157.24, 147.48, 147.25, 143.92, 143.77, 143.73, 141.17, 141.14, 127.63, 
127.08, 127.04, 127.03, 126.44, 126.42, 124.15, 123.63, 123.61, 119.48, 80.21, 66.52, 
53.80, 30.98, 27.50, 27.14, 26.97, 22.74. Calculated Mass: 559.27; ESI+ Mass Found – 
560.28 [M+H]+. 
Fmoc-D-Lysine(4-pyr)(Boc)-OH: Fmoc-D-lysine hydrochloride (1 eq, 6.175 mmol, 
2.5 g) was dissolved in 200 proof ethanol (200 mL) and stirred 
with 3Å molecular sieves as diisopropyl ethylamine (1.0 eq, 6.175 
mmol, 1.10 mL) was added. This caused a chloride salt to crash 
out of solution. To this, 4-pyridine carboxaldehyde (1.5 eq, 9.263 
mmol, 1.137 g) was added. This mixture was allowed to stir for 1 hour before 
sodium cyanoborohydride (1.2 eq, 5.93 mmol, 0.3725 g) was added. This was 
allowed to stir overnight. The mixture was acidified using 1N HCl to a pH of ~2-
3. This was then decanted from the sieves and concentrated by rotary evaporation 
to obtain a yellow solid. The crude solid was dissolved in a 1:1 mixture of water 
and THF (100 mL). To this, sodium bicarbonate (12.0 eq, 74.1 mmol, 6.225 g) was 
added to reach a pH of ~9-10. While stirring, di-tert-butyl dicarbonate (2.0 eq, 12.35 
mmol, 2.695 g) was added. This was stirred overnight. To the mixture, ethyl acetate 
(100 mL) was added and the solution was then acidified using 5% aqueous HCl 
until a pH of ~2 was reached. The organic layer was removed and the aqueous 
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layer was extracted with ethyl acetate (2x100 mL). The organic layers were 
combined and washed with brine (1x200 mL). The final organic solution was dried 
over sodium sulfate and then concentrated to provide a yellow solid. Silica gel 
column purification was run twice. First using 4:3:1 hexane/ethyl acetate/ethanol 
with 1% by volume acetic acid. The product, collected with about 15% impurity, 
was further purified using 25% toluene, 25% of 3:1 ethyl acetate/ethanol, 49% 
hexane and 1% acetic acid by volume. The final product was obtained as a yellow 
solid. Yield: 0.3519 g (10.2% yield). NMRs: δ H (500 MHz, Methanol-d4) 8.52 – 8.38 
(2 H, m), 7.77 (2 H, d, J 7.5), 7.70 – 7.55 (2 H, m), 7.37 (2 H, t, J 7.5), 7.32 – 7.22 (4 H, 
m), 4.46 (2 H, s), 4.33 (2 H, dd, J 7.0, 3.8), 4.20 (1 H, t, J 7.0), 4.14 (1 H, dd, J 9.4, 4.6), 
3.28 – 3.18 (2 H, m), 1.89 – 1.79 (1 H, m), 1.73 – 1.63 (1 H, m), 1.60 – 1.52 (2 H, m), 
1.51 – 1.30 (11 H, m); δ C (126 MHz, cd3od) 174.77, 157.19, 148.61, 143.92, 141.16, 
128.91, 126.72, 124.85, 122.47, 119.49, 80.26, 66.51, 53.91, 31.08, 27.22, 27.16, 23.48, 
22.73. Calculated Mass: 559.27; ESI+ Mass Found – 560.28 [M+H]+. 
Fmoc-D-Lysine(CyMe)(Boc)-OH: Fmoc-D-lysine hydrochloride (1 eq, 3.70 mmol, 
1.5 g) was dissolved in dry methanol (15 mL) and stirred with 3Å 
molecular sieves. To this, cyclohexane carboxaldehyde (1.2 eq, 
4.45 mmol, 0.4987 g) was added. This mixture was allowed to stir 
for 1 hour before sodium cyanoborohydride (1.2 eq, 4.45 mmol, 
0.2800 g) was dissolved in dry methanol (8 mL) and added to the mixture. This 
was allowed to stir overnight. The mixture was acidified with 1N HCl to pH ~2-3 
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and decanted from the sieves. The solvent was removed by rotary evaporation to 
obtain a solid. The crude solid was dissolved in a 1:1 mixture of water and THF 
(100 mL). To this, sodium bicarbonate (3 eq, 11.1 mmol, 0.9324 g) was added to 
bring the pH to ~8-9. While stirring, di-tert-butyl dicarbonate (1.2 eq, 4.45 mmol, 
0.9712 g) was added. This was allowed to stir overnight. The THF was removed 
by rotary evaporation. To the aqueous mixture, ethyl acetate (50 mL) was added. 
While stirring, the mixture was acidified using 2N HCl to pH ~2-3. The organic 
layer was separated and the aqueous mixture was extracted with ethyl acetate 
(2x50 mL). The organic layers were combined and washed with brine (1x200 mL). 
The organic layer was then dried over sodium sulfate. The crude solid was 
obtained as a white solid after removing the solvent by rotary evaporation. Pure 
product was obtained as a white solid after silica gel column purification (4:3:1 
hexane/ethyl acetate/ethanol with 1% acetic acid by volume). Yield: 0.5713 g 
(27.3% yield). δ H (500 MHz, Methanol-d4) 7.79 (2 H, d, J 7.5), 7.67 (2 H, t, J 8.2), 
7.38 (2 H, t, J 7.5), 7.30 (2 H, td, J 7.5, 1.1), 4.34 (2 H, d, J 7.8), 4.22 (1 H, t, J 7.1), 4.15 
(1 H, dd, J 9.2,4.3), 3.24 – 3.09 (2 H, m), 3.01 (2 H, d, J 7.1), 1.93 – 1.81 (1 H, m), 1.74 
– 1.51 (9 H, m), 1.43 (9 H, s), 1.40 – 1.34 (2 H, m), 1.31 – 1.10 (4 H, m), 0.95 – 0.82 (2 
H, m); δ C (126 MHz, cd3od) 174.49, 157.26, 156.26, 143.90, 141.16, 127.35, 126.74, 
124.84, 119.49, 79.31, 66.57, 53.72, 52.98, 52.61, 47.07, 36.64, 30.99, 30.63, 30.50, 27.34, 
26.19, 25.62, 22.81. Calculated Mass: 564.32; ESI+ Mass Found – 565.33 [M+H]+. 
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Fmoc-D-Lysine(Cy)(Boc)-OH: Fmoc-D-lysine hydrochloride (1 eq, 3.71 mmol, 1.51 
g) was dissolved in 200 proof ethanol (15 mL) and stirred with 
3Å molecular sieves. To this, cyclohexanone (2.0 eq, 7.42 mmol, 
0.7291 g) was added. This mixture was allowed to stir for 1 hour 
before sodium cyanoborohydride (1.2 eq, 4.46 mmol, 0.2800 g) was added to the 
mixture. This was allowed to stir overnight. The mixture was acidified with 5% 
aqueous HCl to pH ~3-4 and decanted from the sieves. The solvent was removed 
by rotary evaporation to obtain a solid. The crude solid was dissolved in a 1:1 
mixture of water and THF (20 mL). To this, sodium bicarbonate (3.1 eq, 11.4 mmol, 
0.9610 g) was added to bring the pH to ~8-9. To this, di-tert-butyl dicarbonate (3.1 
eq, 11.5 mmol, 2.5074 g) was added. This was allowed to stir overnight. To the 
mixture, DCM (25 mL) was added. The mixture was acidified using 5% aqueous 
HCl to pH ~3. The DCM was removed and the aqueous layer was extracted with 
DCM (25 mL). The combined organic layers were washed with brine (1x50 mL) 
and then dried over sodium sulfate. The solvent was removed by rotary 
evaporation to provide a solid. The crude solid was purified by silica gel column 
chromatography (25% toluene, 25% of 3:1 ethyl acetate/ethanol, 49% hexane, 1% 
acetic acid) to yield the final product as a white solid. Yield: 0.4516 g (22.1% yield). 
NMR: δ C (126 MHz, cd3od) 174.52, 157.26, 155.83, 143.76, 141.16, 127.35, 126.72, 
124.82, 119.49, 79.36, 66.58, 53.68, 48.08, 46.99, 31.00, 27.39, 25.77, 25.15, 23.04. 
Calculated Mass: 550.30; ESI+ Mass Found – 551.33 [M+H]+. 
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Fmoc-D-Lysine(4AMBn)(Boc)-OH: Fmoc-D-lysine hydrochloride (1 eq, 2.47 
mmol, 1.0g) was dissolved in 200 proof ethanol (25 mL) and 
stirred with 3Å molecular sieves. To this, tert-butyl 4-
formylbenzyl carbamate (1.2 eq, 2.96 mmol, 0.6973 g) was 
added. This mixture was allowed to stir for 1 hour before 
sodium cyanoborohydride (1.2 eq, 2.96 mmol, 0.1862 g) was 
added. This was allowed to stir overnight. After decanting from the molecular 
sieves, the mixture was acidified by adding 5% aqueous hydrochloric acid 
dropwise to reduce any excess sodium cyanoborohydride. Removing the solid by 
rotary evaporation provided an off-white solid. The crude solid was dissolved in 
a 1:1 mixture of water and THF (130 mL) and stirred as sodium bicarbonate (6 eq, 
14.82 mmol, 1.250 g) was added to bring the pH to ~8-9. To this, di-tert-butyl 
dicarbonate was added and the mixture was allowed to stir for 6 hours. The THF 
was removed by rotary evaporation. To the aqueous solution, ethyl acetate (200 
mL) was added. This was then acidified using 1N HCl to a pH of ~2-3. The ethyl 
acetate was removed and the aqueous solution was extracted with ethyl acetate 
(2x200mL). The combined organic layers were washed with brine (1x500mL) and 
dried over sodium sulfate. The solvent was removed by rotary evaporation to 
provide a white solid. The final product was obtained after purification by 
preparative HPLC. Yield: 0.4885 g (28.8% yield). NMRs: δ H (500 MHz, Methanol-
d4) 7.78 (2 H, d, J 7.4), 7.66 (2 H, dd, J 10.6, 7.5), 7.37 (2 H, tt, J 7.4, 3.9), 7.32 – 7.26 
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(2 H, m), 7.25 – 7.14 (4 H, m), 4.43 – 4.32 (4 H, m), 4.24 – 4.16 (3 H, m), 4.10 (1 H, 
dd, J 9.3, 4.6), 3.23 – 3.10 (2 H, m), 1.84 – 1.75 (1 H, broad m), 1.70 – 1.60 (1 H, broad 
m), 1.53 – 1.32 (22 H, m); δ C (126 MHz, cd3od) 174.49, 157.23, 143.92, 141.16, 
138.59, 134.88, 128.91, 127.35, 126.94, 126.74, 124.82, 123.58, 119.49, 119.41, 79.84, 
78.77, 66.51, 53.71, 47.01, 46.17, 43.33, 30.93, 29.71, 27.35, 27.32, 27.23, 26.91, 22.77. 
Calculated Mass: 687.35; ESI+ Mass Found – 688.36 [M+H]+. 
Formyl-L-valine: Synthesis was performed as previously reported by our group.10 
L-Valine (8.35 mmol, 1.0g) was dissolved in formic acid (0.32 mmol, 
12.0 mL) and allowed to stir in an ice bath for 15 minutes. To this, acetic anhydride 
(0.04 mmol, 4.0 mL) was added dropwise. When the addition was complete, the 
ice bath was removed and the reaction was allowed to stir at room temperature 
for 24 hours. The product was recrystallized using ethyl acetate and the product 
was collected as a white solid by vacuum filtration. NMR: δ H (600 MHz, Acetone-
d6) 8.22 (s, 1H), 7.41 (broad m, 1H), 4.50 (m, 1H), 2.22 (m, 1H), 0.98 (m, 6H). 
2.6.3 Peptide Synthesis and Characterization 
Synthesis was performed as previously reported by our group10. All peptides were 
synthesized on Fmoc-Trp-Wang resin (100 mg, 0.500 mmol/g, 0.05 mmol) using 
standard Fmoc/tBu chemistry. Five equivalents of each amino acid were used for 
the coupling reaction with 4.5 equivalents of HBTU. For Fmoc-D-Lys(3pyr)(Boc)-
OH, Fmoc-D-Lys(4pyr)(Boc)-OH and Fmoc-D-Lys(4AMBn)(Boc)-OH), three 
equivalents were used instead of five with 2.25 equivalents of HBTU and the 
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coupling time was extended to 1.5 hours. The peptides were cleaved off the resin 
by treatment with ethanolamine (40% v/v in DMF, 55oC, 5 hours). Then the resin 
was filtered through a medium fritted plastic funnel and rinsed three times with 
DCM and methanol. To precipitate the peptide, six to seven times in volume DI 
water was added. The peptide was collected by centrifugation (14,000 rpm, 1.5 hr) 
and the pellet was dried by lyophilizer to receive the side-chain protected peptide. 
The boc protecting group on D-lysine and L-tryptophan was removed by treating 
the pellet with a mixture of 95% TFA, 2.5% TIS and 2.5% H2O at room temperature 
for two hours. Once the reaction was finished, cold diethyl ether was added to 
precipitate the crude peptide which was again centrifuged (14,000 rpm, 1.5 hours) 
and lyophilized. The crude material was purified by RP-HPLC (Waters Prep LC, 
Jupiter 10 μm C4 300A Column). The identity and purity of each peptide was 
confirmed by LC/MS (Agilent 2630 LC TOF, Phenomenex, Jupiter 5 μm C4 300R 
column) (Table 2-7). All peptides were confirmed to have purity of 95% or higher. 
Table 2-7. Naming Scheme and Mass-spectrometry Characterization of gA Mutants. 
Each amino acid is named according to the functional group added, with the truncated 
structure shown along with the name of each corresponding peptide. 
Peptide m/z Calculated m/z Found 
gA3K(Bn) 2196.24 [M]+ 
733.43 [M+4H]3+, 1099.63 [M+3H]2+, 2198.26 
[M+2H]+ 
gA3K(iPr) 2052.24 [M]+ 
685.42 [M+3H]3+, 1027.63 [M+3H]2+, 2054.25 
[M+2H]+ 
gA3K(CyMe) 2214.38 [M]+ 
739.48 [M+4H]3+, 1108.71 [M+3H]2+, 2216.42 
[M+2H]+ 
gA3K(Cy) 2172.34 [M]+ 
725.48 [M+4H]3+, 1087.72 [M+3H]2+, 2174.44 
[M+2H]+ 
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gA3K(2pyr) 2199.23 [M]+ 
734.43 [M+4H]3+, 1101.12 [M+3H]2+, 2201.24 
[M+2H]+ 
gA3K(3pyr) 2199.23 [M]+ 
551.07 [M+5H]4+, 734.42 [M+4H]3+, 1101.13 
[M+3H]2+ 
gA3K(4pyr) 2199.23[M]+ 
734.42 [M+4H]3+, 1101.12 [M+3H]2+, 2201.24 
[M+2H]+ 
gA3K(4AMBn) 2283.32[M]+ 
572.07 [M+5H]4+, 762.43 [M+4H]3+, 1143.14 
[M+3H]2+, 2285.27 [M+2H]+ 
gA3K(L,D,D) 1926.10[M]+ 643.38 [M+4H]3+, 964.56 [M+3H]2+, 1928.11 [M+2H]+ 
 
2.6.4 Circular Dichroism Spectroscopy with Model Membranes 
Each peptide (0.1 μmol) dissolved in 2,2,2-trifluoroethanol (TFE, 20 μL) was mixed 
with sodium dodecyl sulfate (SDS, 5 μmol) or Fos-phosphatidylcholine-C12 (DPC, 
4 μmol) in water (20 μL). The final samples were diluted to 1 mL with water. The 
samples were transferred into a quartz cuvette and CD spectrum were recorded 
(25◦C, 1 cm path length, scan 190-280 nm with 1 nm step, 10 sec averaging time, 
0.33 sec settling time) on the AVIV model 420 Circular Dichroism Spectrometer 
(Biomedical Inc., Lakewood, NJ). Spectrum of micelles alone were recorded under 
the same conditions and a blank subtraction was done for each peptide. CD spectra 
were replicated and the traces provided were the average of these two trials. The 
wild type peptide has a distinctive positive extreme near 218 nm, corresponding 
to the β-helical conformation of the amide backbone.  In SDS samples, the negative 
control, gA3K(L, D, D), only appeared as a straight line, suggesting no secondary 
structure, and gA3K(CyMe) showed poor structure similarity to gA, with its 
positive extreme being slightly shifted. In the case of gA3K(CyMe), lack of the 
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defined signature was found to be a result of poor solubility in the SDS solution, 
as the sample became cloudy after addition of the peptide but remained clear for 
the other peptides. With its better signature in the sample with DPC micelles, the 
structure was confirmed to not be significantly different from the natural peptide. 
The second positive extreme observed in the wild type sequence appears near 235 
nm and corresponds to the absorbance of the four tryptophans at the C-terminus 
of the peptide. In the studied peptides, this extreme shifted slightly in both 
samples. This reflects the disruption in the local environment of the tryptophans 
caused by the change of neighbouring leucines to the lysine analogues. 
2.6.5 Minimal Inhibitory Concentration Measurements20 
Minimal inhibitory concentrations (MICs) were measured against gram-positive 
Bacillus subtilis (ATCC 663), Staphylococcus aureus (ATCC 6538) and methicillin-
resistant S. aureus (MRSA, ATCC 43300) and gram-negative E. coli (BL21, gift from 
Prof. Mary Roberts), Klebsiella pneumoniae (ATCC 4352) and Pseudomonas aeruginosa 
(ATCC 27853) using the broth microdilution method. Gram-positive bacteria were 
tested in LB media and gram-negative in MH media. Specifically, a single colony 
selected from a LB agar plate was grown overnight in broth at 37℃ with agitation 
and diluted 100 times into fresh broth the next morning. OD600 was monitored 
until a value between 0.5 and 0.6 was reached. The cells were diluted by a factor 
previously determined to a concentration of ~5 x 105 colony forming units per mL 
(cfu/mL). In a sterile 96-well plate, the cell suspension (200 μL) was added to each 
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well. To each well, serial diluted (2-fold) peptides in DMSO (2 μL) were added in 
triplicates. Using a microtiter plate reader (SpectraMax M5, Molecular Devices, 
Sunnyvale, CA), the OD600 was monitored overnight while incubating at 37℃, 
with readings taken every 10 minutes after the plate was shook for 15 seconds. 
Using the time point where OD600 of the blank (untreated) sample began to level 
off, MICs were determined to be the lowest concentration for which cell growth 
was not observed. To confirm this concentration in cases of high background, an 
aliquot was taken from each well and diluted 104 times in fresh broth before being 
spread on LB agar plates (100 μL). This was also done for each blank. After 
overnight incubation of the plates, the MIC was confirmed if no colony growth 
was observed. 
2.6.6 Cell Killing Assay with S. aureus 
A single colony of S. aureus was selected from a LB agar plate and grown overnight 
in LB broth, incubating at 37℃ with agitation. In the morning, an aliquot was taken 
and diluted 100 times in fresh broth. The OD600 was monitored until it reached 
~0.6. This culture was centrifuged (4000 rpm, 5 min) and washed with 10 mM tris 
acetate buffer (pH 7.4) two times. The final cell solution was diluted to ~5 x 105 
cfu/mL in fresh buffer. In a sterile 96-well plate, 200 μL was added to each well. 
To each well, 2 μL of 125μM peptide in DMSO were added in triplicate. The plate 
was incubated for 10 min at 37℃. Aliquots of each sample (10 μL) was diluted into 
fresh buffer (990 μL) and mixed before being spread on LB agar plates. The plates 
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were allowed to incubate at 37℃ overnight. Individual colonies were counted on 
each plate and triplicates were averaged for each peptide. To calculate a percent 
viability, the average number of colonies for each peptide was divided by the 
average number of colonies for blank samples and multiplying by 100. Percent 
killing was then considered to be the percent viability subtracted from 100. 
Experiments were replicated and error was calculated to be the standard deviation 
between percent killing for the six samples. 
2.6.7 Cell Killing Assay with E. coli 
A single colony of E. coli was selected from a LB agar plate and grown overnight 
in LB broth, incubating at 37℃ with agitation. In the morning, an aliquot was taken 
and diluted 100 times in fresh broth. The OD600 was monitored until it reached 
~0.6. This culture was centrifuged (4000 rpm, 5 min) and washed with M9 media 
with 0.20% sodium succinate (pH 7.4) two times. The final cell solution was diluted 
to ~5 x 105 cfu/mL in fresh media. In a sterile 96-well plate, 200 μL of cell 
suspension was added to each well. To each well, 125μM peptide in DMSO (2 μL) 
were added in triplicate. The plate was incubated for two hours at 37℃. Aliquots 
of each sample (10 μL) were diluted into fresh buffer (990 μL) and mixed before 
being spread on LB agar plates. The plates were allowed to incubate at 37℃ 
overnight. Individual colonies were counted on each plate and triplicates were 
averaged for each peptide. To calculate a percent viability, the average number of 
colonies for each peptide was divided by the average number of colonies for blank 
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samples and multiplying by 100. Percent killing was then considered to be the 
percent viability subtracted from 100. Experiments were replicated and error was 
calculated to be the standard deviation between percent killing for the six samples. 
2.6.8 Hemoglobin Release from Human Red Blood Cells22 
Fresh human red blood cells (hRBCs) were centrifuged (3500 rpm, 10 min) and 
washed with sterile PBS buffer until the supernatant was clear. The hRBCs were 
then resuspended and diluted in PBS buffer to a final concentration of 1% v/v and 
used immediately. To sterile Eppendorf tubes, hRBC solution (1.5 mL) was added 
and mixed with serial dilutions (2-fold) of peptides in DMSO or DMSO alone (1.5 
μL). As a positive control, a sample was treated with 1% TritonX-10. The samples 
were incubated at 37℃ for 1 hour and then centrifuged (3500 rpm, 10 min). In a 
sterile 96-well plate, sample supernatant (50 μL) was mixed with fresh Nanopure 
water (50 μL) in triplicate. The absorbance of each sample at 415 nm was recorded. 
The triplicates were averaged and calculated using percentage hemolysis = 100 x 
(A415, peptide – A415, DMSO)/(A415, TritonX-100 – A415, DMSO). 
2.6.9 Binding of gA Mutants to Live Cells 
A single colony of S. aureus or E. coli was grown overnight in LB media while 
incubating at 37℃ with agitation. Cell suspensions were diluted 100 times in fresh 
media the next morning and the OD600 was monitored until a value of ~0.6 was 
obtained. The cell suspension was centrifuged (4000 rpm, 5 min) and washed with 
a 10 mM tris acetate buffer (pH 7.4) two times. After washing, cells were diluted 
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to ~5 x 105 cfu/mL in fresh buffer. The cell suspension was aliquoted (1 mL) into 
sterile Eppendorf tubes to which each peptide at a concentration of 1.25 mM in 
DMSO (1 μL) was added in triplicates, giving the final concentration of 1.25 μM. 
Samples were incubated at room temperature for 10 min then centrifuged (14,000 
rpm, 1 min). 0.5 mL of the supernatant was removed and lyophilized. Once dry, 
50% nanopure water/50% HPLC-grade acetonitrile solution (50 μL) was added to 
each tube. The tubes were sonicated for 10 minutes to ensure full recovery of 
peptide and then centrifuged (14,000 rpm, 10 min) to remove any insoluble salts. 
Samples were analyzed by LC/MS. To determine percent binding, the peak area 
of the triplicate samples was averaged and compared to a corresponding standard. 
Peptide standards were prepared using the same conditions stated above, but 
using buffer that did not contain any cells and also performed in triplicates and 
averaged. By taking the ratio of the averaged sample peak area to the average 
standard peak area x 100, the percent of the peptide remaining in each sample is 
calculated; percent binding is calculated by subtracting this value from 100. 
Experiments were replicated and error is calculated as the standard deviation 
between percent binding of the six individual samples. 
2.6.10 Assessing Cell Permeability Using Flow Cytometry 
Samples of S. aureus and E. coli were subjected to the same conditions as in the 
respective cell killing assays using 1 mL of cell suspension with 1 μL of 1.25 mM 
(for S. aureus) or 10 mM (for E. coli) of peptides dissolved in DMSO. For each 
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sample, a stock solution of PI (0.5 mg/mL in sterile PBS buffer, 0.4 μL) was added 
before the peptide. As a negative control, a blank sample was measured without 
adding any PI. As a positive control, cells were suspended in 70% isopropanol in 
DI water after washing and incubated for 10 minutes at room temperature before 
being diluted to 5 x 105 cfu/mL. Samples were measured on a Bio-Rad S3 Cell 
Sorter (Hercules, CA) and analyzed using FlowJo (Tree Star, Inc.) Samples 
measured of peptides alone showed no significant background except for gA WT. 
To compensate for this, the gA WT samples were gated based on forward and side 
scattering to eliminate the region that the peptide appeared. 
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Chapter 3 
Targeting Lys-PG Based Antibiotic Resistance with 2-Acetylphenyl 
Boronic Acid Presenting Peptides 
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3.1 Introduction 
3.1.1 Bacterial Resistance to Cationic Antimicrobials 
 Similar to small molecule natural products, cationic antimicrobial peptides 
(CAMPs) have suffered from the threats of bacterial resistance. As this class of 
antibiotics typically takes advantage of charge-charge interactions with the 
negatively-charged cell surface of bacteria, resistance mechanisms observed 
include covalent modification of targeted cell surface molecules.1 Through these 
modifications, bacteria decrease their negative charge, thus decreasing the 
energetic favorability of the binding of CAMPs. This has led to several different 
resistance mechanisms in many species (Table 3-1).1–3 
One relevant example of this is observed in gram-negative bacterial 
resistance towards polymyxin B. Polymyxins initially bind the highly anionic 
lipopolysaccharide (LPS), subsequently using the association to cause 
permeabilization of the membrane. To fight against this, bacteria have developed 
different covalent modifications of the lipid A moiety.3 Modifications include the 
addition of phosphoethanolamine (PEtN) and 4-amino-4-deoxy-L-arabinose (L-
Ara4N) to the phosphate groups of Lipid A through an elegant cascade of genes 
being turned on after polymyxin exposure (Figure 3-1). Of these two, the L-
Ara4N modification is not only the most prevalent but also the most effective of 
these, as it completely neutralizes the charge of Lipid A from -1.5 to 0; the 
addition of PEtN only results in a minor shift to -1.0.4 
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 Gram-positive bacteria take a similar approach by modifying negatively 
charged phospholipids in the membrane. Most often, this involves the acylation 
of phosphatidylglycerol (PG) with either lysine or alanine (Figure 3-2).5 Such 
mechanisms have also been implicated in daptomycin resistance, as PG is the 
membrane target of the lipopeptide.6 
Table 3-1: Bacterial Resistance Mechanisms to CAMPs Involving Covalent 
Modifications to Cell Surface Molecules (Modified from Ref. 1) 
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Figure 3-1: Lipid A and its modified structures that can elicit CAMP resistance. The 
two modifications (shown in red) can be made to either the 4’-phosphate, 1-
phosphate or both. 
Figure 3-2: Phosphatidylglycerol and its modified structures that can elicit CAMP 
resistance. The two modifications (shown in red) involve the acylation of a glycerol 
alcohol with either lysine or alanine. 
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3.1.2 Multiple Peptide Resistance Factor (MprF)-Mediated Resistance and the 
Significance of Lys-PG 
 CAMP-resistance in S. aureus has been, in part, attributed to the 
modification of PG in the plasma membrane to include an L-lysine residue 
(Figure 3-2). This new phospholipid is known as lysyl-phosphatidylglycerol 
(Lys-PG) and has a +1 charge, in contrast to the -1 charge of PG. Multiple peptide 
resistance factor (MprF) is the transmembrane protein found to be responsible 
for the presentation of this modification.7 First, the Lys-PG synthase domain of 
MprF acylates PG on the inner leaflet with free L-lysine after which the 
translocase domain flips it to the outer leaflet, presenting the new cationic charge 
to the cell’s environment (Figure 3-3).8,9 
 
Figure 3-3: Depiction of MprF in a bacterial membrane. In the Lys-PG synthase 
domain, a charged lysyl tRNA allows for the modification of PG on the inner leaflet 
of the membrane. The transmembrane flippase domain is responsible for moving 
Lys-PG from the inner leaflet to the outer leaflet, displaying the cationic charge on the 
surface of the cell. Taken from Ref. 9. 
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 Although the existence of aminoacylated-PGs had been known for 
decades,10 the mprF gene in S. aureus had not been reported until the work by 
Peschel and co-workers published in 2001.7 Through their efforts with 
transposon mutagenesis, this group identified MprF as the protein responsible 
for the production of Lys-PG and also observed that activity of several different 
CAMPs could be restored through mprF gene knockout (Table 3-2). Additionally, 
they found that CAMPs bound less efficiently to S. aureus expressing Lys-PG. 
Since then, proteins related to MprF have been identified in 31 gram-positive 
Table 3-2: MICs of Common CAMPs Towards Wild-Type and mprF Knockout S. 
aureus. Gramicidin S and Gramicidin D are provided as representative uncharged 
AMPs, which are not affected by the presence of Lys-PG. Taken from Ref. 7. 
77 
 
genera.11 This data, along with the aforementioned Lys-PG expression observed 
in daptomycin resistant bacteria, has supported MprF and Lys-PG as clinically 
relevant targets. 
3.1.3 Use of Reversible Covalent Interactions for Drug Target Affinity 
 As much of drug development has been steered towards target based 
discovery, a myriad of strategies to achieve potent and selective binding has been 
utilized. In nature, highly selective binding associations are achieved via 
combinations of non-covalent interactions. This allows for reversibility of these 
interactions, such that different activities can be turned on or off as necessary to 
the cell. However, in some drug therapies, it may be more beneficial to 
permanently modify the desired target. For example, a drug which can 
covalently bind a bacteria-specific target can make a potent antibiotic, as is the 
case with penicillin.12 Unfortunately, this strategy comes with a higher 
propensity towards toxic off-target effects via irreversible modification of off-
target proteins. 
 The use of reversible covalent interactions offers a promising intermediate 
between non-covalent and covalent target binding: they offer the potency and 
molecular specificity of their irreversible counterparts, but have a lower risk of 
off-target toxicity, much like non-covalent interactions.13 Further target 
specificity can also be gained through non-covalent modifications with the 
surrounding protein landscape. Currently, there are a few potential or already 
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approved drugs that take advantage of reversible covalent interactions with 
targets displaying cysteines or diols (Figure 3-4).12 
 
 Recently, our group and others have reported the use of 2-formylphenyl 
boronic acid (2-FPBA)14 and 2-acetylphenyl boronic acid (2-APBA)15–17 for 
specific targeting of biological amines. In normal aqueous conditions, Schiff base 
formation is not thermodynamically favorable, due to its required elimination of 
water. However, with the addition of the boronic acid ortho to the carbonyl, a 
stabilizing dative bond can be formed between the nitrogen and boron, 
decreasing the energetic penalty of eliminating water (Figure 3-5). Specifically, 
our group has demonstrated potent and selective binding in vitro to gram-
Figure 3-4: Examples of small molecule drugs that bind using reversible covalent 
interactions. A) Structure of an α-cyanoacrylamide based inhibitor of RSK2 kinase; 
the cyano-substituted acrylamide was added to the structure of a known kinase-
binding scaffold, increasing its potency and selectivity. B) Structure of bortezomib, a 
FDA-approved for multiple myeloma; it is active via boronate formation with an 
activated threonine in the 26S proteasome, mimking the transition state of this 
residue in the proteasome. Structures and information from Ref. 13. 
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positive bacteria over mammalian and gram-negative cells.17 Additionally, by 
incorporating the unnatural amino acid AB1 into a cationic peptide (Hlys-AB1), 
we were able to selectively label S. aureus over Jurkat cells and maintained potent 
binding, even in the presence of serum proteins (Figure 3-6). This stable labeling 
demonstrated the ability for this molecule to resist off-target binding, as serum 
proteins contain a high number of lysines. 
  
 
 
Figure 3-5: Depiction of A) Schiff base and B) iminoboronate formation at 
physiological conditions. The stabilizing effects of the addition of a boronic acid ortho 
to the ketone can be observed in the drastic decrease in Kd for 2-APBA compared to 
acetophenone. 
Figure 3-6: Study of Hlys-AB1 with Jurkat and S. aureus cells. A) Confocal 
microscopic images of a co-culture of Jurkat and S. aureus cells. As can be seen in the 
FITC channel, fluorophore labeled Hlys-AB1 shows preferential staining of the S. 
aureus over Jurkat cells. B) The graph displays the concentration dependent FBS 
inhibition of S. aureus staining as analyzed by flow cytometry. FBS can be included 
up to 10% with only 50% inhibition of staining. Modified from Ref. 17. 
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 To explain this selectivity, we considered the lipid membrane composition 
of the gram-positive bacteria tested compared to Jurkat cells. Mammalian cells 
predominantly contain sphingomyelin (SM) and phosphotidylcholine (PC), 
which both present quaternary amines unable to form Schiff bases. On the other 
hand, S. aureus has been observed to present Lys-PG, as mentioned earlier in this 
section. Using model membrane systems, we were able to demonstrate selective 
binding for Lys-PG and phosphatidylethanolamine (commonly found in B. 
subtilis) containing liposomes compared to those containing PC and PG. As such, 
we concluded our peptides can obtain selectivity for S. aureus over Jurkat cells as 
a result of their varied lipid compositions. 
3.1.4 Designing Peptides Incorporating 2-APBA for Potent Antibacterial Activity 
Towards Lys-PG Presenting S. aureus 
 With the success we saw for selective labeling of S. aureus, we envisioned 
taking this strategy a step further. As stated above, a prevalent mechanism for S. 
aureus to gain resistance against cationic antimicrobials is to express Lys-PG on 
the outer leaflet of their plasma membrane, thus weakening the electrostatic 
interactions used by the antimicrobial peptide to target these cells. In our own 
data provided in the previous chapter, we observed the effects of this change in 
membrane electrostatics, as our mutants saw a greater loss in potency towards S. 
aureus compared to B. subtilis with increasing charge (see Table 2-4). Given this 
trend, we hypothesized that the addition of a Lys-PG specific moiety, namely 
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APBA containing unnatural amino acid AB3, would allow us to regain potency 
of CAMPs, and could possibly increase the selectivity for these bacteria over 
mammalian cells. 
We chose to continue working with gramicidin peptides, as we already 
had extensive experience studying and characterizing them. Gramicidin A (gA) 
naturally exists as part of a mixture of similar peptides (gB and gC) named 
gramicidin D (gD).18 gA is generally considered to be the most responsible for 
the activity of gD, as it makes up 80% of the total mixture. The other two 
peptides, gB and gC, replace the tryptophan at residue 11 with a phenylalanine 
and a tyrosine, respectively. Based on these naturally tolerated differences, we 
were confident that a mutation with similar structure would also be accepted 
without significant perturbation to the peptide. 
Instead of using gA3K as a scaffold for peptides including the 2-APBA 
moiety, we chose to use the triple arginine mutant, gA3R, due to our observation 
that potent iminoboronate formation can occur between intramolecular 2-APBAs 
and lysines, resulting in peptide cyclization.19 Next, we decided to mutate the 
final tryptophan (residue 15) to AB3. Though this is not the position changed in 
gB and gC, the choice of residue 15 was ideal for two reasons. First, this position 
is closest to the lipid head groups when the peptide is properly folded into the 
membrane,20 making it the least likely to disrupt the β-helical structure when 
conjugated through iminoboronates. Additionally, we predicted this position 
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would best tolerate the increase in hydrophilicity from tryptophan to AB3, since 
it resides closest to the membrane-water interface. The proposed sequence for 
this series of gA3R peptides can be seen in Figure 3-7. 
 
To test our hypothesis, we compared antimicrobial activity of gA3R(AB3-
15) to that of gA3R and found that addition of the 2-APBA warhead actually 
decreased our potency. We speculated that this was due to membrane binding 
preventing proper folding or mobility of the peptide once attached to the cell. We 
went on to consider using a co-treatment of gA3R and a Lys-PG targeting 
peptide. Working with Kelly A. McCarthy towards this goal, we found that the 
potency of gA3R could be increased when applied in the presence of a cyclic 
peptide with potent Lys-PG binding. 
Overall, we believe that these results will lead to new strategies for 
targeting bacteria with CAMP resistance. We are currently working towards 
Figure 3-7: Structures of gA3R Mutants 
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exploring this further and improving our knowledge on Lys-PG in gram-positive 
bacteria. 
3.2 Use of gA3R(AB3-15) for Treatment of Lys-PG Presenting Bacteria  
3.2.1 Synthesis of Fmoc-AB3(pin)-OH 
 The unnatural amino acid AB3, synthesized as previously reported by our 
group (Scheme 3-1),19 is a more rigid structure compared to AB1,17 giving it a 
lower entropic penalty for binding. Along with this more favorable characteristic, 
AB3 is closely related to the structure of phenylalanine. This makes its structure 
more similar to mutations observed in gB or gC, suggesting it would be 
accommodated better in the gramicidin structure. 
 
 
Scheme 3-1: Synthetic Route to Fmoc-AB3(pin)-OH 
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Following the reported synthesis, we started with L-tyrosine and 
performed a Friedel-Crafts acylation with acetyl chloride to install the acetyl 
group ortho to the alcohol. As the alcohol is an ortho/para directing group and 
the para position is already occupied by the α-carbon, only one product was 
obtained. The acylated product is obtained by precipitation from concentrated 
HCl and used without purification for Boc-protection of the main chain amine 
and tert-butyl protection of the carboxylic acid. After silica gel column 
chromatography, the yield over these three steps was about 40%. 
 To prepare the material as a substrate for Miyaura borylation, the next 
step was triflate protection of the phenyl alcohol. Following purification, this 
step has near quantitative yield. The crucial and most sensitive step of this 
synthesis was the Miyaura borylation. Done in an inert atmosphere, this cross-
coupling reaction installs the pinacol-protected boronic acid. The temperature 
was found to be very important to limiting the degree of protodeboronation that 
occurred, and thus was strictly maintained at 85-87℃. After purification, this 
step generally yielded 50-60% pure product. Finally, deprotection of both the Boc 
and tButyl groups followed by Fmoc protection of the amine prepared the amino 
acid for SPPS. 
3.2.2 Synthesis of gA3R(AB3-15) 
 To achieve this peptide sequence, we were required to first couple Fmoc-
AB3(pin)-OH to Wang resin. Being a benzyl alcohol functionalized resin, 
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attaching the first residue requires esterification mediated by N,N’-
diisopropylcarbodiimide (DIC) and a catalytic amount of 4-
dimethylaminopyridine (DMAP). After this coupling, the loading efficiency can 
be measured by cleaving Fmoc from a small fraction of the resin and measuring 
the absorbance of dibenzofulvene in the resulting solution.21 In this case, about 
70% loading was achieved. Repeating the procedure, with half the equivalents of 
AB3 and DIC, provided the resin with >90% loading, which was taken on to be 
used in peptide synthesis, following the same synthetic route as previous gA 
peptides. 
 After resin cleavage and side-chain deprotection, the desired peptide mass 
was not obtained. By examining the different steps of our resin treatment after 
peptide synthesis, we concluded that the ethanolamine treatment used to install 
the C-terminal modification was incompatible with our unnatural AB3. 
Specifically, it appeared that ethanolamine treatment could lead to either 
displacement of the pinacol with ethanolamine, which was not reversible by 
acidic RP-HPLC purification, or complete loss of the boronic acid. At this point, 
we investigated alternatives for installing the C-terminal ethanolamine group. 
 To avoid exposing our unnatural amino acid to ethanolamine, we looked 
into ways to install the modification at the beginning of the peptide synthesis. 
This would require the use of a resin to which an alcohol could be conjugated. 
Considering several different options, we chose to work with a 
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trichloroacetimidate-functionalized Wang resin.22 The necessary materials could 
be readily prepared from the Wang resin we used previously and simply 
required the synthesis of Fmoc-protected ethanolamine as a substrate. After 
successful conjugation of Fmoc-ethanolamine, SPPS can proceed normally 
(Figure 3-8). 
 
To convert the benzyl alcohol to the trichloroacetimidate, Wang resin was 
swelled in dry DCM then stirred with trichloroacetonitrile in the presence of 1,8-
diazabicyclo[5.4.0]undec-7-ene (DBU).22 It was found that the degree of 
conversion was dependent on both the resin being thoroughly dried prior to 
swelling and the temperature of the reaction. As such, the resin was dried under 
vacuum and kept under argon for the duration and the reaction, which was 
maintained at 0℃. The conversion of the alcohol to the trichloroacetimidate was 
monitored by FT-IR (see Figure 3-9). Specifically, the disappearance of the peak 
at 3566 nm corresponding to the O-H stretch of the benzyl alcohol and the 
appearance of a new peak at 3338 nm corresponding to the N-H stretch of the 
Figure 3-8: Preparation of Resin for gA3R(AB3-15) Synthesis. A) Conversion of the 
Wang resin alcohol to a trichloracetimidate (TCA); B) Coupling of Fmoc-
ethanolamine to TCA resin. 
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acetimidate were monitored. It was found that one hour of reaction was 
sufficient for full conversion. 
 
 The subsequent reaction to couple the Fmoc-ethanolamine was also found 
to be very dependent on dryness of the solvent. As such, dry THF was removed 
from a still immediately prior to the reaction and the resin was washed twice 
with this solvent before adding the other reagents. The conversion to this ether 
bond was also be monitored by FT-IR, specifically looking for the disappearance 
of the peaks related to the trichloracetimidate at 1662 and 3338 nm and the 
appearance of the ether stretch at 1724 nm (Figure 3-10). Additionally, a capping 
step using methanol was included after it was observed that complete conversion 
was difficult to achieve; this would prevent any undesirable side reactions by 
Figure 3-9: Solid state FT-IR spectra for the conversion of Wang resin to TCA resin. 
A) Spectrum from 1400-3600 nm; B) Segment from 3250 to 3650 nm, displaying the 
peak shifting from the benzyl alcohol O-H stretch (3566 nm) to the acetimidate N-H 
stretch (3338 nm); C) Segment from 1550 to 1750 nm, showing the formation of a peak 
at 1662 nm. 
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quenching remaining reactive trichloroacetimidate groups prior to peptide 
synthesis. Along with the IR analysis, loading of the resin can be determined 
using the same Fmoc-loading test as the Wang resin or also by measuring the 
amount of Fmoc-ethanolamine that can be recovered from resin cleavage. Both of 
these methods provided comparable loadings in the range of 90-95%. 
 With the resin prepared, gA3R(AB3-15) was synthesized as before. 
Unfortunately, similar issues as observed with the original Wang resin were 
encountered, most likely due to poor coupling to the ethanolamine, such that 
free ethanolamine was released during peptide cleavage. This was supported via 
NMR data which confirmed the presence of ethanolamine after TFA cleavage 
Figure 3-10: Solid state FT-IR for the coupling of 2-(Fmoc-amino)ethanol to TCA 
resin. A) Spectrum from 1400-3600 nm; B) Segment from 3250 to 3650 nm, displaying 
the disappearance of the acetimidate N-H stretch (3338 nm); C) Segment from 1550 to 
1750 nm, showing the disappearance of the TCA peak at 1662 nm and the formation 
of the ether stretch at 1724 nm. 
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following a single residue coupling. At this point, we chose to synthesize the 
peptide without this C-terminal modification (Figure 3-11) and compare it to the 
corresponding gA3R peptide. To best mimic the natural structure, we used the 
Rink amide resin, leaving a C-terminal amide instead of the carboxylic acid that 
would result from using the Wang resin. This yielded a relatively clean peptide 
that was straightforward to purify. 
 
 
3.2.3 Characterizing the Antimicrobial Activity of gA3R(AB3-15)-NH2 
 Initially, we analyzed a control with Trp15 mutated to Tyr, mimicking gB. 
As gA is considered to be the most active peptide in the gD mixture, little work 
has been reported investigating the antimicrobial activity of gB or gC. To 
compare gA3R with gA3R(Y-15), we determined the MIC of each peptide with S. 
aureus (Figure 3-12). From this, we observed that there was about a 3-fold 
decrease in activity at a final peptide concentration of 10 µM. These results also 
show a slight decrease in activity when the ethanolamine group is removed. We 
Figure 3-11: Structure of final gA3R(AB3-15)-NH2 peptide from Rink Amide resin. 
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characterized gA3R(AB3-15) in the same way, but unfortunately the results were 
a bit noisy and difficult to interpret (Figure 3-13). 
 
Given the difficulty in drawing conclusions from the MIC results, we 
chose to instead use our cell killing assay to get a more quantitative comparison 
of the effects of adding AB3 to the gA sequence. However, from these results 
(Figure 3-14), it is clear that the addition of AB3 proved to be detrimental to the 
activity of gA3R. Compared to gA3R-NH2 (without ethanolamine), a four-fold 
loss in activity is observed. 
Figure 3-12: MIC Assay of gA3R mutants with S. aureus. 
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We considered two possibilities that may have led to these results. First, it 
could be that the reversible covalent binding of AB3 to Lys-PG on the cell surface 
Figure 3-13: MIC Assay of gA3R(AB3-15)-NH2 with S. aureus. 
Figure 3-14: Cell killing assay of gA3R mutants with S. aureus. Percent cell killing is 
reported above each peptide. 
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hinders the peptide’s ability to insert and properly fold into the membrane. If the 
peptide is folding properly, it could also be that this interaction between AB3 
and Lys-PG either slows or completely prevents its mobility in the membrane, 
limiting pore-forming dimerization. With gA3R(AB3-15) performing worse in the 
MIC assay than gA3R(Y15), we were confident that this loss in activity was not 
solely due to decreased membrane association caused by the mutation from 
tryptophan. We began to think of other ways to prove our hypothesis that 
targeting and neutralizing Lys-PG would improve the activity of cationic gA 
peptides. 
3.3 Resensitizing S. aureus to gA3R Using a Lys-PG Binding Peptide 
 Given that including AB3 in a CAMP did not enhance its antimicrobial 
potency, we looked towards treating cells with two separate peptides: a peptide 
displaying a Lys-PG-specific binding motif and a cationic antimicrobial peptide. 
To achieve this, a collaboration was initiated with Kelly A. McCarthy. 
 In her work, Kelly sought to create 2-APBA presenting peptides with 
selectivity for Lys-PG (found in S. aureus) over the other prevalent amine 
presenting lipid phosphatidylethanolamine (PE; a major lipid found in B. 
subtilis). Towards this goal, Kelly investigated the effects of multivalency and 
peptide cyclization on binding potency. Using flow cytometry, she found the 
93 
 
cyclic trimer peptide (referred to as KAM-CT, structure shown in Figure 3-15 A) 
to have the most potent binding to S. aureus cells (Figure 3-15 B), saturating at 
about 1.0 µM. Additionally, through fluorescence microscopy, she observed that 
KAM-CT was not binding to B. subtilis cells at relevant concentrations (Figure 3-
Figure 3-15: Structure and characterization of KAM-CT. A) Structure of KAM-CT, 
with 2-APBA structures shown in red. B) Flow cytometry data of different 2-APBA 
presenting peptides with S. aureus. This showed that the cyclic trimer was the most 
potent binder, saturating fluorescence at around 1 µM. C) White light microscopy 
image of B. subtlis. D) Fluorescence microscopy image of B. subtilis.  E) White light 
microscopy image of S. aureus. F) Fluorescence microscopy image of S. aureus. All 
microscopy experiments were done using 500 nM KAM-CT. Data collected and 
analyzed by Kelly A. McCarthy. 
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15 C-F), demonstrating selectivity for S. aureus. Given these results, we chose to 
use KAM-CT for our antimicrobial studies. 
 We first looked at the antimicrobial activity of KAM-CT alone. At 
concentrations up to its cell binding saturation point, we saw no activity in the 
MIC assay (Figure 3-16). Moreover, no significant reduction in cell counts were 
observed in the cell killing assay at a concentration of 1 µM (data not shown). 
This confirms that the cell binding alone of this peptide is not enough to elicit 
changes in bacterial viability. 
 
Next, we studied KAM-CT as part of a combination treatment with gA3R. 
For this, we used the same MIC conditions, but added the cyclic trimer at a final 
concentration of 1 µM to each sample. We observed a two-fold decrease of the 
Figure 3-16: MIC experiment with various concentrations of KAM-CT against S. 
aureus. gA WT is included as a positive control. This data shows no significant 
inhibition up to 1.0 µM peptide. 
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MIC of gA3R for the cyclic trimer treated samples compared to untreated 
controls (Figure 3-17). Based off the original reports by Peschel and co-workers,7 
this small increase is not unexpected, as fully knocking out the mprF gene 
decreased the MIC with S. aureus of linear AMPs similar to gA3R by only about 
four- to five-fold. Considering KAM-CT is unlikely to be sequestering every Lys-
PG, a two-fold difference is still considered to be relatively significant. As such, 
our experiments demonstrate an important proof-of-concept for this strategy 
towards resensitizing Lys-PG presenting bacteria to cationic antibiotics. 
 
3.4 Conclusions and Future Work 
 Through this work, we have learned that the targeting of Lys-PG is a 
promising strategy for combating bacterial resistance to cationic antimicrobials. 
Figure 3-17: MIC data of gA3R with and without KAM-CT against S. aureus. This 
data suggests that the co-treatment with KAM-CT can increase the potency of gA3R 
by two-fold. 
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Our initial work with gA3R(AB3-15)-NH2 demonstrated that incorporating the 
Lys-PG targeting moiety directly into a membrane active AMP was not effective 
for gA. We believe this is most likely due to the tight binding interaction between 
AB3 and Lys-PG limiting peptide mobility. This could be preventing the 
peptide’s proper folding into the membrane as the active β-helical structure or 
slowing its dimerization through the membrane. However, we cannot make a 
general conclusion on whether this would work or not for other less structured 
AMPs. Fortunately, by separating the potent Lys-PG binding and antimicrobial 
activities into two different peptides, we demonstrated that co-treatment of these 
molecules can increase the potency of the antimicrobial agent alone. 
Work is currently being continued to explore this strategy and its 
applicability beyond gA3R. This includes the study of other potent Lys-PG 
binding peptides. Additionally, alternative strategies to target and reverse the 
resistance caused by Lys-PG are being investigated. 
3.5 Experimental Procedures 
3.5.1 General Methods 
Fmoc-Trp-Wang resin and all Fmoc-protected amino acids were purchased from 
either Advanced Chemtech (Louisville, KL) or Chem Impex Int. Inc. (Wood Dale, 
IL). Unprotected valine and other chemicals were obtained from Sigma-Aldrich 
or Fisher Scientific unless otherwise indicated. Peptide synthesis was carried out 
on a Tribute peptide synthesizer (Protein Technologies, Tucson, AZ). 1H NMR 
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data were collected on a VNMRS 500 MHz or 600MHz NMR spectrometer, as 
indicated. Mass spectrometry data were generated by using an Agilent 6230 LC 
TOF mass spectrometer. The peptide concentration of all gA3R samples used in 
this study was determined by measuring their absorbance at 280 nm (ε = 22,760 
M-1cm-1 total of four tryptophan residues) on a Nanodrop 2000c UV/Vis 
spectrometer by cuvette. KAM-CT concentrations were determined by mass, as 
they did not include a chromophore with known extinction coefficient. Gram-
positive Staphylococcus aureus (ATCC 6538) were purchased as lyophilized cell 
pellets from Microbiologics (Cloud, MN). FT-IR data was recorded on Nicolet 
iS10 FT-IR spectrometer (ThermoFisher Scientific, Waltham, MA). 
3.5.2 Synthesis of Fmoc-AB3(pin)-OH19 
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Synthesis of (S)-2-(3-acetyl-4-hydroxyphenyl)-1-carboxyethanaminium 
chloride (1) 
Anhydrous aluminum chloride (14.7 g, 111 mmol) was added slowly to a 
solution of L-tyrosine (5 g, 28 mmol) in dry nitrobenzene (100 mL) at RT.  This 
slightly exothermic reaction was stirred at RT for 15 minutes. Then, acetyl 
chloride (2.59 g, 33 mmol) was added dropwise, during which a color change 
was observed from red to yellow. The reaction mixture was heated at 100 ℃ with 
stirring for six hours and turned to a dark green thick solid after cooling to room 
temperature. The solid was dissolved in 1N HCl and the nitrobenzene layer was 
removed. The aqueous layer was washed with ethyl acetate (3 x 150mL), then 
concentrated until precipitation was observed. It was allowed to continue to 
precipitate at 4 ℃ overnight. The desired product (1) precipitated as a light tan 
solid and was collected via vacuum filtration. 
Synthesis of (S)-tert-butyl 3-(3-acetyl-4-hydroxyphenyl)-2-((tert-
butoxycarbonyl)amino)propanoate (2) 
1 (used as is from previous reaction) was dissolved in 120 mL water, neutralized 
with NaOH pellets, and brought to pH 9 with sodium bicarbonate. While stirring 
in an ice bath, 80 mL of THF was added to the reaction mixture. To this, Boc-
anhydride (7.2 g, 33.1 mmol) was added. The reaction mixture was warmed to 
room temperature and stirred for 3 hours. Before extraction, THF was removed 
by rotary evaporation. Then 250 mL ethyl acetate was added before the mixture 
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was acidified to pH ~2-3 with 1N HCl. The product was extracted with ethyl 
acetate (3 x 150 mL), then the combined organic layers were washed with brine 
(200 mL) and dried over Na2SO4. Solvent was removed by rotary evaporation 
and the product was dried further under high vacuum. The resulting solid was 
dissolved in dry ethyl acetate (120 mL), to which tert-butyl 2,2,2-
trichloroacetimidate (6.8 g, 31.1 mmol) was added. The reaction mixture was 
refluxed for 6 hours, at which point half equivalent more of tert-butyl 2,2,2-
trichloroacetimidate (2.3 g, 10.4 mmol) was added and the reaction mixture was 
refluxed overnight. After solvent removal, the residue was purified through 
silica gel using 10% ethyl acetate in hexane to give the desired product 3 as a 
white solid (3.53 g, 33.7% over three steps). 1H NMR (CDCl3) δ: 12.15 (s, 1H), 7.51 
(s, 1H), 7.29-7.27 (d, J=7.4 Hz, 1H), 6.91-6.89 (d, J=7.6 Hz, 1H), 5.04-5.02 (d, J=8.2 
Hz, 1H), 4.45-4.41 (q, J=4.6 Hz, 1H), 3.08-2.98 (m, 2H), 2.61 (s, 3H), 1.42 (s, 18H); 
13C NMR (CDCl3) δ: 204.31, 170.77, 161.34, 154.99, 137.81, 131.33, 126.80, 119.38, 
118.28, 82.27, 79.83, 77.82, 54.69, 28.95, 26.59. MS-ESI+: m/z calculated for 
C20H29NO6 [M+Na]+ = 402.1893, found 402.1963. 
Synthesis of (S)-tert-butyl 3-(3-acetyl-4-
(((trifluoromethyl)sulfonyl)oxy)phenyl)-2-((tert-
butoxycarbonyl)amino)propanoate (3) 
2 (1.49 g, 3.93 mmol) was dissolved in anhydrous dichloromethane (8.0 mL) and 
triethylamine (1.59 g, 15.7 mmol) was added while stirring under an argon 
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environment. The reaction mixture was cooled to -78℃ using a dry ice/acetone 
bath and trifluoromethane sulfonic anhydride (1.67 g, 5.89 mmol) was added 
slowly over the course of five minutes. The reaction mixture was allowed to stir 
at room temperature for 30-60 min. Afterwards, the reaction was quenched with 
saturated sodium bicarbonate (50 mL) and the mixture was allowed to stir for 5 
min. The product was extracted with dichloromethane (3 x 50 mL). The 
combined organic layers were washed with brine (50 mL) and dried over 
Na2SO4. After removing the solvent, the crude product was purified on silica gel 
with 15% ethyl acetate in hexane to yield 3 as a yellow gummy product (1.58 g, 
79%). 1H NMR (CDCl3) δ: 7.62 (s, 1H), 7.44-7.41 (d, J=8.2 Hz, 1H), 7.26-7.25 (d, 
J=7.2 Hz, 1H), 5.12-5.10 (d, J-8.3 Hz, 1H), 4.50-4.46 (q, J=5.4 Hz, 1H), 3.20-3.07 (m, 
2H), 2.62 (s, 3H), 1.42 (s, 9H), 1.40 (s, 9H); 13C NMR (CDCl3) δ: 196.38, 170.22, 
150.94, 145.60, 137.74, 134.81, 131.78, 122.15, 119.84, 117.29, 82.83, 80.08, 54.84, 
37.93, 28.49, 27.98, 27.81; MS-ESI+: m/z calculated for C12H12F3NO6S [M-
(Boc+tBu)+H] = 356.0416, found 356.0391. 
Synthesis of Boc-AB3(pin)-OtBu (4) 
3 (1.58 g, 3.09 mmol), B2pin2 (2.37 g, 9.32 mmol), Pd(dppf)Cl2 (177 mg, 0.242 
mmol, 8 mol%) 1,1’-Bis(diphenylphosphino)ferrocene(dppf) (244 mg, 0.244 
mmol) and potassium acetate (915 mg, 9.32 mmol) were dissolved in anhydrous 
dioxane (20 mL). The reaction mixture was bubbled with argon for 20 minutes 
and it was allowed to stir at 85-88℃ for 1 hour. Water (80 mL) was then added to 
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quench the reaction and the product was extracted with ethyl acetate (3 x 80 mL). 
The combined organic layers were washed with brine (100 mL) and dried over 
Na2SO4. The solvent was removed under vacuum and the crude product was 
purified on silica gel using 17.5% ethyl acetate in hexane to yield 4 (762.5 mg, 
50.4%). 1H NMR (CDCl3) δ: 7.58 (s, 1H), 7.43-7.42 (d, J=7.6 Hz, 1H), 7.33-7.31 (d, 
J=7.3 Hz, 1H), 4.90-4.89 (d, J=8.1 Hz, 1H), 4.48-4.44 (q, J=5.3 Hz, 1H), 3.19-3.08 (m, 
2H), 2.57 (s, 3H), 1.41 (s, 30H); 13C NMR (CDCl3) δ: 199.81, 170.53, 155.00, 140.92, 
137.30, 133.57, 132.27, 129.58, 83.68, 82.30, 79.79, 54.39, 37.87, 28.30, 28.00, 24.85; 
11B NMR (CDCl3) δ: 31.10; MS-ESI+: m/z calculated for C26H40BNO7 [M+H]+ = 
490.2976, found 490.2996. 
Synthesis of Fmoc-AB3(pin)-OH 
4 (1.96 g, 4.0 mmol) was dissolved in 10 mL anhydrous DCM and stirred in an ice 
bath as 15 mL TFA was added. This was allowed to come to room temperature 
and stirred for 2.5 hours. The solvent was reduced to a minimal volume by rotary 
evaporation. The sticky residue was dissolved in neat TFA (15 mL) and stirred 
for an additional one hour. The solvent was removed by rotary evaporation and 
dried further through the addition and subsequent rotary evaporation of DCM 
and methanol. To remove any residual TFA, it was azeotroped with toluene until 
dry. Before moving on to the next reaction, the mixture was dried under high 
vacuum for 45 min. The residue was then dissolved in anhydrous DCM (10 mL) 
and stirred as NMM (2.20 mL, 20.0 mmol) was added. To this, Fmoc-Osu (1.08 g, 
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3.20 mmol) was added and the mixture was allowed to stir under argon 
overnight. The next day, additional Fmoc-Osu (0.20 mmol, 68 mg) was added 
every 30 min until all the starting material appeared to be consumed by TLC. To 
this, 2N HCl (75 mL) was added and the product was then extracted with ethyl 
acetate (3x75 mL). The combined organic layers were washed with brine (100 
mL) then dried over Na2SO4. The resulting solid was purified by silica gel 
chromatography using 50% ethyl acetate, 1% acetic acid in hexane to yield Fmoc-
AB3(pin)-OH (1.41 g, 63.4%). 1H NMR (600 MHz, CDCl3) δ 7.77-7.73 (d, J = 7.6 
Hz, 2H), 7.59 (s, 1H), 7.56-7.52 (d, J = 7.6 Hz, 2H), 7.44-7.41 (d, J = 7.4 Hz, 1H), 
7.41-7.37 (t, J = 7.5 Hz, 3H), 7.32-7.26 (dddd, J = 8.7, 7.5, 2.9, 1.3 Hz, 3H), 5.36-5.32 
(d, J = 8.2 Hz, 1H), 4.72-4.68 (q, J = 6.8 Hz, 1H), 4.40-4.36 (d, J = 7.1 Hz, 2H), 4.21-
4.15 (t, J = 7.1 Hz, 1H), 3.26-3.13 (ddd, J = 42.4, 14.1, 5.7 Hz, 2H), 2.50 (s, 3H), 1.44 
(s, 12H). 13C NMR (CDCl3) δ 200.33, 173.65, 155.79, 143.68, 141.27, 136.77, 133.47, 
132.41, 129.40, 127.75, 127.10, 125.04, 119.97, 83.92, 67.20, 54.23, 47.05, 37.50, 31.57, 
24.82, 22.64, 14.11; MS-ESI+: m/z calculated for C32H35BNO7 [M+H]+ = 556.2507, 
found 556.2606. 
3.5.3 Conjugation of AB3 to Wang Resin 
Wang resin (0.100 mmol, loading=0.600 mmol/g, 167 mg) was swelled in the 
minimal amount of DMF for 1 hour. At the same time, Fmoc-AB3(pin)-OH (1.00 
mmol, 555.43 mg) was dissolved in the minimal amount of dry DCM with a few 
drops of DMF added to aid solubility. This was put in an ice bath and 
diisopropylcarbodiimide (0.500 mmol, 63.1 mg, 78.3 μL) was added. This was 
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stirred for 20 min, then the solvent was removed by rotary evaporation. The 
resulting solid was resuspended in the minimal amount of DMF then added to 
the resin. This was stirred for 1 hour, then washed 6xDMF, 6xDCM and dried. 
Loading of the resin was determined using the standard Fmoc cleavage test.21 
This gave a loading of 0.332 mmol/g. The procedure was repeated using 5 eq 
Fmoc-AB3(pin)-OH and 2.5 eq DIC, instead of 10 and 5, respectively. This 
resulted in a loading of 0.550 mmol/g. 
3.5.4 Synthesis of 2-(Fmoc-amino)ethanol23 
Ethanolamine (364.1 mg, 5.96 mmol) was dissolved in acetone/saturated 
aqueous sodium bicarbonate (2:1, 60 mL) and stirred as Fmoc-Osu (2.02 g, 5.99 
mmol) was added. This was allowed to stir at room temperature overnight. To 
the mixture, water (40 mL) and ethyl acetate (50 mL) were added. The mixture 
was then acidified to pH ~3 using 1 N HCl. The aqueous layer was removed and 
the organic layer was washed with 1 N HCl (3 x 40 mL), saturated aqueous 
sodium bicarbonate (1 x 40 mL) and brine (1 x 40 mL) then dried over Na2SO4. 
The solvent was removed by rotary evaporation providing a white solid in 
quantitative yield. Proton NMR showed less than 8% free ethanolamine. 1H 
NMR (600 MHz, CDCl3) δ 7.78 – 7.74 (d, J = 7.5 Hz, 2H), 7.61 – 7.56 (d, J = 7.4 Hz, 
2H), 7.43 – 7.37 (t, J = 7.4 Hz, 2H), 7.34 – 7.28 (t, 2H), 5.29 – 5.13 (s, 1H), 4.45 – 4.40 
(d, J = 6.8 Hz, 2H), 4.24 – 4.18 (t, J = 6.9 Hz, 1H), 3.73 – 3.67 (q, J = 5.1 Hz, 2H), 
3.37 – 3.31 (q, J = 5.4 Hz, 2H), 2.27 – 2.21 (d, J = 5.3 Hz, 1H). 
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3.5.5 Preparation of 2-(Fmoc-amino)ethanol Resin22 
Wang resin (0.500 mmol, 557.2 mg) was suspended in anhydrous DCM (5 mL). 
To this, trichloroacetonitrile (1 mL) was added. This was put into an ice bath and 
stirred for 5 min before the addition of DBU (100 µL). This was continued to stir 
in the ice bath for 1 hour. The resin was then washed (2 x DMF, 5 mL, 5 min; 2 x 
DCM, 5 mL, 5 min). Full conversion of the benzyl alcohol was confirmed by the 
disappearance of an IR stretch at 3566 nm. Without drying, the TCA resin was 
reswelled in anhydrous DCM (5 mL) for 15 min. The resin was then washed with 
dry THF (2 x 5 mL). To this, 2-(Fmoc-amino)ethanol (425.0 mg, 1.5 mmol) was 
added, dissolved in dry THF (5 mL). This was stirred under nitrogen for 5 min 
before BF3· OEt2 (35 µL, 0.28 mmol) was added. The suspension was stirred for 1 
hour, 45 min. To cap any unreacted trichloroacetimidate, methanol (1.0 mL) was 
added and the mixture was stirred for an additional 5 min. The resin was 
collected by filtration and washed several times with THF (5 mL), methanol (5 
mL) and then DCM (5 mL). The resin was fully dried under vacuum before 
checking conversion by FT-IR. Conversion was monitored by the disappearance 
of the TCA stretches at 3338 nm and 1662 nm and the formation of the stretch at 
1724 nm, corresponding to the ether bond formed between the resin and the 
alcohol from 2-(Fmoc-amino)ethanol. Loading efficiency was checked via two 
different methods. Using a standard Fmoc-cleavage procedure21 performed in 
triplicate, the loading was found to be 0.497 mmol/g. Additionally, 2-(Fmoc-
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amino)ethanol was cleaved from the resin (61 mg) using 10% TFA in DCM for 1 
hour. The resin was washed with DCM and methanol, then all filtrates were 
combined and the solvent was removed by rotary evaporation. The resulting 
mixture was suspended in water (20 mL) and extracted using ethyl acetate (3 x 15 
mL). Combined organic layers were washed with brine (20 mL) then dried over 
Na2SO4 before the solvent was removed by rotary evaporation. This yielded 9.3 
mg 2-(Fmoc-amino)ethanol, confirmed by 1H NMR, providing a loading of 0.537 
mmol/g. 
3.5.7 Synthesis of gA3R Peptides 
Synthesis was performed as previously reported by our group24. Ethanolamine 
derivatized peptides were synthesized on Fmoc-Trp-Wang resin (100 mg, 0.500 
mmol/g, 0.05 mmol) or Fmoc-Tyr(tBu)-Wang resin (loading) using standard 
Fmoc/tBu chemistry. The peptides were cleaved off the resin by treating the 
resin with ethanolamine (40% v/v in DMF, 55oC, 5 hours). Then the resin was 
filtered through a medium fritted plastic funnel and rinsed three times with 
DCM and methanol. Prior to precipitation, the mixture was reduced to a minimal 
volume. To precipitate the peptide, six to seven times in volume DI water was 
then added. The peptide was collected by centrifugation (14,000 rpm, 1.5 hr) and 
the pellet was dried by lyophilization to obtain the side-chain protected peptide. 
The side chain protecting groups were removed by treating the pellet with 
Reagent K at room temperature for two hours. Once the reaction is finished, cold 
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diethyl ether was added to precipitate the crude peptide which was again 
centrifuged (14,000 rpm, 1.5 hours) and lyophilized. For peptides using 2-(Fmoc-
amino)ethanol resin, peptide synthesis was carried out the same way. The crude 
peptide was cleaved using Reagent K, as the ethanolamine treatment was 
unnessary. For peptides on Rink amide resin, peptide synthesis was carried out 
as stated above and the crude peptide was cleaved using Reagent K to yield the 
C-terminal amidated peptide. The crude material was purified by RP-HPLC 
(Waters Prep LC, Jupiter 10 μm C4 300A Column). The identity and purity of 
each peptide was confirmed by LC/MS (Agilent 2630 LC TOF, Phenomenex, 
Jupiter 5 μm C4 300R column). All peptides were confirmed to have purity of 
95% or higher. 
3.5.8 Minimum Inhibitory Concentration Measurements25 
Minimal inhibitory concentrations (MICs) were measured against gram-positive 
Staphylococcus aureus (ATCC 6538) in LB media. Specifically, a single colony 
selected from an LB agar plate was grown overnight in broth at 37℃ with 
agitation and diluted 100 times into fresh broth the next morning. OD600 was 
monitored until a value between 0.5 and 0.6 was reached. The cells were diluted 
by a factor previously determined to achieve a concentration of ~5 x 105 colony 
forming units per mL (cfu/mL). In a sterile 96-well plate, the cell suspension (200 
μL) was added to each well. To each well, serial diluted (2-fold) peptides in 
DMSO (2 μL) were added in triplicates. For experiments studying co-treatment 
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of peptides, KAM-CT was added at a final concentration of 1.0 µM immediately 
before the AMP. Using a microtiter plate reader (SpectraMax M5, Molecular 
Devices, Sunnyvale, CA), the OD600 was monitored overnight while incubating 
at 37℃, with readings taken every 10 minutes after the plate was shaken for 15 
seconds. Using the time point where OD600 of the blank (untreated) sample 
began to reach stationary phase, MICs were determined to be the lowest 
concentration for which cell growth was not observed. 
3.5.9 Cell Killing Assays with S. aureus 
A single colony of S. aureus was selected from an LB agar plate and grown 
overnight in LB broth, incubating at 37℃ with agitation. In the morning, this was 
a small aliquot was taken and diluted 100 times in fresh broth. The OD600 was 
monitored until it reached ~0.6. This culture was centrifuged (4000 rpm, 5 min) 
and washed with 10 mM tris acetate buffer (pH 7.4) two times. The final cell 
solution was diluted to ~5 x 105 cfu/mL in fresh buffer. In a sterile 96-well plate, 
the cell suspension (200 μL) was added to each well and 2 μL of 125μM peptide 
in DMSO were added in triplicate. The plate was incubated for 10 min at 37℃. 
Aliquots of each sample (10 μL) were diluted into fresh buffer (990 μL) and 
mixed before an aliquot (100 μL) was spread on LB agar plates. The plates were 
allowed to incubate at 37℃ overnight. Individual colonies were counted on each 
plate and triplicates were averaged for each peptide. To calculate a percent 
viability, the average number of colonies for each peptide was divided by the 
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average number of colonies for blank samples and multiplying by 100. Percent 
killing was then considered to be the percent viability subtracted from 100. 
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Chapter 4 
Design and Screen of a Cyclic Peptide Library Containing a 
2-APBA Warhead for the Discovery of Novel Binders to Lipid II 
Stem Peptide* 
 
 
 
 
 
 
 
 
 
 
*The work of this chapter has been jointly performed with Kaicheng Li. 
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4.1 Introduction 
4.1.1 Use of Libraries for Novel Peptide Discovery 
 The use of library based ligand discovery has many benefits over rational 
design strategies. First, it allows for investigating multiple related structures at the 
same time, yielding an extensive structure-activity study in a single screen. Library 
screening also allows for a less biased selection of compounds to study. 
Additionally, pharmaceutical companies typically use library screens as a fast and 
efficient method for looking at a catalog of unrelated compounds. However, this 
approach is not without its downfalls. Due to the arbitrary nature of screening, 
libraries can yield varying amounts of false positives, making hit validation a very 
crucial step. Furthermore, designing screening schemes which can incorporate a 
graded output, such that hits can be compared for potency within the experiment 
before validation, is nontrivial. 
 In the case of peptides, library approaches have taken several leaps forward 
in the past decade or so. Peptide libraries can be split into two separate families: 
biological or chemical synthetic approaches (Figure 4-1).1 For biology-based 
library platforms, including phage and bacteria display, genetic materials are used 
to generate and sequence libraries. In these techniques, the host organism’s 
machinery is used to produce the library of interest, and then the library 
compounds are displayed on the surface of the organism. Drawbacks to these 
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techniques include being limited to canonical amino acids,2 although modification 
strategies for incorporating unnatural functionalities are becoming much more 
prevalent (Figure 4-2).3–7 Additional limitations include the dependence on the 
organism’s tolerance of the library compound for its successful expression. 
 The fully synthetic approach can be viewed as more challenging to generate 
than biological libraries, but it allows for much more exotic structures and 
unnatural sequences.2 A major limitation for the structures of synthetic peptide 
libraries is their compatibility with mass spectrometry, which is used for 
sequencing. In the past, this has limited the incorporation of cyclic structures or 
Figure 4-1: Depiction of two major classes of peptide library scaffolds. Biological 
libraries display peptides of interest on the exterior of a given organism, using a 
designed DNA plasmid for generation of the library such that hits can be sequenced 
using Sanger sequencing. Chemical libraries involve strategies of splitting resin at 
designed steps in peptide synthesis and typically use mass-spectrometry techniques 
for sequencing. Modified from ref. 1. 
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unnatural linkages difficult to sequencing with typical mass-spectrometry 
techniques.8 However, this limitation is commonly circumvented with the use of 
one-bead-two compound (OBTC) libraries,9 such that two peptides are produced 
for each desired library member. For screening of a OBTC library, one peptide is 
used as the screening compound and is assumed to be the active entity, while the 
other moiety, which is compatible with the sequencing technique chosen, simply 
affords a way to identify each library hit (Figure 4-3).1  
 As the usage of library screening has grown, techniques that are hybrids 
between biological and synthetic approaches have emerged, such as DNA-
encoded libraries.10–12 Taking a similar approach as one-bead-two-compound 
libraries, DNA-encoded libraries have the desired library compound attached to a 
DNA fragment, which can act as the coding sequence (Figure 4-4). To achieve this, 
a short DNA sequence (four to eight base pairs) is assigned to each variable library 
Figure 4-2: Literature reported examples of modifications that can be made on phage 
display libraries. a) side-chain specific modifications for the covalent attachment of 
unnatural structures, including the incorporation of azido-Phe using Amber codon 
suppression; b) N-terminal serine specific modification using various oxime α-
nucleophiles; c) bicyclization through the chemical crosslinking of three cysteines. 
Figure used with permission from Kelly A. McCarthy.  
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component and ligated to the corresponding resin after splitting. As such, a unique 
DNA sequence can be obtained for each library member. This has allowed for the 
use of high throughput DNA sequencing to identify library hits without the 
limitations on library design.13 Most often, this approach has been reported for 
small molecule libraries, but has the unfortunate drawback of being relatively 
expensive, as many short oligomers are required to ensure that each code in 
unique. Also, distinct overhangs are typically included for each split step as a way 
to prevent incorrect ligation of truncated chains in subsequent steps. As such, the 
number of oligomers required quickly increases with an increasing number of 
variable positions. 
 
Figure 4-3: Cartoon of a one-bead-two-compound library. In this example, the amino 
acids kept constant for cyclization (A1 and A2) are eliminated in the sequencing 
compound to present a linear structure compatible with either Edmund degradation 
or MS/MS analysis. 
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 The power in DNA-encoded libraries comes from the breadth of 
information that can be gathered during a single screen and its allowance for 
unnatural structures. As is the case with biological library approaches, sequencing 
from genetic information can be much less convoluted than mass spectrometry 
based approaches, allowing for quicker analysis of a larger pool of hits. This 
information can generate a structure-activity relationship, and clarify which hits 
are most likely to give the desired response to the target based on the identification 
of common features.11 
4.1.2 Peptidoglycan and Vancomycin 
 Gram-positive bacteria consist of a plasma lipid membrane surrounded by 
a thick cell wall. The cell wall, specifically referred to as the peptidoglycan, is a 
Figure 4-4: Depiction of DNA-encoded library. With each step, a DNA ligation and 
chemical reaction, in this case a peptide coupling, is performed. Color scheme shows 
corresponding amino acid and DNA segments. Yellow represents the universal 
beginning and ending primers, used for PCR and sequencing. Figure modified from 
Ref. 11. 
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structured polymer of sugars and amino acids with a lipid anchor attaching it to 
the plasma membrane. Its main purpose is to provide structural strength to the 
cell, especially as a way to counteract osmotic pressure.14,15 Strands of 
peptidoglycan in gram-positive bacteria are crosslinked through short peptides, 
creating a lattice structure from which the cell wall gets its strength. A depiction 
of the exterior of a gram-positive cell can be seen in Figure 4-5. 
 
 As the outermost cellular component, the peptidoglycan is a readily 
available target for antibacterial drugs. By eliminating the necessity of ligands to 
pass through the plasma membrane, this target avoids the complications of 
membrane permeability in designing drugs. Additionally, peptidoglycan’s vital 
role in cellular viability makes it ideal for bactericidal targeting. Hallmark drugs, 
Figure 4-5: Cartoon depiction of the exterior of a gram-positive cell. Sugars in the 
peptidoglycan are represented as hexagons, with N-acetylmuramic acid (NAM) 
shown in yellow and N-acetylglucosamine (NAG) in green. Peptide crosslinks 
between NAM sugars and shown as grey lines. Modified from Ref. 14. 
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such as penicillin,16 and even our own immune system have mechanisms that act 
by targeting different bacterial cell wall components to weaken the 
peptidoglycan.17 
 Vancomycin is a glycopeptide antibiotic produced by the soil bacterium 
Streptomyces orientalis.18 When originally isolated and studied, it was found 
especially promising as it was active against penicillin-resistant S. aureus and 
originally elicited very little propensity towards resistance. Vancomycin binds to 
the terminal D-Ala-D-Ala sequence of the crosslinking pentapeptide in gram-
positive peptidoglycan via a network of five hydrogen bonds (Figure 4-6A).19 This 
binding event prevents crosslinking, thus destroying the cell wall’s integrity and 
resulting in cell death due to lack of osmotic pressure regulation. However, 
resistance to vancomycin has increased since its clinical introduction, causing the 
drug to be limited to gram-positive infections that are unresponsive to other 
antibiotics. 
 Resistance to vancomycin occurs through a fairly small target modification 
that is triggered by an elegant gene cascade.20 The modification involves the 
substitution of the final D-Ala with a D-Lac, which transforms the final amide bond 
into an ester bond. The disruption of this single hydrogen bond was found to be 
significant enough to abolish vancomycin binding (Figure 4-6B). Although this 
modification was originally observed in Enterococci species,21 the eminent threat of 
horizontal gene transfer to S. aureus resulted in reassignment of vancomycin to use 
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only in highly resistant infections. Nonetheless, vancomycin resistance was 
ultimately observed in S. aureus in the late 1990s.22 
 
4.1.3 Design and Evolution of Library Scaffold 
 As mentioned in the introduction (Chapter 1), bacterial resistance has been 
observed within the first few years of clinical use of an antibiotic. Vancomycin, 
however, can be considered one of the exceptions to this; resistance was not 
observed until about 30 years after the drug had been deployed. Such a privileged 
structure is ideal to mimic for the development of new antibiotics. 
Figure 4-6: Structure of vancomycin binding to the lipid II stem peptide. Shown with 
A) wild-type and B) vancomycin-resistant strains S. aureus. Hydrogen bonds are 
shown in red. The mutation to D-Lac is shown in the resistant strain with the disrupted 
hydrogen bond. 
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 Immediately preceding the terminal D-Ala-D-Ala fragment of the lipid II 
stem peptide in S. aureus is a lysine. This was of special interest to us, as our group 
has been successful in targeting biologically relevant amines with our 2-APBA 
derivatives. We hypothesized that a cyclic or multicyclic peptide could be 
designed to mimic the potent binding of vancomycin and including a 2-APBA 
moiety would be advantageous in targeting this lysine (Figure 4-7). With the 
unique reactivity and critical function of this lysine, we envisioned its targeting 
would decrease the risk of resistance development compared to vancomycin. 
Furthermore, we expected that the elimination of a hydrogen bond observed in 
vancomycin-resistant strains of bacteria would be less detrimental for our 
designed peptides, as the additional iminoboronate interaction is stronger than the 
lost contact. With vancomycin being an especially difficult scaffold to manipulate 
for rational design, we chose to explore the use of library screening to discover 2-
APBA presenting peptides with potent lipid II stem peptide binding. 
 
Figure 4-7: Depiction of iminoboronate formation between the lysine of the lipid II 
stem peptide and AB3 in a designed peptide. 
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 Seeking not only to include an unnatural amino acid, but also a cyclic 
peptide structure, we proposed the use of a DNA-encoded library platform. This 
would allow us to perform sequencing using a separate entity from the peptides 
being screened. Unfortunately, this platform proved to be relatively expensive, 
even just during the original optimization of synthetic conditions. As a result, we 
moved forward using a one-bead-two-compound library synthesized through a 
core-and-shell strategy. 
4.1.4 Design of a Stringent Screening Process 
 The rapid reversibility of iminoboronates makes these structures non-ideal 
for traditional screening methods. Furthermore, our target of interest is a short 
peptide. Unlike a protein target, this peptide will not contain a well-defined 
binding pocket. This makes washing during screening more likely to remove 
potent binders, as the location of binding is more solvent exposed. Without 
washing, we would likely have a much higher percentage of false positives, 
decreasing our chances of success. However, the structure of the iminoboronate 
can be covalently captured via reduction of the imine bond, as we have observed 
for intramolecular cyclization of peptides.23 Creating a covalent linkage between 
our target and library hits would allow us to perform stringent washes to remove 
any false positives due to non-specific interactions (Figure 4-8), thus increasing our 
confidence in obtaining successful hits. 
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 To increase our screening stringency even further, we chose to use a two-
step screening approach. The first step, involving an avidity pulldown, would 
allow us to screen a large scale library with a rapid output. The second step, using 
fluorescence microscopy for hit isolation, would provide a much more careful 
selection of positive hits. 
 While we were successful in optimizing the synthesis and accurate 
sequencing of our library, gathering about 20 hits and synthesizing nine for 
validation, we found no potent binders during validation. We attempted multiple 
strategies to confirm the success of our screen to no avail.  
In light of these results, we decided to validate our library and covalent 
capture screening approach by screening against transferrin. We were successful 
in sequencing 20 of hits from this screen using fluorescence microscopy following 
NaBH4 reduction. Of these, three have been synthesized and studied for binding 
to transferrin using fluorescence anisotropy. From this validation, we observed 
Figure 4-8: Proposed strategy for the covalent capture of hits via iminoboronate 
reduction. After the reversible conjugation of AB3 with the lysine side chain in the lipid 
II stem peptide, addition of a hydride donor will reduce the imine, producing a 
covalent bond between the target peptide and the hit peptide on resin. 
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selective binding for transferrin over human serum albumin, with the best hit 
tested so far having a Kd of 25-30 µM. Collectively, we conclude our hit selection 
for the screen with lipid II stem peptide was flawed but that our library has the 
potential to produce potent and selective binders in a model protein system. 
4.2 Exploration of a DNA-Encoded Peptide Library 
4.2.1 Preparation of Tentagel Resin 
 To synthesize our library, we chose to use a 90 μm Tentagel NH2 resin. 
Tentagel resins include a poly(ethylene glycol) (PEG) shell surrounding the 
polystyrene base found in normal SPPS resins. PEG based resins are very 
commonly used when synthesizing peptide libraries for on-bead screening due to 
the fact that they can readily swell in both organic and aqueous solvents. This 
allows for the resin to be taken from synthetic conditions in DMF and put into 
aqueous buffers for screening. 
 To prepare the resin for library synthesis, we first coupled Fmoc-glycine 
and measured the efficiency by the Fmoc-loading procedure. It has been reported 
that coupling the first amino acid to the Tentagel resin, despite having a terminal 
free amine, can be relatively more difficult than subsequent residues.24 As such, 
we used 5 eq Fmoc-glycine with 5 eq each of HATU and HOBt to the resin for a 
coupling time of two hours. This procedure was repeated if less than 90% coupling 
was measured, such that the peptide capacity per bead could be maximized. After 
this, any remaining amines were acetyl-capped to prevent any heterogeneity in 
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the peptide chains on the same beads. Next, to provide a sufficient spacer from the 
resin, we coupled a second Fmoc-glycine using standard HBTU-chemistry. 
 We chose to use a photolabile linker (PLL)25 to attach our desired peptide 
to the resin. As the peptides were going to be screened while still on the resin, we 
needed a resin cleavage strategy that would allow us to deprotect the side chain 
protecting groups with TFA. Using a PLL, the library hits could be cleaved 
individually by exposing the resin to UV light at a wavelength of 365 nm (Figure 
4-9). To incorporate this into our library resin, we coupled the commercially 
available Fmoc-Photolabile Linker after the double glycine linker, providing the 
final resin prepared for library synthesis. After this coupling, the resin was 
protected from light to prevent premature cleavage. 
 
4.2.2 Optimization of DNA Tag Synthesis and Sequencing 
 Synthesis of a DNA-encoded library involves alternating steps of peptide 
synthesis and DNA ligation. As we are much more familiar with peptide synthesis 
and strategies to optimize it in a library setting, we chose to first optimize the 
necessary steps toward creating the DNA tag following a published procedure.26 
A test set of DNA oligomers corresponding to each residue was purchased, along 
Figure 4-9: Structure of the photolabile linker used for the library and resulting 
products after UV cleavage. 
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with the necessary headpiece to covalently attach the DNA to the peptide and 
primers for PCR amplification. 
 
 We chose to covalently attach the DNA to the Tentagel resin using Cu(I)-
catalyzed alkyne-azide cycloaddition (CuAAC). This required the inclusion of 
propargylglycine between the PLL and our library peptide sequence, as the DNA 
headpiece included an azide handle (Scheme 4-1). Without an effective way to 
monitor the DNA headpiece attachment, we first used azido-lysine to confirm the 
effectiveness of our conditions (Scheme 4-2). For this, a test peptide was 
synthesized to include diaminopropionic acid (Dap) and Trp such that the reaction 
could be analyzed by LC/MS. We were happy to see that our desired product was 
the only new mass observed in the LC/MS after the CuAAC reaction (Figure 4-
10). These conditions were then used for attachment of the DNA headpiece. 
Scheme 4-1: CuAAC Reaction for the Covalent Attachment of DNA to Tentagel Resin 
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 As mentioned above, no effective readout was found to analyze the yield of 
the CuAAC reaction between the peptide on resin and the DNA headpiece. This 
required us to move on with subsequent DNA ligation steps and analyze our final 
product by polymerase chain reaction (PCR) and denaturing polyacrylamide gel 
electrophoresis (PAGE). We ligated a universal starting sequence followed by six 
variable sequences (one for each diversity element in the peptide sequence) and 
ending with a universal ending sequence using T4 ligase. Maintaining an identical 
sequence at the beginning and the end of the DNA tag would allow for a single 
primer to be used for sequencing and provide an alignment sequence for tag 
identification after sequencing (Figure 4-11). 
Scheme 4-2: Test CuAAC Reaction for Conjugation to Tentagel Resin 
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Figure 4-10: LC/MS Data for CuAAC Test Reaction with Azido-lysine. UV traces at 
280 nm of A) peptide starting material and B) reaction mixture after CuAAC treatment. 
C) Extracted mass for peak at 13.8 min ([433.6972]2+, [866.3845]1+) correspond to the 
product. D) Extacted mass for peak at 14.3 min ([512.2240]1+) corresponds to peptide 
starting material missing Pra. E) Extracted mass for peak at 14.4 min ([607.2603]+1) 
corresponds to the starting material including Pra. 
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 Conveniently, PCR can be performed on the DNA oligomers while still on 
resin. After optimization of the PCR and PAGE conditions, we found that 
sufficient amounts of DNA were ligated on resin to allow for detection of 
oligomers with the desired length by ethidium bromide staining (Figure 4-12A). 
The DNA samples were excised from the gel, run through a second round of PCR 
with extension primer and analyzed by PAGE before preparing samples for 
sequencing (Figure 4-12B). All samples sent to Eton Bioscience for Sanger 
sequencing provided the expected coding sequence. 
         
 
5’-TGACTCCCGCCGCCCAGTCCTGCTCGCTTCGCTACATGGAAGAGAGGTCA 
AGTTTCAGGTTACGGAGCACTAAACCTCAATTCACAAAGAGCGCAATCCCATG 
CCTGTTTGCCCGCCAGTTGTTGTGCCAC-3’ 
 
Figure 4-11: Sequence of DNA used for testing of library ligation conditions. Black = 
headpiece sequence; Red = universal sequences used for alignment; Blue = encoding 
sequence; Orange = position specific overhangs. 
Figure 4-12: Denaturing PAGE of PCR reactions for single beads. A) Resin as template 
and B) with excised DNA from gel A as template. The product from gel B is expected 
to be longer original template (starting DNA) as an extra primer is included to provide 
extra length.  
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4.2.3 Simultaneous Peptide Synthesis and DNA Ligation Conditions 
 Having confirmed our DNA ligation and sequencing conditions were 
successful, we moved on to optimize the simultaneous synthesis of library 
peptides and DNA tags. It has been reported,27 and is not surprising, that different 
chemical reaction conditions can result in scission of DNA backbones or 
modification of DNA bases. Considering this, we needed to confirm that the 
conditions of our proposed library synthesis would not have such a detrimental 
effect on the DNA tag that it could no longer yield enough DNA for confident 
sequencing after hit selection. 
 
 Using a model peptide sequence (Figure 4-13), we performed a mock 
library synthesis. After the full process, the resin was checked for quality of both 
the DNA and the peptide. Fortunately, despite the harsh conditions of peptide 
synthesis and side chain deprotection, enough DNA remained intact providing 
Figure 4-13: Structure of bicyclic peptide used to test conditions for simultaneous DNA 
ligation and peptide synthesis. 
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the correct sequence (Figure 4-14). However, we were not as successful with the 
peptide synthesis, observing what appeared to be deletion products (Figure 4-15). 
 
 We thoughtfully considered what may have been going wrong with the 
peptide synthesis. Changing the peptide sequence and running controls which did 
not include DNA ligation did not improve our peptide product. Previously, we 
had experienced issues with using Reagent K with AB3 containing peptides. 
However, using an optimized cleavage cocktail also did not improve the final 
peptide quality. By comparing to other peptide sequences that had been 
successfully synthesized, we determined that the route of the problem was the 
combination of AB3 and propargylglycine. This was confirmed by performing an 
alkyne capping reaction using azidoacetic acid prior to side chain deprotection 
Sequence 1 
AGGTGTAACCCCAACCCACACACAACAACAGCCG
CCCAGTCCTGCTCGCTTCGCTACATGGAAGAGAG
GTCAAGTTTCAGGTTACGGAGCACTAAACCTCAAT
TCACAAAGAGCGCAATCCCATGCCTGTTTGCCCGC
CAGTTGTGTGCCACA 
Sequence 2 
AGACCAACCCCAACCCACACACAACAACAGCCGC
CCAGTCCTGCTCGCTTCGCTACATGGAAGAGAGG
TCAAGTTTCAGGTTACGGAGCACTAAACCTCAATT
CACAAAGAGCGCAATCCCATGCCTGTTTGCCCGC
CAGTTGTTGTGCCACA 
Sequence 3 
ACAATCCAAACCCCAACCCAACACACAACAACAGC
CGCCCAGTCCTGCTCGCTTCGCTACATGGAAGAG
AGGTCAAGTTTCAGGTTACGGAGCACTAAACCTCA
ATTCACAAAGAGCGCAATCCCATGCCTGTTTGCCC
GCCAGTTGTTGTGCCACA 
 
Figure 4-14: Results of library test ligation. A) Denaturing PAGE gel for single bead 
samples after reactions to mimic the DNA encoded library synthesis and B) sequences 
provided by Eton Bioscience, Inc. In the gel, the positive control included was a single 
bead sample from previous test of ligation. In the sequencing data, black = DNA base 
pairs outside of the alignment sequence, red = universal alignment sequences, blue = 
coding sequence and green = base pairs with the incorrect sequence. 
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(Figure 4-16). We concluded that this issue could be remedied by performing a 
capping step of the alkyne after attachment of the DNA headpiece. Strangely, we 
the second major product was the peptide containing the unreacted alkyne. It was 
unclear why this did not interfere with the side-chain deprotection in the same 
way it did under the original conditions. However, at this time we determined the 
cost of the platform was not sustainable and therefore did not explore this further. 
Figure 4-15: LC/MS analysis of peptide from test DNA encoded library synthesis. A) 
TIC trace and B) UV trace at 254 nm for sample. Extracted masses C) at 14.4 min 
([418.1994]3+, [835.3894]2+) and D) 14.5 min ([462.8853]3+, [693.8237]2+) did not 
correspond to any desired peptide sequences. 
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4.3 One-Bead Two-Compound Library of Monocyclic Peptides 
4.3.1 Library Structure Design 
 As our goal for the design of this library was to mimic the privileged 
scaffold and peptide targeting of vancomycin, we wanted to incorporate a cyclic 
structure with various amino acids displaying both hydrogen bond donors and 
acceptors. We chose a set of seven amino acids (Figure 4-17) that represent the 
different structural characteristics we were interested in, along with different 
hydrophobic structures to incorporate the possibility for hydrophobic 
interactions. We believed that this sampling of the amino acids would be sufficient 
Figure 4-16: LC/MS analysis of peptide from test DNA encoded library synthesis after 
capping with azido acetic acid. Extracted masses for C) peak at 12.9 min ([598.7670]2+) 
corresponds to peptide with unreacted propargylglycine and D) peak at 13.1 min 
([649.2775]2+) corresponds to product with the alkyne capped with azido acetic acid. 
This demonstrated that desired peptide masses were not observed in Figure 4-15 due 
to reactivity of the alkyne during side chain deprotection. 
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for a preliminary screen from which we could gather structure-activity 
relationships to influence later optimization. 
 
4.3.2 Utilization of a Core-and-Shell Strategy 
 In collaboration with Aaron J. Mauris in the Weerapana lab, we were able 
to pursue a mass-spectrometry based sequencing approach. We learned early on 
that the presence of our unnatural amino acid, AB3, prevented us from obtaining 
confident sequencing results from the modified SEQUEST program, as the correct 
sequence from a known sample was not found. This was most likely due to the 
fact that the boronic acid functionality can exist in different hydroxylated forms 
when analyzed by ESI, such that an expected mass fingerprint could not be 
extracted. As a result, we chose to use a core-and-shell arrangement for the 
incorporation of AB3 into our sequence, creating separate library peptides with 
and without this functional group. 
Figure 4-17: Structures of seven amino acids chosen for library. Arginine, Glutamine, 
Tyrosine, Aspartic acid, Proline, Histidine and Isoleucine. 
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 Core-and-shell arrangements are a common way to construct one-bead-
two-compound libraries and are dependent on certain qualities of the resin used 
for library synthesis. In our case, the characteristic of Tentagel resin that makes it 
ideal for on-resin screens, swelling in aqueous and organic solvents, can also be 
taken advantage of during library synthesis. By using water and an immiscible 
organic solvent, distinct layers within the resin can be created. Reactions can then 
be limited to the outer layer of the resin using reagents only soluble in the solvent 
in this layer (Figure 4-18). 
In order to obtain a core-and-shell arrangement, the resin transferred from 
DMF to water by washing with increasing ratios of water to DMF at the desired 
step in synthesis; in our case, this was performed directly before the coupling of 
AB3. The resin was then fully equilibrated in water by soaking it overnight. The  
 
Figure 4-18: Structure of core/shell arrangement for our one-bead-two-compound 
library. The sequence in blue represents the core structure, contained within the water 
layer and unable to react. The sequence in black represents the shell structure, 
contained within the organic layer and accessible to coupling reagents for AB3. 
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excess solvent is removed, such that the resin remains swollen, and the desired 
reagents are added as a solution in a 50:50 mixture of diethyl ether and 
dichloromethane (DCM).28 Since neither of these solvents are miscible with water, 
only the peptide chains on the outermost section of the resin are exposed to the 
peptide coupling reagents. After the AB3 coupling is complete, the resin is washed 
with DCM, to prevent exposure of the core peptide chains to any remaining 
activated AB3, then with DMF. The resin is then re-equilibrated in DMF and 
library synthesis is continued on. 
In our hands, the use of DIC as a coupling agent for AB3 with the core-and-
shell arrangement provided 70% coupling of AB3, as determined by LC/MS 
analysis (Figure 4-19). Completing the full peptide synthesis and submitting 
samples to Aaron demonstrated that the 30% peptide not containing AB3 was 
sufficient to provide confident sequencing results on a single bead level. 
136 
 
 
4.3.3 Cysteine Disulfide Formation for Reversible Cyclization 
Next, we attempted to achieve a second core-and-shell arrangement for the 
final residue. We pursued this step with the aim of incorporating a second AB3, 
allowing for a multicyclic structure to be formed through the selective reduction 
of iminoboronates between AB3 and lysine (i.e. sequence seen in Figure 4-13). 
Unfortunately, we were unsuccessful towards this goal. Creating a second 
core/shell arrangement yielded us with four different peptide sequences, yielding 
a mixture too complicated for our analysis. As a result, we settled on first exploring 
a monocyclic structure formed via disulfide bond between N- and C-terminal 
cysteines (Figure 4-20). The use of disulfide cyclization allowed for the 
Figure 4-19: LC/MS analysis of a model core/shell peptide. The peptide sequence is 
Ac-Cys-Val-His-Val-(AB3)-Gln-Pro-Arg-Cys-Tyr-NH2 with both cysteines capped 
using iodoacetamide. Both displayed masses are for [M+2H]2+, matching expected 
masses of 1260.58 and 1493.67 for the core and shell sequences, respectively. The mass 
difference of 233.09 matches the residue mass of AB3. 
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linearization of the sequencing compound prior to UV cleavage and mass-spec 
sample preparation. 
 
Originally, we pursued both air and DMSO-mediated on-resin oxidation 
for cyclization. Unfortunately, neither of these methods yielded the desired result. 
We observed that air oxidation proceeded on the time scale of days, while DMSO-
mediated oxidation created a relatively significant impurity. Looking into the 
literature, we found a method for on-resin peptide disulfide formation using N-
chlorosuccinimide (2 equivalents) in DMF. An appealing feature to this cyclization 
method was that it was complete within 15 min using relatively mild reagents. 
Using these conditions, we found complete cyclization without the formation of 
significant impurities. For mass-spec analysis, subsequent reduction of the 
Figure 4-20: Structure of final library design. The sequence displayed in blue 
corresponds to the screening compound while the sequence in red displays the 
sequencing compound. X = variable side chain, from the amino acids in Figure 4-17. 
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disulfide using TCEP and iodoacetamide capping of the free thiols after the full 
synthesis of our test library member yielded the desired sequence. 
4.3.4 Total Synthesis of the Library 
 In order to create the library, we utilized a split-and-pool strategy. Taking 
the bulk resin prepared up to the PLL, we coupled the first cysteine. After Fmoc 
deprotection, the resin was suspended in DMF and evenly distributed into seven 
RVs, one for each amino acid. The individual amino acids were dissolved in 0.4 M 
NMM in DMF and each was added to a RV. After a one hour coupling, the resin 
was combined into the original RV, washed with DMF six times then Fmoc 
deprotected, ready for the next split. This procedure was repeated two more times, 
yielding the peptide up to the AB3 residue. AB3 is coupled to the peptide in the 
established core/shell procedure and the split-and-pool is carried on after this. 
 When all of the variable residues have been added, the N-terminal cysteine 
is coupled to the bulk library resin. We chose to also acetyl cap the N-terminus, 
providing us with a possible location for fluorophore labeling during hit 
validation without altering the overall charge and characteristics of the peptide. 
The side chains are then deprotected using 10% water in TFA for four hours. 
Finally, peptides are cyclized using the established conditions, yielding the 
desired final library structure. 
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4.3.5 Quality Control Analysis of the Library 
 As we could not analyze the success of the library synthesis by analyzing a 
bulk sample, we prepared single bead samples and submitted for MS/MS 
sequencing. Of 20 beads, we observed ten beads to have clean enough spectra for 
confident sequencing (Table 4-1). 
Table 4-1: Quality Control Analysis of Library Sequencing 
Sample 
Top Hit 
Sequence 
QC 
Check? 
Sample 
Top Hit 
Sequence 
Pass 
QC? 
1 YPPDYQ  11 No sequences X 
2 RDYDPD  12 No sequences X 
3 HPHIRQ  13 IRDHYQ  
4 No sequences X 14 No sequences X 
5 IDYDYR  15 YRHDYH  
6 No sequences X 16 No sequences X 
7 PDQDHQ  17 HPHYPI  
8 No sequences X 18 No sequences X 
9 IQHHII  19 YYHIHD  
10 IQHHII  20 No sequences X 
Top hit sequences are listed with just the six variable amino acids. For samples 
which did not pass QC, the SEQUEST program was either unable to find a 
library peptide sequences matching the mass spec data, the top two sequences 
were too close in spectral counts or the number of spectral counts for the top 
sequence was below 80. 
4.4 Design and Validation of a Screening Scheme for Lipid II Stem Peptide Binders 
4.4.1 Developing Intermolecular Imine Reduction Conditions for 2-APBA and Lysine 
 Our earliest work studying the association between 2-APBA functionalities 
and lysine demonstrated that the iminoboronate formed was rapidly reversible. 
Under the conditions of library screening, this would result in many of the hits 
being lost during washing steps as a result of a shift in the equilibrium towards 
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the dissociated forms after resuspension in fresh buffer. On the other hand, not 
performing any washing steps throughout our screen would result in the 
collection of false positives, as non-specific binders would not be removed. 
However, iminoboronate formation has a distinctive feature that could overcome 
both of these potential downfalls. 
 The quintessential feature of screening for library hits with reversible 
iminoboronate binding became that they could be covalently captured using 
hydride reduction. In a similar way as reductive amination was used in Chapter 
2, reduction of iminoboronates yields amines which are no longer freely 
dissociable (displayed in Figure 4-8). Our group has already demonstrated the 
utility of this in the case of intramolecular peptide cyclization,23 though it has yet 
to be obtained when the 2-APBA and amine are located on separate molecules. 
  In our previous work, reduction was achieved using sodium 
cyanoborohydride; as such, we used these conditions as our starting point for 
analyzing the possibility of intermolecular iminoboronate reduction. We chose to 
study a model reaction of the reduction between simple 2-APBA and lysine 
(Figure 4-21), analyzing the degree of reduction by 1H NMR. We explored changes 
in the concentration of NaCNBH3 and the temperature the reaction (Table 4-2). 
However, the only change we observed was the reduction of the acetyl group to 
the corresponding secondary alcohol. 
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Table 4-2: Optimization of Iminoboronate Reduction 
Reducing Agent (Conc.) Temperature Imine Reduction Observed? 
NaCNBH3 (50 mM) RT No 
NaCNBH3 (25 mM) RT No 
NaCNBH3 (12.5 mM) RT No 
NaCNBH3 (50 mM) 0℃ No 
NaBH4 (50 mM) RT Yes 
Analysis of imine reduction between 2-APBA and lysine performed using NMR 
 We hypothesized that the kinetics of NaCNBH3 imine reduction were not 
rapid enough to capture the iminoboronate before dissociation occurred. We chose 
to attempt the iminoboronate capture using a stronger hydride donor, namely 
sodium borohydride (NaBH4). Studying the same original reaction conditions as 
with NaCNBH3, we were happy to see reduction of the imine was occurring with 
NaBH4 at about 10-15% conversion (Figure 4-22). Furthermore, we observed that 
the acetyl groups on the unreacted AB3 were also reduced, which could be 
beneficial to our screen, as it would prevent any secondary binding of the target 
from occurring after the reduction. To more clearly quantify the amount of 
conjugated product captured, we switched the amine used to Fmoc-lysine, 
providing us with a chromophore to use in LC/MS analysis (Figure 4-23). Based 
on the Kd obtained via NMR titration, we expect about 30% conjugate to be formed 
Figure 4-21: Test reaction used for optimizing conditions of intermolecular 
iminoboronate reduction. 
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under these conditions before reduction. Considering this, we estimated that we 
obtained about 50% of the expected reduced product. 
 
Figure 4-22: NMR Spectrum of 2-APBA and Lysine Reduction with NaBH4. In the inset, 
the peaks between 3.55 and 3.70 ppm show the proton on the α-carbon with the 
conjugate peak integrating to 0.13 and the unmodified lysine peak integrating to 0.95. 
The peaks between 2.90 and 3.00 correspond to the protons on the ε-carbon and amine 
with the unmodified lysine peak integrating to 5.05 and the conjugate peak integrating 
to 0.44. 
Figure 4-23: Test reaction between 2-APBA and Fmoc-lysine. LC/MS data shows 14.5% 
conversion to the iminoboronate reduction product with the other peak corresponding 
to unchanged starting material. 
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4.4.2 Hit Selection via Affinity-mediated Pull-down 
 A common strategy to extract binders during library screening is through 
an affinity tag on the target, such as with the addition of a target-specific antibody 
or by biotinylating the target for binding to streptavidin, for pull-down.29,30 As our 
target was only a short peptide, we saw the best option as being to add a biotin 
handle at the end of the peptide, opening up a wide variety of pull-down methods. 
The biotin group was expected to be small enough to not interfere significantly 
with target binding of the library, and could be easily attached to the N-terminus 
through amide bond formation, as biotin contains a free carboxylic acid not 
involved in its interaction with streptavidin. 
 We were interested in the streptavidin-coated magnetic Dynabeads to 
perform our desired affinity pull-down. The magnetic beads are straightforward 
in practice and would not require us to obtain any extra equipment in order to use 
them. They also have an added benefit in being rapid for pull-down. However, 
they do suffer from high false positive rates and a somewhat lower false negative 
rates.31 With the library screen we envisioned, both of these could be overcome. In 
the case of the high false positive rate, we were planning on doing a second 
fluorescence microscopy-based screen. This would give us an opportunity to 
discard false positives from the initial screen before sequencing. As for the false 
negatives, literature has shown that this can be remedied by including multiple 
copies of all the library members.31 For the scale we planned to screen against, we 
144 
 
expected eight to nine copies of each library peptide, greatly decreasing the 
probability of all copies of a hit being left behind as a false negative. 
 We moved on to study the necessary conditions for magnetic bead pull-
down as they pertained to our own screen. To do this, we synthesized the desired 
screening target on Tentagel beads, such that the biotin was covalently attached to 
the bead, similar to what we expected for our library hits in the actual screen 
(Figure 4-24). Conveniently, the fluorescein tag resulted in the positive control 
beads turning from colorless to orange. This allowed us to analyze the mixture 
using simple white light microscopy. 
 
Taking these positive control beads, we doped them into samples of blank 
beads at hit rates of 1% and 0.1%. After equilibrating the beads in PBS buffer with 
0.1 mg/mL BSA overnight, the streptavidin-coated magnetic beads were added 
and the mixture was allowed to incubate for two hours. A magnet was applied to 
Figure 4-24: Structure of positive control on Tentagel resin. This sequence was used as 
a control for optimizing the magnetic pull-down and fluorescence microscopy 
screening conditions. The biotin handle is shown in blue and fluorescein is shown in 
green. 
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the sample and the supernatant with any unbound Tentagel beads was removed. 
The magnet was removed to release the magnetic beads with captured Tentagel 
resin which were then resuspended in PBS buffer with 0.1 mg/mL BSA for 
washing. The pull-down was repeated and the final collection was analyzed under 
the microscope to determine the numbers of recovered positive control vs. blank 
beads. 
In the 1% hit rate experiment, we were able to recover 75% of the positive 
control beads with only 12% of the blank beads, resulting in a six-times enrichment 
of the positive control and a close to nine-times reduction in the blank beads. In 
the 0.1% hit rate experiment, we recovered 55% of the positive control beads with 
only 3.4% of the blank beads, resulting in a 15-times enrichment of the positive 
control and about a 30-times reduction in the blank beads. Additionally, we looked 
at the captured beads under the fluorescence microscope. By fluorescence, positive 
controls were easily distinguished from the blank beads (Figure 4-25). Given the 
success of these control experiments, we were confident the magnetic pull-down 
would be a viable option for our first screening step. 
4.4.3 Selection of Hits Using Fluorescence Microscopy 
Fluorescence-based screening is a common strategy used in library 
selections. Targets containing a fluorophore tag are relatively easy to obtain and  
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performing selections with fluorescence microscopy or large particle sorting tend 
to be fairly straightforward. In our case, we would need to use microscopy in order 
to separate single beads for sequencing. This made fluorescence microscopy an 
attractive strategy as it would combine the necessary hit separation with a second 
round of screening. 
A degree of binding caused by non-specific interactions between the library 
and the target is widely known to occur during on-resin screening. Typically, this 
is caused by hydrophobic interactions between the resin material and the target of 
interest. As such, we wanted to be sure that this would not hinder the distinction 
between hit and non-hit beads during fluorescence analysis. We looked at three 
different sets of prepared Tentagel resin: the first was the blank resin, serving as 
our negative control; the second had carboxyfluorescein coupled to the resin, 
serving as our positive control with the theoretical maximum fluorescence we 
Figure 4-25: Microscopy images from Dynabead magnetic pull-down optimization. A) 
White light; B) FITC channel; C) Overlay. From the overlay, the positive control beads 
(colored green to show fluorescence) are easily distinguished from the blank beads. 
Dynabeads can be seen as small black dots in the white light and speckle the positive 
control beads in the FITC channel. 
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could observe; the third had a random peptide sequence containing AB3 (P13)23 
on it to demonstrate the expected fluorescence from a naïve sequence (Figure 4-
26). 
For the blank and P13 resin, samples were first incubated for 1 hour with 
the fluorescent target peptide. We looked at both resins without any washing and 
with a single wash using PBS buffer, pH 7.4. The positive control resin was not 
treated with the target and therefore was not washed any further before imaging. 
Without washing, the blank and P13 resins appear to have a similar average 
fluorescence values along with a considerable amount of background 
fluorescence. After washing, the P13 resin fluorescence decreased by about two-
fold while the blank resin decreased by about four-fold. These values were still 
close to an order of magnitude lower than that of the positive control resin. 
Microscopy images can be seen in Figure 4-27. 
Figure 4-26: Structure of P13 peptide on Tentagel resin. This peptide was used as a 
naïve structure when examining fluorescence microscopy conditions. 
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With these images, we were confident that hits would be distinguishable 
from false positives after the magnetic pull-down selection. This is better 
displayed by a sample of mixed resin, where the blank, P13 and positive control 
resins were imaged in the same sample. They also demonstrate that we could 
expect little non-specific binding caused by the resin alone after just a single wash, 
decreasing the occurrence of false positives. After the iminoboronate reduction, 
we planned to perform multiple washes to remove any remaining target peptide 
and to alleviate non-specific interactions. 
Figure 4-27: Fluorescence microscopy images of various sets of prepared Tentagel 
resin. A) White light and B) FITC channel images of blank resin with target peptide, no 
washes; C) White light and D) FITC channel images of blank resin with target peptide 
after one wash; E) White light and F) FITC channel images of P13 resin with target 
peptide, no washes; G) White light and H) FITC channel images of P13 resin with target 
peptide after one wash; I) White light and J) FITC channel images of positive control 
resin; K) White light and L) FITC channel images of all three resins mixed together. 
Positive control resin is observed to have the brightest fluorescence, but blank and P13 
resins are still distinguishable when contained in the same sample. 
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4.4.4 Final Screening Scheme and Known Sequence Validation 
 With all steps in our proposed screen optimized, we designed a final 
screening scheme (Figure of 4-28). After side chain deprotection and cyclization of 
the peptide resin, it would first be equilibrated in PBS buffer (pH 7.4) overnight. 
The resin was then washed three times with PBS buffer (pH 7.4) containing 1.0 
mg/mL BSA to serve as a blocking agent. The final solution suspended the library 
beads at a concentration of 17.5 mg beads/mL. To this, the target peptide was 
added to a final concentration of 10 µM and the suspension was rotated while 
incubating at 37℃ for 1 hour. The iminoboronate was reduced by adding sodium 
borohydride at a concentration of 50 mM and rotating the sample for 15 min. The 
resin was then washed PBS buffer (pH 7.4) six times and resuspended in PBS 
Figure 4-28: Depiction of final optimized screening scheme for our cyclic library 
against lipid II stem peptide. 
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buffer + 1.0 mg/mL BSA. To this, streptavidin magnetic beads (stock=10 mg/mL) 
were added to a final concentration of 0.1 mg/mL. This solution was allowed to 
rotate while incubating at 37℃ for two hours to allow for efficient association of 
the biotin and streptavidin. The magnetic selection was performed and washed 
once. After washing, the collected hits and magnetic beads were suspended in PBS 
buffer (pH 7.4). 
 The collection of hits would then be examined under the fluorescent 
microscope and selected based on relative fluorescence. All the hits were 
segregated from the non-hits and treated with TCEP to break the disulfide 
cyclization then capped with iodoacetamide. Individual beads were then 
separated into individual microconical tubes for UV cleavage. The individual 
samples were provided to Aaron as a 20 µL solution in 95% water, 5% acetonitrile 
and 0.1% TFA. 
 It was not completely clear whether any of the steps in our screen would 
have negative effects on our confidence in the sequencing results. As such, we 
prepared 1 mg of a known sequence and subjected it to a round of screening. The 
expected sequence was successfully obtained from the mass-spec analysis of all 
four single bead samples submitted. With this, we were confident that the 
sequences obtained from hits after screening would be accurate. 
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4.4.5 Screening and Sequencing of the Library 
 We subjected 350 mg of our library, a scale which provides eight or nine 
repeats of each library peptide, to our screen. We collected 29 hits, treated them to 
disulfide reduction, cysteine capping and resin cleavage. The samples were 
prepared for LC/MS/MS analysis and submitted for sequencing. From analyzing 
this data, we established 18 hit sequences (Table of 4-3). Of these, we selected 10 
to move forward to validation. Hits for validation were picked based on our 
confidence in sequencing, which includes observing the corresponding mass for 
the screening peptide with the given top hit sequence. 
Table 4-3: Hits from Library Screening of Lipid II Stem Peptide 
Sample Sequence 
Picked for 
Validation 
Sample Sequence 
Picked for 
Validation 
1 RHYRYQ  16 YRYPPR  
2 N/A X 17 YRIRDI X 
3 PHPRQQ X 18 HQYYYR X 
4 PRHYHH X 19 N/A X 
5 RRRYHR X 20 YDDDDP X 
6 N/A X 21 IRYHYP  
7 N/A X 22 HYQRRY  
8 N/A X 23 PHRRQI X 
9 RIIHPI  24 IHHRQY X 
10 N/A X 25 HIDPRR  
11 HRHDYR  26 IHQYPH  
12 RRIYRQ X 27 N/A X 
13 RQHYPQ  28 PIPHRQ X 
14 YHIDQP X 29 YIDIQP X 
15 YIDHQH     
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4.5 Hit Validation 
4.5.1 Synthesis of Selected Hits 
 Selected hits were synthesized on Rink amide resin then cleaved using 
82.5% TFA, 5% phenol, 5% water, 5% thioanisole and 2.5% triisopropylsilane. The 
peptide was precipitated two times using cold diethyl ether and dried under 
vacuum to yield the crude peptide. Each peptide was purified by reverse-phase 
HPLC and collected samples were lyophilized. To cyclize the peptide, the 
lyophilized peptide was then dissolved in 10% DMSO in water at a final 
concentration of 1 mM. This was allowed to stir open to air and was monitored by 
LC/MS for conversion to the cyclic product. After full conversion was observed, 
the peptide was lyophilized and stored at -20℃. 
4.5.2 Validating Hits using MIC 
 Initially, we chose to perform hit validation by examining the peptides’ 
ability to inhibit the growth of S. aureus using an MIC assay. As our goal from this 
library was to find a peptide with potent antimicrobial activity, using an MIC 
assay was the most direct way to measure this. We studied the first four hits that 
had been synthesized (Hit 1, 13, 16 and 21) at concentrations up to 10 µM in the 
standard micro-dilution MIC assay. Unfortunately, none of these gave any 
significant inhibition within this concentration range (Figure 4-29). 
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4.5.3 Validating Hits using a UV-Vis Titration with the Target Peptide 
 After the lack of success in using the MIC assay, we decided to look instead 
at the binding potency of our hits to the target peptide, as this is what we had 
explicitly selected for. As fluorescence anisotropy did not appear to be the best 
assay to use in this case, we considered using a titration monitored by UV-vis 
spectroscopy. We have observed that the absorption maximum of 2-APBA shifts 
from 254 nm to 280 nm upon the formation of iminoboronates. As such, a titration 
can be used to calculate Kd of the binding between the 2-APBA moiety and an 
amine by plotting the change in absorbance at 280 nm with the increasing 
concentration of the amine (Figure 4-30) In our case, this would be the hit and 
target peptides, respectively. 
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Figure 4-29: MIC plots for first four hits with S. aureus. None of the hits appear to 
demonstrate any growth inhibition towards the bacteria. 
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 To confirm the effectiveness of this strategy, hit peptides were first titrated 
with simple 2-methoxyethylamine. These titrations showed similar UV-vis 
profiles to that of 2-APBA with 2-methoxyethylamine with similar Kd’s (Figure 4-
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Figure 4-30: Titration of AB3 with lysine monitored by UV-vis absorbance. A) UV trace 
for changing concentration of lysine; B) Titration curve for the absorbance at 280 nm 
with increasing concentration of lysine. 
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31). Based on this data, we found the hit peptides sufficiently capable of 
iminoboronate formation with a simple amine. However, when the titrations were 
performed between the hit peptides and our biotin-labelled target peptide, no shift 
in the UV-vis spectrum appeared, even in the range of low millimolar target 
concentration (Figure 4-32). We found this very strange, as even if the rest of the 
target peptide was not contributing to binding interactions, we should observe a 
Kd similar to lysine alone. To confirm that the target peptide behaved as expected 
under these titration conditions, we titrated AB3 alone with this peptide. We saw 
similar results as with the hit peptides, with no significant change in the UV-vis 
trace (Figure 4-33A). Additionally, we estimated the Kd of 2-APBA with the target 
peptide to be about 14 mM by proton NMR (Figure 4-33B). As this is very close to 
that of 2-APBA with lysine, we expected to see a similar change in the absorbance 
profile during the titration of AB3 with the target, but this was not the case. We 
concluded that this type of titration would not be an effective way to validate our 
hits and considered alternative options. 
 
156 
 
 
0.08
0.1
0.12
0.14
0.16
0.18
0.2
0.05 0.5 5
A
bs
or
ba
nc
e 
@
 2
80
 n
m
Concentration of 2-methoxyethylamine (mM)
Example Hit Titrations with 2-Methoxyethylamine
Hit 16
Hit 21
0
0.02
0.04
0.06
0.08
0.1
0.12
0.14
0.16
0.05 0.5
A
bs
or
ba
nc
e 
@
 2
80
 n
m
Concentrations of Biotin-Lipid II Stem Peptide (mM)
Hit Titrations with Biotin-Lipid II Stem Peptide
Hit 13 Hit 16
Hit 21 Hit 25
Figure 4-31: Example titrations of hit peptides with 2-methoxyethylamine (2-MEA). 2-
MEA was used a positive control for UV-vis titrations of the hit peptides. 
Figure 4-32: Titrations of hit peptides with biotin-lipid II stem peptide. Even up to 2 
mM, very little change was observed. The small decrease in absorbance at 280 nm was 
likely an artifact of the peptides’ dilutions. 
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Figure 4-33: Titrations of AB3 with biotin-lipid II stem peptide. A) UV-vis absorbance 
shows no change at 280 nm, indicating no binding; B) NMR of 5 mM 2-APBA and 5 
mM biotin-lipid II stem peptide in 10% D2O in PBS buffer (pH 7.4). The inset shows 
acetyl peaks assigned to the ketone of 2-APBA (2.56 ppm) and to the iminoboronate 
comples (2.42 ppm). Based on the relative integration of the acetyl peaks, the KD is 
estimated to be 14 mM. 
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4.5.4 Validating Hits using Iminoboronate Reduction 
 In our last attempt to validate our hit peptides from our screen, we again 
sought to imitate conditions from our screen using sodium borohydride reduction. 
To do this, we chose to mix each hit peptide at equal concentrations with the target 
peptide and attempt to capture the covalent conjugate in this same way. 
 Each hit at 500 µM was mixed with the target peptide at 500 µM in PBS 
buffer, adjusting the pH to 7.4 as necessary. This was allowed to equilibrate at 37℃ 
for one hour before sodium borohydride was added to a final concentration of 50 
mM. The sample was analyzed by LC/MS to evaluate the degree of reduction. 
Unfortunately, among all the hits tested, none were observed to have any 
detectable conjugated product. 
4.5.5 Hit Validation – What May Have Gone Wrong? 
 The only conclusion we were able to draw from our attempts at hit 
validation was that our screen was unsuccessful. Despite all the controls run 
before the screen to best optimize it, none of the hits collected demonstrated 
detectable binding.  Discouraged by these results, we have speculated on several 
reasons that may have led our screen to not yield effective results.  
One possibility for the poor hit validation considers the mutlivalency effect. 
Not an uncommon pitfall in library screening, having multiple copies of the same 
library molecule in close proximity can increase the apparent potency of binding. 
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When the hit is then dispersed in a homogenous solution, the cooperative binding 
potency is lost. Another possibility we have considered was that the difficulty 
associated with targeting a peptide prevented us from obtaining real hits, as it 
provides much fewer points of interactions compared to a protein. Thus, it could 
be that the observed hits were caused by random binding that could not be 
recreated in the conditions used for validation. 
Additionally, it is possible our fluorescence intensity was not properly 
normalized. When selecting hits, it would have been better to keep the microscope 
settings for lamp intensity and exposure time consistent with our positive control 
images. Although we cannot be sure, there is the possibility that the fluorescence 
observed was falsely high, making selected hits appear brighter. When returning 
to the library resin to consider new targets, we observed a high amount of auto-
fluorescence from the beads alone. This corresponded with poor quality 
sequencing of the resin at this time. Since we were not diligent in monitoring the 
change in auto-fluorescence over time, it also cannot be confirmed that this did not 
have a negative effect on our screen. We did learn that this auto-fluorescence is 
mostly limited to the FITC fluorescence channel, demonstrating that the best way 
to avoid this interference would be to not use a green fluorophore. 
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4.6 Targeting Transferrin: Selective Binding to a Single Protein in a Complex 
Mixture 
 Gaining selectivity for a single protein in a complex mixture is typically a 
nontrivial undertaking. Playing a very important role in pharmacokinetics and 
pharmacodynamics, selectivity can also be difficult to predict. However, one of the 
advantages of library-based ligand discovery is that it can offer avenues towards 
tightening selectivity. Library selections can include other relevant proteins as 
competitors or negative screens to remove strong binders of undesired proteins, 
providing a better chance at selectivity. 
 A relevant complex mixture of proteins can be seen in blood serum. The 
human plasma proteome is estimated to contain about 100,000 proteins with these 
spanning concentrations over 12 orders of magnitude.32 The clinical relevance of 
these proteins is easy to see: any drug, regardless of its mode of administration, 
first encounters these proteins as it is transported through the blood. As such, the 
degree to which a drug binds to these proteins can have a high impact on its 
pharmacokinetics, and finding the correct balance for this is critical for a drug’s 
clinical success. As a way to take advantage of this, much work has been done 
investigating serum protein binding as a method of drug delivery. 
 Transferrin (Tf), as one of the more abundant serum protein, has been 
studied for its drug carrier capabilities. Specifically, clinical trials were taken to 
phase III for the convection-enhanced delivery (CED) of diphtheria toxin by 
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linking it to Tf for the treatment of brain glioblastomas.33 The complex is taken up 
through Tf-mediated endocytosis upon binding to the glioma cells and the toxin 
is cleaved after cell entry. Although it was found effective through phase I and II 
trials,33 the clinical trial was stopped by the sponsor (Xenova Biomedix) during 
phase III in the anticipation that the study’s endpoints would not be reached.32 
Nonetheless, this study demonstrated the potential for Tf-based drug delivery. 
 With the advantages of reversible covalent binding included in our 
platform, drug delivery via Tf binding could be achieved without the need for ex 
vivo formulation of the protein-drug conjugate. Additionally, having a small 
peptide drug, rather than a large protein, can increase the number of possible 
administration methods. Finally, a lower immune response can be expected from 
the treatment if the endogenous Tf is used instead. 
 Toward this end, we sought to perform screening of our library against Tf. 
By performing our screen in the presence of relevant concentrations of human 
serum albumin (HSA), the most abundant protein in the blood, we expected to 
find a selective binder for Tf. 
4.6.1 Designing a Screen for Transferrin 
 To design our screen, we first investigated the availability of modified Tf 
protein. We found that there were many possible modifications available, 
including biotinylated and fluorescent proteins. Unfortunately, there did not 
appear to be any commercially available protein with both a biotin handle and a 
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fluorescent tag, causing us to reconsider our previous screening scheme. With the 
fluorescence microscopy screen being more sensitive and less prone to false 
positives, we decided on using a fluorescently labelled Tf for our screen. 
Specifically, we purchased rhodamine-labelled Tf; we chose to switch from 
fluorescein to rhodamine after observing some degree of Tentagel auto-
fluorescence in the FITC channel. In contrast, library beads visualized in the 
rhodamine channel were nearly undetectable. 
 To favor Tf-selective hits, we chose to include HSA in the screening matrix. 
We chose only to include HSA instead of screening all serum proteins as it is the 
most abundant and, therefore, the most likely protein to interfere with selective 
binding in the blood. Using the rhodamine-Tf at a concentration of 0.08 mg/mL, 
we included HSA at a concentration of 1.6 mg/mL, as it is typically observed at 
concentrations 10-20 times higher than that of Tf in serum samples. 
4.6.2 Screen and Hit Selection for Transferrin Binding Cyclic Peptides 
 In order to examine non-specific binding, we examined the blank Tentagel 
resin within the same conditions of our screen. We observed very little non-specific 
fluorescence on the beads, even without any washing (Figure 4-34). With this, we 
were confident that beads with better binding would have an increased 
fluorescence when looking under the fluorescence microscope. 
 After equilibrating 50 mg of the library resin in PBS buffer (pH 7.4) 
overnight, it was washed three times with PBS buffer then suspended in PBS 
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buffer with 1.6 mg/mL HSA (2.3 mL). To this, a 1 mg/mL stock of rhodamine-Tf 
(200 µL) was added. The library was allowed to incubate with the protein at 37℃ 
while rotating for one hour. Sodium borohydride was added to a final 
concentration of 50 mM and the reduction was allowed to occur for 15 min. The 
library was then washed four times with PBS buffer (pH 7.4), once with PBS buffer 
(pH 5) and one final time with PBS buffer (pH 7.4). Microscopy images of the 
library resin after screening can be seen in Figure 4-35. 
 
4.6.3 Sequencing and Analysis of Hits from Screening Transferrin 
 A total of 21 hits were collected and provided to Aaron for sequencing. Of 
these, 18 yielded sequences with confident data (Table 4-4). In contrast to our 
sequencing data for the lipid II stem peptide screen, a few different common 
Figure 4-34: Microscopy images of blank Tentagel resin under the rhodamine-Tf 
screening conditions. A) White light and B) rhodamine channel images without any 
washes. C) White light and D) rhodamine channel images of resin after complete 
washing protocol for screen. 
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patterns were observed amongst these sequences. This included a tyrosine repeat 
and an RYY sequence, which were observed in five and two of hits, respectively. 
 
Table 4-4: Hits from Library Screening of Transferrin 
Sample Sequence 
Picked for 
Validation 
Sample Sequence 
Picked for 
Validation 
1 RYYHRH  12 YRIDQP X 
2 IYYPRY  13 N/A X 
3 HIRRQY X 14 RYQQRY  
4 RHQIIH  15 DYYRYP X 
5 QIRHDH  16 PHRDYI X 
6 DHDYYI  17 HIYQHY X 
7 N/A X 18 YDRHRY  
8 YPHYRD X 19 RDYRHY X 
9 N/A X 20 RHRYRY  
10 IYHQDY  21 RHPRQY  
11 HDYYRH     
 
 
 
Figure 4-35: Microscopy images of library resin under the rhodamine-Tf screening 
conditions after reduction. A&C) White light; B&D) rhodamine channel images. 
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4.6.4 Hit Validation for Transferrin 
 Initially encouraged by the YY repeats, we chose to synthesize the first two 
hits for validation, which were also two of the brightest beads observed during 
screening. As it had somewhat contrasting qualities to hits 1 and 2, we also chose 
hit 10 for validation. All three peptides were synthesized using standard Fmoc-
based SPPS on Rink amide resin. The N-terminus was labelled on resin using 
carboxyfluorescein, providing a fluorophore necessary for validation using 
fluorescence anisotropy. The peptides were then cleaved with a modified Reagent 
K (80% TFA, 7.5% w/v phenol, 5% water, 5% thioanisole and 2.5% 
triisopropylsilane) and purified by RP-HPLC. The final purity was confirmed by 
LC/MS analysis to be >90%. The purified peptides were cyclized using DMSO-
mediated air oxidation to provide the final peptide structure, monitoring for 
complete oxidation by LC/MS. 
 For validation using fluorescence anisotropy, we studied each peptide at a 
concentration of 200 nM with varying concentrations from 0-10 mg/mL of human 
Tf.  In this experiment, carboxyfluorescein was used a negative control (Figure 4-
39), to distinguish any non-specific binding as a result of the fluorophore. From 
this data, it would appear that Hit 1 (Figure 4-36) and 10 (Figure 4-38) bind well to 
Tf while Hit 2 (Figure 4-37) performed worse than fluorescein alone, indicating 
very little to no binding. We can make a preliminary conclusion that Hit 1 has the 
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best binding to Tf with an estimated Kd of 2-2.5 mg/mL (25-30 µM). This is 
significant, as the serum concentration range of Tf is 2.5-3.5 mg/mL.32 
 The hits were also studied with human serum albumin (HSA) to 
demonstrate their degree of selectivity for transferrin. We were happy to see that 
Hit 1 (Figure 4-36) showed nearly zero binding to HSA compared to fluorescein 
alone. Comparatively, Hit 10 had more significant binding to HSA (Figure 4-38), 
although it is still very low. Hit 2 appeared to have better binding to HSA than Tf 
(Figure 4-37), suggesting it may have been in a false positive from our screen. 
Overall, we concluded that Hit 1 and 10 both had preferential binding to Tf, with 
Hit 1 performing slightly better. Our current and future plans include determining  
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Figure 4-36: Hit 1 validation by fluorescence anisotropy with Tf and HSA. Hit 1 was 
studied at 200 nM with various concentrations of each protein. Points represent 
averages of triplicate samples. 
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Figure 4-37: Hit 2 validation by fluorescence anisotropy with Tf and HSA. Hit 2 was 
studied at 200 nM with various concentrations of each protein. Points represent 
averages of triplicate samples. 
Figure 4-38: Hit 10 validation by fluorescence anisotropy with Tf and HSA. Hit 10 was 
studied at 200 nM with various concentrations of each protein. Points represent 
averages of triplicate samples. 
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dependence of this selective binding on the iminoboronate interaction and 
compare the binding of selected hits to that of other random sequences from the 
library. 
4.7 Conclusions and Future Work 
 In this work, we have demonstrated the utility of a cyclic library containing 
a 2-APBA warhead for the discovery of selective protein binders. We have 
established a confident sequencing technique for OBTC libraries using 
LC/MS/MS analysis with Aaron J. Mauris in the Weerapana lab, which can easily 
be transferred for use with other poorly behaving unnatural amino acids. 
Although we were unsuccessful in identifying binders to the lipid II stem peptide, 
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Figure 4-39: Fluorescein control for hit validation by fluorescence anisotropy with Tf 
and HSA. Fluorescein was studied at 200 nM with various concentrations of each 
protein. Points represent averages of triplicate samples. 
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our screen with transferrin demonstrated our ability to pullout selective binders 
in a physiologically relevant complex mixture. 
 Potent binding to Tf offers many potential applications beyond simply a 
proof-of-concept experiment. This includes drug delivery and antimicrobial 
applications. Transferrin is already well documented for its use in drug-protein 
fusion products for drug delivery, but this requires ex vivo production of the fusion 
before administration of the drug. With our reversible covalent binding, one could 
imagine a drug of interest could be conjugated to one of our peptides instead for 
binding to natural Tf in the patient’s blood. 
 Several bacterial species, including Neisseriaceae meningitides and N. 
gonorrhoeae, contain membrane bound transferrin binding proteins (Tbp). TbpA 
and TbpB bind host Tf and function together to extract iron;34,35 both have been 
found necessary to the bacteria for colonization and infection of their host. If our 
peptides are observed to bind in the same location as TbpA or TbpB, they could 
be used as an indirect treatment for these infections. Targeting the host rather than 
the bacterial protein could be imagined to illicit lower degrees of resistance, as the 
bacterium is not being directly engaged by the drug. However, for such an 
application, it would be critical to be demonstrate that the peptide drug is 
occupying the same binding location as these proteins. 
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 For future work, we plan to further validate hits of our Tf screen. This 
includes synthesizing and studying more hit sequences as well as demonstrating 
the role of iminoboronate formation in the protein binding. 
4.8 Experimental Procedures 
4.8.1 General Materials and Methods 
All Fmoc-protected amino acids and Rink amide resin were purchased from either 
Advanced Chemtech (Louisville, KY) or Chem Impex Int. Inc. (Wood Dale, IL). 
Tentagel S NH2 resin was purchased from Peptides International (Louisville, KY). 
DNA oligomers were purchased from Integrated DNA Technologies (Coralville, 
IA) and sequencing was performed by Eton Bioscience, Inc. (Charlestown, MA). 
Other chemicals were obtained from Sigma-Aldrich or Fisher Scientific unless 
otherwise indicated. Peptide synthesis was carried out on a Tribute peptide 
synthesizer (Protein Technologies, Tucson, AZ). 1H NMR data were collected on a 
VNMRS 500 MHz or 600MHz NMR spectrometer, as indicated. Mass 
spectrometry data were generated by using an Agilent 6230 LC TOF mass 
spectrometer. The peptide concentration of all hit peptide samples used in this 
study was determined by measuring their absorbance at 254 nm (ε = 6,960 M-1cm-
1 for AB3) on a Nanodrop 2000c UV/Vis spectrometer by cuvette. Gram-positive 
Staphylococcus aureus (ATCC 6538) was purchased as lyophilized cell pellet from 
Microbiologics (Cloud, MN). 
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4.8.2 Preparation of Tentagel Resin for Library Synthesis (Tentagel-Gly Resin) 
 Tentagel resin (357 mg, 0.100 mmol) was swelled in DMF (3.0 mL) for two 
hours then washed with DMF (3 x 3.0mL). Fmoc-glycine (0.500 mmol, 148.6 mg), 
HOBt (0.500 mmol, 67.6 mg) and HATU (0.500 mmol, 190.1 mg) was dissolved 0.4 
M NMM in DMF (3.0 mL) then added to the resin. The resin was mixed for two 
hours then washed with DMF (6 x 3.0 mL) and DCM (3 x 3.0 mL). The resin was 
fully dried before determining the loading via Fmoc cleavage. When preparing the 
library, if the loading was below 0.220 mmol/g, the procedure was repeated. The 
resin was then swelled again for two hours and mixed with acetyl capping 
reagents (1.0 mL DMF, 500 µL DIPEA, 600 µL acetic anhydride) for 1 hour then 
washed with DMF (6 x 3.0 mL) before use in peptide synthesis. 
4.8.3 Preparation of Peptide for On-Resin DNA Ligation 
Tentagel-gly resin (98.5 mg, 0.203 mmol/g, 0.020 mmol) was swelled in DMF (2.0 
mL) for 1.5 hours on the synthesizer. To this was coupled Fmoc-Gly (0.100 mmol, 
29.73 mg + 0.090 mmol HBTU, 34.13 mg – 30 min), Fmoc Photolabile linker (0.060 
mmol, 31.23 mg + 0.055 mmol HBTU, 20.86 mg – 90 min), Fmoc-Propargylglycine 
(0.060 mmol, 20.12 mg + 0.055 mmol HBTU, 20.86 mg – 90 min), Fmoc-Dap(Boc) 
(0.060 mmol, 25.59 mg + 0.055 mmol HBTU, 20.86 mg – 90 min) and Fmoc-Trp(boc) 
(0.100 mmol, 52.66 mg + 0.090 mmol HBTU, 34.13 mg – 30 min). The resin was 
washed with DCM (6 x 2.0 mL) then dried. A small portion of the resin was 
analyzed by LC/MS. This showed two major products, including the desired 
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peptide and a propargylglycine deletion. As so few equivalents are used for the 
azide-DNA headpiece in the click reaction, the amount of full peptide observed 
was deemed sufficient and the peptide was not remade for test reactions. When 
preparing for test peptide synthesis and simultaneous DNA ligation, the peptide 
was remade using 0.100 mmol Fmoc-Pra and 0.100 mmol Fmoc-Dap(Boc) to 
increase the amount of the full length peptide. 
4.8.4 Click Reaction for the Attachment of DNA Headpiece26 
The prepared resin (5 mg) was soaked in click reaction buffer (CRB, 50% DMSO, 
30 mM triethylammonium acetate (TEAA), 0.04% Tween 20, pH 7.5) (120 µL) for 
two horus. It was then washed with CRB (2 x 120 µL) then suspended in CRB (170 
µL). A prepared solution of Cu(II) sulfate (6.3 mM) and ascorbic acid (0.3 M) in 
66% DMSO in H2O was added to the resin (17.1 µL) along with Tris[(1-benzyl-1H-
1,2,3-triazol-(4-yl)-methyl]amine (2 nmol). This was incubated for 5 min at 40℃. 
The resin was centrifuged for 30 sec at 1000 rcf. A stock of N3-HDNA (1 mM in 
DMSO, 4 µL) was diluted in a 200 mM triethyl ammonium acetate buffer + 2mM 
ascorbic acid (3.7 µL). This solution was added to the resin and immediately mixed 
via vortexing then incubated while stirring (4 hours, 40°C). After incubation, the 
resin was centrifuged again and the supernatant was removed. The resin was 
washed with Bis-Tris propane breaking buffer (BTPBB, 100 mM NaCl, 10 mM 
EDTA, 1% SDS, 1% Tween 20, 10 mM Bis-Tris, pH 7.6) (3 x 120 µL). The resin was 
then incubated in BTPBB (120 µL, overnight, RT) then washed with Bis-Tris 
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propane wash buffer (BTPWB, 50 mM NaCl, 0.04% Tween 20, 10 mM Bis-Tris, pH 
7.6) (3 x 120 µL), DI water (3 x 120 µL) and DMF (3 x 120 µL). The resin was stored 
in a solution of DMF at -20°C. 
4.8.5 DNA Ligation to Resin26 
Top and bottom strands of each encoding oligomer were prepared as 120 µM 
stocks in 50 mM NaCl, 1 mM Bis-Tris, pH 7.6. Prior to use in ligation to resin, the 
corresponding strands (50 µL each) were mixed, heated at 60°C for 5 min then 
allow to cool to RT for 5 min to anneal the two strands together. To prepare the 
resin for DNA ligation, it was first washed with 50:50 DMF/H2O (1 x 3.75 mL) 
followed by BTPWB (4 x 3.75 mL). After the final wash, the resin was incubated 
with shaking (30 min, RT, 700 rpm) then washed with Bis-Tris propane ligation 
buffer (BTPLB, 50 mM NaCl, 10 mM MgCl2, 1 mM ATP, 0.02% Tween 20, 10 mM 
Bis-Tris, pH 7.6) (1 x 3.75 mL). The oligomer sequences can be seen in Table 4-5. 
For encoding step 1, the resin was washed with BTPWB (3 x 600 µL) then rotated 
for 1 hour at RT. After rotation, the resin was washed with Bis-tris propane ligation 
buffer (BTPLB, 500 mM NaCl, 100 mM MgCl2, 10 mM ATP, 0.2% Tween 20, 100 
mM Bis-tris, pH 7.6) (1 x 600 µL) and left in a minimal amount of solvent. To resin, 
720U of T4 ligase (1.8 µL), 10xBTPLB (60 µL), the front primer duplex (≈0001[±]) 
and coding sequence 1 duplex (≈1101[±]) were added and diluted to 600 µL with 
DI water. The solution was rotated at room temperature overnight then washed 
with BTPWB (3 x 600 µL), methanol (1 x 600 µL) and DMF (2 x 600 µL). This was 
174 
 
then rotated at 37℃ for 2 hours. For encoding steps 2-5, resin was washed with 
BTPLB (1 x 600 µL). To the resin the corresponding DNA duplex solution (100 µL), 
T4 ligase (0.9 µL), 10XBTPLB (60 µL) and DI water (439 µL) were added and the 
solution was rotated for 3 hours at RT. For the final encoding step, the resin was 
washed with BTPLB (1 x 600 µL). To this coding sequence 6 (≈2603[±]) (100 µL), 
end primer (≈0701[±]) (100 µL), 10XBTPLB (60 µL), T4 ligase (1.8 µL) and DI water 
(338 µL) were added. The solution was rotated for 4 hours at RT then washed with 
BTPWB (3 x 600 µL), methanol (1 x 600 µL) and DMF (3 x 600 µL). The resin was 
stored as a solution in DMF at -20℃. 
Table 4-5: Sequences of Oligomers for DNA-Encoded Library 
Identifier # Sequence 
Headpiece /5Phos/GAGTCA/iSp9//iAzideN//iSp9/TGACTCCC 
≈0001[+] /5Phos/GCCGCCCAGTCCTGCTCGCTTCGCTAC 
≈0001[-] /5Phos/CCATGTAGCGAAGCGAGCAGGACTGGGCGGCGG 
≈1101[+] /5Phos/ATGGAAGAGAGG 
≈1101[-] /5Phos/TGACCTCTCTT 
≈2201[+] /5Phos/TCAAGTTTCAG 
≈2201[-] /5Phos/AACCTGAAACT 
≈1302[+] /5Phos/GTTACGGAGCA 
≈1302[-] /5Phos/TAGTGCTCCGT 
≈2402[+] /5Phos/CTAAACCTCAA 
≈2402[-] /5Phos/GAATTGAGGTT 
≈1503[+] /5Phos/TTCACAAAGAG 
≈1503[-] /5Phos/GCGCTCTTTGT 
≈2603[+] /5Phos/CGCAATCCCAT 
≈2603[-] /5Phos/AGGCATGGGATT 
≈0701[+] /5Phos/GCCTGTTTGCCCGCCAGTTGTTGTGCCAC 
≈0701[-] /5AmMC6/GTGGCACAACAACTGGCGGGCAAAC 
Overhangs are shown in italics; [+] – top strand, [-] – bottom strand 
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4.8.6 Simultaneous Peptide Synthesis and DNA Ligation 
The prepared resin with clicked DNA headpiece (5.2 mg) was washed with DMF 
(3 x 120 µL). The terminal Fmoc was removed with 20% piperidine in DMF (2 x 
120 µL, 5 min) then washed with DMF (6 x 120 µL) and BTPWB (3 x 600 µL). This 
was rotated in BTPWB (600 µL) for 1 hour then washed with BTPWB (1 x 600 µL) 
and BTPLB (1 x 600 µL). The first ligation step was then performed in the same 
way as above. After ligation, the resin was washed with BTPWB (3 x 600 µL), 
methanol (3 x 600 µL) and DMF (3 x 600 µL) then rotated in DMF for 2 hours at 
37℃. The DMF was removed and a solution of Fmoc-Arg(Pbf) (0.0200 mmol, 12.98 
mg) and HBTU (0.0195 mmol, 7.40 mg) in 0.4M NMM in DMF (120 µL) was added. 
This was rotated for 30 min the washed with DMF (6 x 120 µL). This alternating 
Fmoc deprotection, DNA ligation and amino acid coupling was repeated for two 
more steps, leading to residue 5 in the sequence. After the coupling of Fmoc-
Arg(pbf), the resin was maintained in DMF for the coupling of Fmoc-Dap(boc), 
Fmoc-Gly and Fmoc-AB3(pin). After the Fmoc deprotection of AB3, the resin was 
washed with DMF (6 x 200 ul) and BTPWB (3 x 600 µL) then rotated in BTPWB 
(600 µL) for one hour. At this point, the alternating DNA ligation and amino acid 
coupling procedure was continued for the last two encoding sequences and the 
end primer. After the final ligation, the resin was washed with BTPWB (3 x 600 
µL), methanol (3 x 600 µL) and DMF (3 x 200 µL) then rotated in DMF (200 µL) 
overnight. The final two residues (Fmoc-Trp(boc) and Fmoc-AB3(pin)) were 
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coupled to the resin. After the final Fmoc deprotection, the resin was treated with 
Reagent K (200 µL) for one hour. At this point, the resin was split in half. One half 
the of the resin was treated with NaCNBH3 (25 mM in 10xPBS, 120 µL) for 5 min 
then washed with 1XPBS (6 x 200 µL). Samples from both halves were analyzed 
by single bead PCR and PAGE to determine the success of the DNA ligation and 
by LC/MS after photocleavage to determine the success of peptide synthesis. 
4.8.7 PCR Analysis of DNA Tag 
For single bead samples, one bead was selected under the microscope into a PCR 
tube and suspended in water (5 µL). To each sample 10xStandard Taq reaction 
buffer (2 µL), dNTP stocks (10 mM, 0.4 µL), Taq enzyme (0.2 µL), primer 1 and 
primer 2 (10 µM stock, 0.6 µL for each primer) were added then diluted to 20 µL 
with 10% DMS0, 1.23M betaine in water. To prepare DNA for sequencing, PCR 
samples were prepared with purified excised DNA (2 µL), 10xStandard Taq 
reaction buffer (5 µL), dNTP stocks (10 mM, 1.0 µL), Taq enzyme (0.5 µL), 
sequencing primer (0.5 µL), primer 2 (1.4 µL) and primer 3 (1.5 µL) were mixed 
together then diluted to 50 µL with 10% DMS0, 1.23M betaine in water Primer 
sequences can be seen in table 4-6. Thermocycling conditions can be seen in Table 
4-7. PCR reaction mixtures were purified using denaturing PAGE (8% 19:1 
polyacrylamide:bis, 8 M urea in 1XTBE) The gel was stained using 0.5 µg/mL 
ethidium bromide in 1XTBE. For sequencing samples, PCR reactions were run 
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through a PCR clean up and submitted to Eton Bioscience, Inc. at concentration of 
10-20 ng/µL (20 µL samples). Sequencing was done using primer M13F(-40). 
Table 4-6: Sequences of PCR Primers 
Identifier # Sequence 
Primer 1 5’-GCCGCCCAGTCCTGCTCGCTTCGCTAC-3’ 
Primer 2 5’-GTGGCACAACAACTGGCGGCCAAAC-3’ 
Primer 3 5’-GTTTCCCAAGTCACGAC-3’ 
Sequencing 
Primer 
5’-CGCCAGGTTTTCCCAGTCACGACCAACCACCCAAACCACAAA 
CCCAAACCCCAAACCCAACACACAACAACAGCCGCCCAGTCCT 
GCTCGCTTCGCTAC-3’ 
 
Table 4-7: Thermocycling Conditions for PCR 
Step Temperature Time 
1 95℃ 30 sec 
2 95℃ 20 sec 
3 52℃ 15 sec 
4 72℃ 20 sec 
5 68℃ 5 min 
6 4℃ Hold 
Steps 2-5 repeated for 30 cycles 
4.8.8 DNA Extraction from Gel 
Single bead PCR products were excised from the gel and corresponding pieces 
were mixed with acrylamide gel elution buffer (0.5 M ammonium acetate, 10 mM 
magnesium acetate tetrahydrate, 1 mM EDTA and 0.1% w/v SDS) (2xvolume of 
gel piece). The samples were incubated at 37℃ while shaking overnight then 
centrifuged (14,000 rpm, 1 min, 4℃). The supernatant was removed and put into 
a fresh microcentrifuge tube. The gel pieces were washed with acrylamide gel 
elution buffer (25% volume of original solution), centrifuged and the supernatant 
was combined with that of the first step. The DNA was extracted from this solution 
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by adding an equal volume of 1:1 v/v phenol/chloroform solution, centrifuging 
(14,000 rpm, 1 min, 4℃) and removing the top aqueous layer. This was then 
washed with an equal volume of chloroform. The DNA was precipitated from the 
aqueous layer by adding 200 proof ethanol (2xvolume of sample) and keeping on 
ice for 30 min. The sample was centrifuged (14,000 rpm, 15 min, 4℃), the 
supernatant was removed and the pellet was dissolved in TE buffer (pH 8.0). This 
was precipitated a second time and dissolved in water. Concentration of samples 
were determined by NanoDrop and the final sample was stored at 4℃. 
4.8.9 UV Cleavage of Peptides from Tentagel Resin 
Resin was suspended in HPLC-grade methanol (20 µL/bead) and irradiated with 
UV light (365 nm) for one hour. Before LC/MS analysis, the methanol was 
removed by evaporation and the sample was dissolved in buffer A. 
4.8.10 Peptide Library Preparation 
Tentagel-gly resin (800 mg, 0.197 mmol) was swelled for 2 hours in DMF (8.0 mL) 
then washed with DMF (3 x 8.0 mL). To this, Fmoc-Gly (0.984 mmol, 292.55 mg + 
HBTU, 0.886 mmol, 335.86 mg), Fmoc-Photolabile linker (0.984 mmol, 512.20 mg + 
HBTU, 0.886 mmol, 335.86 mg) and Fmoc-Cys(trt) (0.984 mmol, 576.34 mg + 
HBTU, 0.886 mmol, 335.86) were coupled. The resin was then split into seven 
fractions. Amounts of each amino acid can be found in Table 4- . The amino acids 
were dissolved in 1.5 mL and each was added to a separate fraction of resin. After 
1 hour of stirring, the resin was recombined, Fmoc deprotected then split again. 
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This was repeated for a total of three amino acids. After Fmoc deprotection of the 
third amino acid, the combined resin was washed with DMF (3 x 8.0 mL), 3:1 
DMF/water (3 x 8.0 mL), 1:1 DMF/water (3 x 8.0 mL), 1:3 DMF/water (3 x 8.0 mL) 
and water (3 x 8.0 mL). The resin was stirred in water overnight and excess solvent 
was removed. To the resin, a solution of Fmoc-AB3(pin) (0.197 mmol, 109.42 mg), 
DIC (0.197 mmol, 31 µL) in 1:1 DCM/Et2O (8.0 mL) was added. This was mixed 
for 1 hour, then washed with DCM (3 x 8.0 mL) and DMF (6 x 8.0 mL). Fmoc 
deprotection was performed and the split-and-pool procedure was carried on for 
three additional residues. After the final split, Fmoc-Cys(trt) (0.984 mmol, 576.34 
mg + HBTU, 0.886 mmol, 335.86) was coupled. The resin was stored at -20℃ as the 
fully protected peptides until needed for screening. Library resin was freshly 
prepared from this stock before the screen. To prepare the library for screening, a 
portion of resin (350 mg) was Fmoc deprotected (3 x 3.0 mL, 5 min), acetyl capped 
(1.0 mL DMF, 600 µL DIPEA, 500 µL acetic anhydride), side chain deprotected (4 
x 5.0 mL 10% water in TFA, 1 hour) and cyclized (15 mM N-chlorosuccinimide in 
DMF, 5.0 mL for 15 min). 
4.8.11 Synthesis of Dual-labelled Target Peptide 
The peptide was prepared using Fmoc-based SPPS with Fmoc-D-Ala Wang resin. 
To install the fluorescein, Fmoc-Lys(alloc) was added to the end of the sequence. 
After installation of 6-(Fmoc-amino)caproic acid and biotin, the alloc deprotection 
was performed with on resin (0.01 mmol) using phenylsilane (120 µL) and Pd-
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tetrakis (22 mg) in DCM (680 µL). 5(6)-Carboxyfluorescein (0.050 mmol, 18.82 mg 
+ HBTU, 0.045 mmol, 17.07 mg) was coupled to the free lysine side chain. The 
peptide was cleaved from resin using Reagent K then purified by RP-HPLC and 
lyophilized. The peptide was stored protected from light at -20℃. 
4.8.12 Preparation of Quality Control Single-Bead Samples 
A fraction of the library resin (10 mg) was removed and swelled for 2 hours in 
DMF (1.0 mL). It was then subjected to Fmoc deprotection, acetyl cap and side 
chain deprotection conditions. The cysteines were capped with iodoacetamide (20 
mM in PBS, pH 7.4, 500 µL) for 1 hour. Single beads were separated into PCR tubes 
and cleaved in methanol (20 µL) according to UV cleavage conditions. The 
methanol was evaporated and the samples were dissolved in 100 µL Buffer A. Each 
sample was filtered through a 0.45 μm PTFE syringe filter and the filter was 
washed with an additional 100 µL Buffer A. This was then concentrated by speed-
vac to 20 µL total volume. Samples were submitted to Aaron J. Mauris for LC-
MS/MS analysis. 
4.8.13 LC-MS/MS Sequencing of Single Bead Samples 
Mass Spectrometry was performed on a LTQ Orbitrap Discovery XL (Thermo 
Fisher) coupled to an EASY-nLC 1000 nanoLC (Thermo Fisher).  Samples (10uL) 
were loaded on to a 100 µm fused silica column with a 5 µm tip, hand packed with 
10 cm of Aqua C18 reverse-phase resin (Phenomenex), using the EASY-nLC 
autosampler.  Samples were eluted using a gradient 0-100% buffer B in buffer A 
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over 180 minutes (buffer A: 95% water, 5% acetonitrile, 0.1% formic acid; buffer B: 
20% water, 80% acetonitrile, 0.1% formic acid).  The flowrate was set to 400 nL/min 
and the spray voltage was set to 3.5 kV.  One full MS1 scan (400-1800 m/z) was 
followed by 8 data dependent scans of the nth most intense ion.   
Peptides were assigned to MS2s using the SEQUEST algorithm,36 searching 
against a reverse-concatenated database of all possible library sequences.  To 
account for the n-terminal acetyl group, a glycine residue was added to the n-
terminus of all peptide sequences in the database, and a static modification was 
specified for glycine (-15.0109 m/z), to modify the mass of glycine to that of an 
acetyl group.  Static modifications were also specified for cysteine residues 
(+57.0215 m/z, iodoacetamide alkylation), and the C-terminus (-0.98402 m/z, c-
terminal amide).  MS2 matches were assembled by library member matches using 
DTASelect 2.0.37 Peptides were required to be intact (-Smn 9), single peptide 
matches were allowed (-p 1), and the delta mass was used for statistics (--mass). 
4.8.14 Sodium Borohydride Reduction of Intermolecular Iminoboronates 
For NMR analysis, 2-APBA (8 mM) and lysine (8 mM) were dissolved in 10% D2O 
in PBS buffer (pH 7.4). The corresponding conditions for reduction with NaCNBH3 
or NaBH4 were performed and the 1H NMR was taken at 600 MHz. For LC/MS 
analysis, 2-APBA and Fmoc-D-Lysine hydrochloride were dissolved in PBS buffer, 
pH 7.4. To this, NaBH4 (final concentration = 50 mM) was added and mixed for 15 
min. 
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4.8.15 Screening of Library against Lipid II Stem Peptide 
Prepared library resin (350 mg) was equilibrated in PBS buffer, pH 7.4 (20 mL) in 
a Falcon tube overnight. This was washed with PBS buffer (3 x 20 mL) then 
suspended in 0.1 mg/mL BSA solution in PBS buffer (20 mL). To this, the dual-
labelled target peptide was added and the solution was incubated at 37℃ while 
rotating for 1 hour. NaBH4 (38 mg) was added and the reaction was mixed for 15 
min. The resin was then washed with PBS buffer (6 x 20 mL) and resuspended in 
0.1 mg/mL BSA solution in PBS buffer (20 mL). To this, streptavidin-coated 
Dynabeads (200 µL) were added and the resin was incubated at 37℃ while 
rotating for 2 hours. A rare Earth metal magnet was applied to the side of the 
Falcon tube and kept in place for 2 minutes to allow for all of the Dynabeads to be 
collected. The supernatant was then removed along with any library resin that did 
associate with the Dynabeads. The magnet was then removed and the Dynabeads 
with remaining library resin was resuspended in 0.1 mg/mL BSA solution in PBS 
buffer (20 mL). The magnetic pull down was repeated two more times to remove 
any non-specific binders and the final hits and Dynabeads were suspended in 0.1 
mg/mL BSA solution in PBS buffer (10 mL). The solution was pipetted onto a glass 
slide (10 µL at a time) and the brightest beads were extracted and collected into a 
microcentrifuge tube. 
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4.8.16 Preparation of Hit Samples for Sequencing 
The collected hits were washed 3 times with PBS buffer, pH 7.4 then subjected to 
TCEP reduction (50 mM in PBS buffer) and iodoacetamide capping (20 mM in PBS 
buffer). Beads were segregated into individual PCR tubes, suspended in HPLC-
grade methanol (20 µL) and subjected to UV cleavage. After cleaving, the methanol 
was removed by evaporation and the samples were dissolved in 100 µL Buffer A. 
Each sample was filtered through a 0.45 μm PTFE syringe filter and the filter was 
washed with an additional 100 µL Buffer A. This was then concentrated by speed-
vac to 20 µL total volume. Samples were submitted to Aaron J. Mauris for LC-
MS/MS analysis. 
4.8.17 Synthesis of Hit Peptides for Validation 
All hits were synthesized using Fmoc-based SPPS on Rink amide resin. The N-
terminus was acetyl capped. Crude peptides were cleaved from resin using a 
modified Reagent K (80% TFA, 7.5% w/v phenol, 5% water, 5% thioanisole and 
2.5% triisopropylsilane) then precipitated twice using cold diethyl ether. Crude 
peptides were purified using RP-HPLC to >90% purity. Lyophilized pure peptides 
were cyclized using DMSO-mediated oxidation by dissolving in 10% DMSO in 
water and stirring at RT until LC/MS analysis showed no remaining linear 
peptide. DMSO and water were removed by lyophilization and final peptides 
were stored at -20℃. 
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4.8.18 Minimum Inhibitory Concentration Assay 
Minimal inhibitory concentrations (MICs) were measured against gram-positive 
Staphylococcus aureus (ATCC 6538) using the broth microdilution method in LB 
media. Specifically, a single colony selected from a LB agar plate was grown 
overnight in broth at 37℃ with agitation and diluted 100 times into fresh broth the 
next morning. OD600 was monitored until a value between 0.5 and 0.6 was 
reached. The cells were diluted by a factor previously determined to a 
concentration of ~5 x 105 colony forming units per mL (cfu/mL). In a sterile 96-
well plate, the cell suspension (200 μL) was added to each well. To each well, serial 
diluted (2-fold) peptides in DMSO (2 μL) were added in triplicates. Using a 
microtiter plate reader (SpectraMax M5, Molecular Devices, Sunnyvale, CA), the 
OD600 was monitored overnight while incubating at 37℃, with readings taken 
every 10 minutes after the plate was shook for 15 seconds. Using the time point 
where OD600 of the blank (untreated) sample began to level off, MICs were 
determined to be the lowest concentration for which cell growth was not observed. 
4.8.19 UV-Vis Titration of Hit Peptides with Biotin-Lipid II Stem Peptide 
Hit peptide stocks were diluted to a concentration of 50 µM in PBS buffer, pH 7.4. 
2-methoxyethylamine and biotin-lipid II target peptide, dissolved in PBS buffer, 
pH 7.4, were titrated into both blank and hit peptide solutions and the UV 
spectrum was recorded. A blank subtraction was performed for each new 
concentration of 2-MEA or biotin-lipid II target peptide. Plots were made stacking 
185 
 
the UV spectrum at each concentration of amine as well as a plot of concentration 
of amine vs. absorbance at 280 nm. Kd’s could be estimated as the midway point 
of the titration curve from the absorbance at 280. 
4.8.20 Sodium Borohydride Reduction of Hit Peptides and Biotin-Lipid II Stem Peptide 
Hit peptides and biotin-lipid II target peptide (dissolved in PBS buffer, pH 7.4) 
were mixed at 500 µM each. The pH was checked and adjusted to 7.4 as necessary. 
The samples were allowed to incubate at 37℃ for 1 hour before sodium 
borohydride was added to a concentration of 50 mM. This was allowed to react for 
15 min, then samples were diluted to a peptide concentration of 100 µM and 
analyzed by LC/MS. 
4.8.21 Screening of Library against Rhodamine-Transferrin 
Prepared library resin (50 mg) was suspended in PBS buffer, pH 7.4 (2.5 mL) and 
equilibrated overnight. The resin was washed with PBS buffer (3 x 2.5 mL) and 
suspended in a 1.6 mg/mL solution of human serum albumin in PBS buffer (2.3 
mL). To this, rhodamine-labelled transferrin (1 mg/mL stock, 200 µL) was added. 
The mixture was incubated at 37℃ with rotation of one hour. Sodium borohydride 
was added to a final concentration of 50 mM and allowed to react for 15 min. The 
resin was then washed with PBS buffer, pH 7.4 (4 x 2.5 mL), PBS buffer, pH 5 (1 x 
2.5 mL) and finally again PBS buffer, pH 7.4 (1 x 2.5 mL). The resin was analyzed 
using fluorescent light microscopy with a rhodamine filter. The brightest beads 
were segregated from others and collected. The peptides were linearized using 
186 
 
TCEP treatment and cysteines were capped with iodoacetamide. Single beads 
were separated into PCR tubes, suspended in HPLC-grade methanol (20 µL) and 
subjected to UV cleavage conditions. The methanol was removed by evaporation 
and the samples were dissolved in 100 µL Buffer A. Each sample was filtered 
through a 0.45 μm PTFE syringe filter and the filter was washed with an additional 
100 µL Buffer A. This was then concentrated by speed-vac to 20 µL total volume. 
Samples were submitted to Aaron J. Mauris for LC-MS/MS analysis. 
4.8.22 Synthesis of Hit Peptides for Validation 
All hits were synthesized using Fmoc-based SPPS on Rink amide resin. After full 
peptide synthesis, carboxyfluorescein was coupled to the N-terminus. Crude 
peptides were cleaved from resin using a modified Reagent K (80% TFA, 7.5% w/v 
phenol, 5% water, 5% thioanisole and 2.5% triisopropylsilane) then precipitated 
twice using cold diethyl ether. Crude peptides were purified using RP-HPLC to 
>90% purity. Lyophilized pure peptides were cyclized using DMSO-mediated 
oxidation by dissolving in 10% DMSO in water and stirring at RT until LC/MS 
analysis showed no remaining linear peptide. DMSO and water were removed by 
lyophilization and final peptides were stored at -20℃. 
4.8.23 Fluorescence Anisotropy for Hit Validation with Transferrin 
In a 96-well plate (Costar 3603, black plate, clear bottom), the desired protein was 
added at varying concentrations from 0-10 mg/mL in triplicates from a protein 
stock (20 mg/mL in PBS buffer, pH 7.4). To this, the hit peptide (2 µL, 20 µM stock 
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in PBS buffer, pH 7.4) was added to each well. Anisotropy was measured every 5 
min over 1 hour with an excitation wavelength of 495 nm and an emission 
wavelength 532 nm with a 515 nm cutoff. Change in anisotropy is recorded as the 
average of triplicate samples for the given protein concentration with the average 
of triplicate samples for the peptide alone subtracted. Kd’s are estimated based on 
the protein concentration where 50% binding is observed. 
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Chapter 5 
Conclusions 
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The overarching theme throughout this dissertation is the use of peptides 
as new antibiotics. With the major advancements for peptides in the past few 
decades, they are becoming more therapeutically realistic and can fit a niche that 
is not obtained by small molecules or biological therapeutics. Specifically in the 
work described in this thesis, we have explored the use of peptides as bacterial 
selective transmembrane channels and as synthetic receptors of important lipids. 
While some success has been achieved, it is important not to forget some possible 
limitations. 
 In the case of gramicidin A, we were unable to gather as much 
mechanistic characterization as we had hoped for. As such, it is unclear whether 
these cationic mutants are active using the same mechanism of action as the 
natural structure. This also made it difficult to define a more than rudimentary 
structure activity relationship, providing only limited insight to direct our next 
step. 
Furthermore, it remains to be seen whether this scaffold would be able to 
produce a structure that is sufficiently potent and selective for clinical 
applications. The wild-type structure itself has low micromolar potency and 
those cationic mutants that were able to come back to this did so at the expense 
of selectivity. This could be a consequence of the non-specific membrane binding 
at the route of gA’s mechanism of action. Looking at relevant examples of 
peptides in the clinic such as vancomycin, they are able to achieve mid-
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nanomolar to sub-micromolar potency as they have a much more specific target 
for binding. Even in the case of nisin and daptomycin, which bind PE and PG 
head groups, respectively, potent activity is achieved with membrane-targeting 
mechanisms. 
These thoughts and the difficulties met with rational design of gA peptides 
initially steered us towards the use of library synthesis and screening. We 
believed that, with careful crafting of experimental conditions, we could also 
achieve this type of potent binding. With this, we set out with the goal of 
discovering a potent binder of the lipid II stem peptide, which is the target for 
vancomycin. Due to technical challenges, our work has heretofore focused on 
libraries of monocyclic peptides that incorporate reversible covalent binding 
motifs, namely the 2-APBA moiety for iminoboronate formation.  Despite the 
carefully designed screening scheme, the initial library has yet to yield positive 
hits for lipid II binding.  
This failed endeavor, however, taught us many things about working with 
a peptide library and designing appropriate screening conditions. For example, 
the auto-fluorescence of aged TentaGel beads could give false positive hits while 
screening with green fluorescence. Using this knowledge, we were able to 
discover peptides with selective binding to transferrin labeled with a red-
emitting fluorophore, which avoids the interference by the auto-fluorescence of 
the beads. The potency achieved from just our first few validated hits is already 
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significant in physiological conditions, as the estimated Kd is less than the natural 
protein concentration. Furthermore, by including human serum albumin at a 
physiologically relevant ratio to transferrin in our screen, we were able to select a 
specific peptide with nearly no observable binding to albumin. 
Moving forward, there is still much left to be learned. For example, how 
specific is our binding within transferrin? Given that transferrin is roughly 80 
kDa and contains 58 different lysines, it is unlikely that every hit binds in the 
same way. Yet, with the selectivity observed for hit 1, it is possible that the 
binding mechanism is specific for each peptide. The possibility of discovering 
multiple transferrin-specific peptides with distinct binding mechanisms opens 
many avenues for future research and applications.  
It is conceivable that our cyclic peptide library with a 2-APBA motif 
would be best suitable for proteins with activated lysines. Lysine is commonly 
used in the active sites of proteins as a nucleophile. However, with the pKa of the 
lysine side chain being about 10.5, only about 0.1% of the amines will be left 
deprotonated at physiological conditions. In all its cleverness, nature has found a 
way to remedy this in necessary proteins. By controlling the local environment 
with neighboring amino acids, several proteins have been found to contain 
lysines with perturbed pKa’s, allowing for the amine to be more nucleophilic in 
the active site.1 
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 Our system could be ideal for targeting proteins that contain these 
perturbed lysines. As the binding of our 2-APBA moiety occurs through 
nucleophilic attack by a free amine, we expect better potency and selectivity can 
be gained by targeting a more active lysine. Some potential targets including 
perturbed lysines in their active sites include penicillin binding protein 2 and 
acetoacetate decarboxylase. 
Penicillin Binding Protein 2 
 In S. aureus, penicillin binding protein 2a (PBP2a) is commonly linked to 
methicillin resistance.2 This mutant protein, obtained through horizontal gene 
transfer, is very similar to the natural penicillin binding protein 2 (PBP2), but has 
a much lower affinity for β-lactam antibiotics.3,4 With this lower affinity, PBP2a is 
able to evade inhibition of its transpeptidation activity. However, PBP2 and 2a 
and most other high molecular weight penicillin binding proteins (PBPs) have a 
second critical domain responsible for transglycoslation.5 PBPs use this second 
domain to extend the glycan chain of peptidoglycan and contain conserved pairs 
of lysine and serine in their active site. 
 The proposed mechanism of PBP transglycosylation involves several 
proton-transfer events, initiated by the activation of a serine residue by a 
neighboring lysine.5 This mechanism implies that the lysine must exist in its free 
base form to be able to abstract the proton from serine. With the example of 
moenomycin A (MmA), binding this domain, specifically including interactions 
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with the active site lysine, has been validated to have antibiotic potential.6 
Furthermore, binding to the transglycosylation domain has been observed to also 
shut down the PBP’s transpeptdidase activity,7 suggesting this strategy would be 
effective against MRSA expressing PBP2a. 
 By screening our peptide library against PBP2a, we could directly inhibit 
the active site lysines, gaining specificity through interactions between the local 
environment of the lysine and the remaining residues in our cyclic peptide. 
Validated hits would be expected to have similar activity towards both S. aureus 
and MRSA. 
Acetoacetate Decarboxylase 
 Acetoacetate decarboxylase (AADase), found in mammals as well as 
solventogenic bacteria, is responsible for the conversion of acetoacetate to 
acetone. With a mechanism proceeding through a Schiff-base intermediate, 
AADase is one of the earliest examples of a protein containing a lysine with a 
perturbed pKa in its active site.1 When the pKa of Lys115 was measured directly, 
it was found to be equal to 5.96, which is 4.5 orders of magnitude lower than a 
typical lysine side chain.8,9 
 Given the binding mechanism of our 2-APBA structures, we expect that 
the stabilization provided by the nitrogen-boron dative bond would allow us to 
compete with the natural substrate of this enzyme. Furthermore, with its 
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perturbed pKa, the potency of a library hit should be enough to avoid off-target 
binding with other lysines. 
Finally, it is worthwhile to redo the lipid II stem peptide screening with 
optimized screening conditions. Admittedly, the lipid II stem peptide presents a 
more difficult target than large proteins such as transferrin as the development of 
synthetic receptors for small molecules still remains in its infancy. However, the 
impressive potency and selectivity of vancomycin (and other related molecules) 
toward its target suggest it is feasible to have synthetic receptors for small 
molecule targets. Of course, our current library of monocyclic peptides is still 
structurally primitive in comparison to the vancomycin scaffold. However, we 
submit that the utilization of novel binding mechanisms such as the 
iminoboronate formation improves our chance of success. In addition, it is highly 
desirable to build and screen multicyclic peptide libraries, which will 
undoubtedly better our chances of success to identify synthetic binder of lipid II 
stem peptide. Lastly, it is important to note that the screening platforms that we 
are developing, once established, should be applicable to discovering synthetic 
receptors for a variety of small molecule targets, which may have significant 
ramifications in various aspects of biology. 
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